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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by the rapid
and progressive degeneration of upper and lower motor neurons in the spinal cord, brain stem
and motor cortex. Approximately 90% of ALS cases are sporadic (sALS) in nature, and the
remaining 10% are termed familial (fALS), being associated with mutations in a broad set of
genes including SOD1, TDP-43, OPTN, C9orf72, ALS2, FUS, and UBQLN2. The first of
these genes linked to ALS was the gene encoding the ubiquitous free radical scavenging
enzyme superoxide dismutase-1 (SOD1), which currently has over 180, mostly missense,
ALS-associated mutations identified. Curiously, SOD1-associated fALS patients show
remarkably broad mean survival times (< 1 year to ~17 years death post-diagnosis) which are
mutation dependent, indicating that mutation may govern disease severity. In its native fold,
SOD1 is a 32 kDa homodimer where each 153 amino acid subunit contains an intramolecular
disulfide, as well as zinc and copper cofactors; the latter of which catalyses the conversion of
oxygen radicals to either molecular oxygen or hydrogen peroxide, and all of which confer
significant thermal and kinetic stability. Early research, using knockout animal models,
determined that a loss of enzymatic activity is not the cause of SOD1-associated fALS
pathology, suggesting that mutation is inducing a gain of cytotoxic function. A hallmark of
SOD1-associated ALS is the deposition of SOD1 into large insoluble aggregates in motor
neurons. This is thought to be a consequence of mutation induced structural destabilisation
(dimer dissociation, metal binding disruption, and disulfide reduction) and/or oxidative
damage leading to the misfolding of SOD1 into a neurotoxic species. Recent work has
emphasised the ability of SOD1 to transmit misfolding molecularly, intercellularly, and from
organism-to-organism in a prion-like manner, providing some rationale for the
spatiotemporal spread of pathology observed in ALS. In this study we investigate the effects
iv

of fALS-associated mutations and their consequences on protein structure and aggregation
using recombinant protein and cultured cell models. Using native mass spectrometry (MS) to
direct the dissociation and unfolding of purified SOD1 variant dimers in vacuo, we
determined that the SOD1G37R variant had significantly altered charactersitics comparative to
the other variants examined, where it presented a more asymmetric partitioning of charge yet
did not dissociate more readily. Following from this we observed that our SOD1 variants
were modified at Cys111 by glutathione, which the data present here suggested alters the
dimer dissociation constant (KD) of SOD1. MS analysis determined the extent of
glutathionylation, as well as the dimer KD’s of several SOD1 variants in their unmodified
(uSOD1) and glutathionylated (gsSOD1) forms, finding that glutathionylation increased the
dimer KD’s differentially, where specific wild-type-like mutants were significantly
augmented (uSOD1G93A = 12 ± 1 nM, gsSOD1G93A = 160 ± 32 nM) compared to SOD1WT
(uSOD1WT = 9 ± 1 nM, gsSOD1WT = 34 ± 5 nM). These data suggest that glutathionylation,
and potentially other modifications, of Cys111 in SOD1 may contribute to its misfolding and
subsequent aggregation, and highlights the necessity of identifying post-translational
modifications prior to biophysical analysis.
Owing to the ability of native MS to resolve differentially modified protein species, provide
information on oligomeric distribution, as well as information on protein conformation, we
utilised MS to interrogate the structural consequences of metal loss and disulfide reduction on
fALS-associated SOD1 variants. We determined that, after DTT/EDTA-treatment, the most
abundant SOD1 species was reduced apo-SOD1 for all variants, and that the conformational
state of this species was dependent on mutation. All variants showed evidence of unfolded,
intermediate, and compact conformations (as determined by Gaussian distributions of massto-charge ratios), with SOD1G37R, SOD1G93A and SOD1V148G having the greatest abundance
of intermediate and unfolded SOD1. SOD1G37R was a curious outlier as it did not aggregate to
v

the same extent (measured by thioflavin T) as SOD1G93A and SOD1V148G in aggregation
assays. Furthermore, seeding the aggregation of DTT/EDTA-treated SOD1G37R with
preformed SOD1G93A fibrils elicited minimal response, indicating that the arginine
substitution at position-37 blocks the templating of SOD1 onto preformed fibrils. Position-37
is encompassed by a sequence segment (30KVWGSIKGL38) identified as having a high
aggregation propensity and being involved in the intermolecular transmission of misfolding.
Within this sequence segment is Trp32 which has previously been identified as a contributor
to SOD1 misfolding and aggregation. We investigated the effect of Trp32 on aggregation by
generating SOD1 variants with a W32S mutation. Our analysis established that the W32S
substitution decreased the stability of the reduced apo-form of each SOD1 variant, but
remarkably decreased their aggregation propensity both in isolated protein assays and in cell
culture. We found that SOD1G93A-W32S had a decreased ability to template onto preformed
SOD1G93A aggregates, suggesting that Trp32 is an aggregation modulating residue.
This study clearly demonstrates the utility of native mass spectrometry in the study of
disordered and modified proteins in the ability to assess both conformational and
modification state simultaneously. The data reported here illustrate the complexity involved
in unravelling the cause of SOD1-associated fALS, but provides evidence that strongly
indicates the role of a sequence segment encompassing Trp32 in aggregation and
propagation. It is hoped that by understanding the interplay between mutation effect on SOD1
stability and subsequent aggregation formation may help identify the particular aggregate
species responsible for toxicity and provide targets for therapeutic intervention.
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1. Introduction to Protein Folding, Mass
Spectrometry, Protein Misfolding Related
Disease, ALS and SOD1
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1.1 Overview
Proteins that misfold or unfold are sometimes able to bypass or overwhelm the cellular
protein quality control mechanisms, often leading to aggregation in the form of insoluble
protein deposits (Dobson, 2003). Normal cellular function can be disrupted by aggregates
interacting inappropriately with cellular components such as membranes, receptors and other
proteins (Chiti and Dobson, 2006). Protein aggregation has been associated with multiple
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and
amyotrophic lateral sclerosis (ALS). Most ALS cases are sporadic, but 10% are associated
with inheritance of a mutation in a number of possible genes, with much research focusing on
superoxide dismutase-1 (SOD1), due to its early discovery and the fact that mutants of this
protein are associated with 20% of familial ALS (fALS) cases (Benatar et al., 2006).
Sufferers of SOD1-linked fALS often have protein inclusions comprised primarily of SOD1
in their affected neurons (Boillée et al., 2006). How mutation results in aggregation of SOD1
is not well understood; over 180 possible mutations in SOD1 are linked to fALS and as a
result a variety of physical properties are implicated as contributing to the aggregation
mechanism. It is clear that aggregation of SOD1 is dependent primarily on dissociation of the
dimer, the release of bound metals, and the reduction of the disulfide bond (Chattopadhyay
and Valentine, 2009), implicating that an immature form of SOD1 may be responsible for
aggregation. Although there is good evidence to suggest metal binding and disulfide
reduction are involved in the aggregation of SOD1, not all mutations directly disrupt these
properties, leaving the precise intermolecular and intramolecular interactions taking place
during this process unclear.
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1.2 Protein Folding and Quality Control
Protein folding is key to the correct functioning of most cellular processes, and if proper
folding of newly synthesised proteins is disturbed, the consequences can be fatal (Dobson,
2003). When a polypeptide is newly synthesised it is acted upon by physical forces and
cellular machinery to reach its native conformation (Anfinsen, 1973, Hartl et al., 2011).
Paradoxically, proceeding from a polypeptide strand to a complex three dimensional structure
by cycling through all possible conformations would take years, but when observed
experimentally, folding processes take milliseconds to occur (Levinthal, 1968). The energy
landscape (Fig. 1.1) theory of protein folding addresses this issue by suggesting that the
folding is determined by a funnel-like progression from highest free energy to lowest free
energy in the protein structure (Onuchic and Wolynes, 2004). This infers that the number of
possible conformations a protein can occupy becomes smaller as free energy decreases,
effectively directing folding towards a single end state commonly known as the ‘native
conformation’. The native conformation of most proteins is thermodynamically favourable
and is thought to be the form responsible for carrying out processes within a cell (Karplus and
Sali, 1995). Even though the energy landscape theory suggests a funnel-like progression
towards native conformation, the process of folding can see polypeptide chains transition
through many partially-folded and unfolded states that facilitate subsequent folding steps,
before assuming its lowest energy state (Karplus and Sali, 1995, Dobson, 2003, Ecroyd and
Carver, 2008). These above processes are, for the most part, dictated by amino acid sequence.
Small proteins (60-110 amino acid residues) have been the focus of many studies
investigating the molecular steps in protein folding (Fersht and Daggett, 2002, McLaughlin
and Weeds, 1995, Radford and Dobson, 1999). It has been proposed that small proteins fold
into their native conformation in a single step, bypassing the need for intermediate folding
states (Jackson, 1998). Evidence from nuclear magnetic resonance, fluorescence and circular
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dichroism spectroscopy experiments have been used to conclude that smaller proteins
transition from unfolded polypeptides to their native conformation by nucleation of
hydrophobic residues followed by a hydrophobic collapse (Fersht, 2000, Kim and Baldwin,
1982, Vendruscolo et al., 2001).

Figure 1.1: The energy landscape of protein folding. The pathways that lead to a protein’s native
conformation (blue). The free energy decreases as order increases when polypeptides fold. The
intermediates (green) limit the ways a large polypeptide can fold, thus narrowing the funnel. Unfolded
polypeptides (red) can either reach the native conformation or become misfolded (orange) (Schultz
2000).

In contrast, the three main physical states for larger proteins have been described as the initial
unfolded state, followed by an ensemble of intermediate states, and lastly the native
conformation (Radford and Dobson, 1999). This sequential theory of the protein folding
pathway begins with the formation of secondary structures, such as α-helices and β-sheets,
which is then followed by the formation of the tertiary structure (Pace et al., 1996). Another
theory suggests that the intermediate states induce the formation of a molten globule that is
similar to the native state (Vendruscolo et al., 2001). The concentration of the native
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interactions in the molten globule forces the peptide into its native conformation (Makarov
and Plaxco, 2003). Both theories state that the final step in the folding of large proteins
includes the exclusion of water from the hydrophobic core (Cheung et al., 2002). Once a
protein is in its native conformation it is stabilised by interactions between amino acid side
chains that include hydrogen bonding, hydrophobic, electrostatic and covalent interactions
(Murphy and Kendrick, 2007). These types of bonds can also occur between side-chains not
normally found in the native fold or between individual polypeptides during the folding
process, leading to inappropriate interactions. The maintenance of the entire proteome in its
collective native conformation, and at a concentration and location that promotes correct
function, is termed protein homeostasis or proteostasis.
Protein quality control processes that maintain proetostasis have evolved in cells due to the
importance of proper protein folding (Yerbury et al., 2005). Proteins can misfold or unfold
from the native conformation as a consequence of changes in the intracellular environment
that can include oxidation/reduction potential, pH, and resource availability. It is also
necessary for some proteins to remain partially folded for transport in the cellular
environment, potentially leading to unwanted interactions. The inhibition of inappropriate
interactions is facilitated by molecular chaperones; which are proteins that mediate correct
folding, and stabilise unfolded proteins during cellular stress or membrane translocation, and
can even refold, hold, or unfold and disaggregate proteins for delivery to degradation systems
(Arrigo et al., 2007, Gregersen et al., 2006, Muchowski, 2002, Neuwald et al., 1999). Many
chaperones are heat-shock proteins, meaning their expression is up-regulated when a cell is
undergoing heat or other stresses. If chaperones are unable to fold a protein to its native
conformation, then it is necessary for the protein to be degraded to prevent the formation of
cytotoxic aggregates (Goldberg, 2003, Muchowski and Wacker, 2005).
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Misfolded proteins are degraded via two main pathways within eukaryotic cells, that
essentially break down the stubbornly misfolded protein material for recycling (Goldberg,
2003). Primarily, the cell uses the ubiquitin-proteasome system to degrade soluble proteins;
misfolded proteins are covalently modified with the small marker protein ubiquitin (typically
multiple times to form a poly-ubiquitin chain) and transported to the proteasome for
degradation (Wilkinson, 2005). A proteasome is a large protein complex that forms a barrellike structure in to which an unfolded protein is delivered (after removal of ubiquitin) and
internal active protease sites mediate the degradation of the protein (Wilkinson, 2005). The
second major pathway for degradation in the cell is the autophagy-lysosomal pathway in
which membranous vacuoles, called autophagosomes, encase cell organelles or large protein
aggregates, merge with lysosomes to facilitate degradation of the cargo via acidic hydrolases
(Yorimitsu and Klionsky, 2005). If either of these two processes are operating at reduced
capacity, or overwhelmed by an influx of misfolding, then protein aggregation can occur.

1.3

Native Mass Spectrometry

Protein folding is a multifaceted process, requiring the utilisation of a diverse set of
techniques to elucidate specific information about different levels of structure within a
protein. Assessment of protein structure on primary, secondary, tertiary, and quaternary
levels is essential for understanding protein function and dysfunction within biology. A
technique which can allow for the rapid assessment of protein structure, ranging from
primary to quaternary structure is mass spectrometry (MS). A mass spectrometer, by its very
definition, is a device that measures mass as a function of intensity, giving an output
spectrum where the specific mass of a molecule has the most intense signal. In order to
analyse samples via MS they must first be buffer exchanged into a volatile buffer to facilitate
their conversion into a gas-phase ion (Figure 1.2 A). Native MS, as the name implies, is the
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MS based study of biological molecules in a ‘native-like’ state. The term ‘native-like’ is used
to describe native studies of biological molecules using MS because the molecules are
required to transition from the solution-phase into the gas-phase, which alters the
physicochemical forces that govern protein structure such as hydrophobicity and electrostatic
interactions (Bich et al., 2010b). This phase transition has been extensively optimised
throughout the history of the technique, resulting in the ability to maintain important native
features of biological molecules in vacuo. Native mass spectrometry has been especially
useful in the investigation of the non-covalent interactions within biological assemblies,
binding stoichiometries, and protein complex architectures (Benesch et al., 2007).
In the case of native MS of biological macromolecules, ‘soft ionisation’ is essential to
transfer the molecule into the gas-phase whilst maintaining native structure (e.g. non-covalent
interactions between binding partners). The most commonly used form of soft ionisation
technique in native MS studies is electrospray ionisation (ESI), in which an electrical
potential (typically positive charge) is applied to an inert gold-coated glass capillary
containing aqueous sample for analysis, resulting in the expulsion of small charged droplets
containing analyte from the capillary into an electric field of opposite charge. As these
droplets traverse from the capillary into the instrument, they undergo both evaporation and
fission until very little, or none, of the solvent is left surrounding an analyte, resulting in a
multiply charged gas-phase ion

(Kebarle and Verkerk, 2009). Droplet evaporation and

fission are important to the production and accurate measurement of gas-phase ions, and in
some cases, facilitation of evaporation and fission requires harsh conditions which are
unsuitable for the analysis of intact complexes. The production of multiply charged ions from
ESI is a consequence of the ionisation of solvent exposed basic (positive ion mode) or acidic
residues (negative ion mode), resulting in the generation of mass spectra containing multiple
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peaks, which can be a useful measure of relative protein fold in response to changes in
solution-phase conditions (Mann et al., 1989).
Nano-electrospray ionization (nano-ESI) has many advantages over typical ESI, including the
use of smaller sample volumes (microlitres instead of millilitres), production of smaller
droplets (nanometres instead of micrometres), and higher tolerance to salts (which can
suppress signal in typical ESI), all of which contribute to an enhanced analysis of native
protein dynamics. The smaller droplet size produced in nano-ESI is particularly useful for
native MS as there is a reduced chance that multiple analyte species are present in one droplet
and therefore the likelihood of non-specific interactions are decreased. In conjunction with
this, the smaller droplet size requires less energy to desolvate, which results in a lower
internal energy of measured ions and decreases the chance of unwanted gas-phase
dissociation and fragmentation (Juraschek et al., 1999). These features, in conjunction with
the aforementioned production of a multiply charged ion, as well as complementary
technologies combined result in an extremely powerful tool for the examination of protein
structure.
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Figure 1.2: A Typical protein native mass spectrometry workflow. (A) Samples must be partially
or fully purified for native MS and exchanged into a volatile buffer. Ammonium acetate (10 µM –
1 M, over a wide pH range) is the most commonly used buffer system for native MS. (B) Samples are
ionised to convert them into gas-phase ions using ESI where a capillary is charged with electric
potential (positive for most proteins) increasing attraction of the sample to an oppositely charged
field. This creates a fine nebulising spray from the capillary where proteins inhabit the droplets.
Droplets undergo desolvation and fission until there is minimal or no aqueous buffer remaining on the
protein. (C) Typical protein MS measures denatured proteins that are usually unfolded monomers
carrying high levels of charge due to exposure of basic residues during ionisation. Native protein MS
can result in the measurement of protein multimers in a ‘native-like’ conformation, carrying low
charge due to basic residues being buried during ionisation.
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1.4

Ion Mobility-Mass Spectrometry

The combination of ion mobility separation to MS (IM-MS) has vastly increased level of
structural data that can be obtained from, MS based experiments. In simple terms, the size
and shape of an ion can be measured through the addition of a drift cell to a mass
spectrometer. Drift cells are chambers that produce a weak electric field that promotes the
passage of an ion against an inert countering gas-flow (typically argon). Both the electric
field and gas flow can be modified to augment the passage of ions through a drift cell, giving
the user a high degree of control and separation in IM experiments (Kanu et al., 2008). IM
studies have been conducted using various technologies, the first of which is a simple linear
drift-tube that works as described above (McDaniel et al., 1962). Later IM-MS based studies
have made use of a travelling wave system (TWIMS), which is a more compact IM cell that
utilises alternating electric potentials to generate waves that gas-phase ions ‘surf’ against the
countering gas flow (Shvartsburg and Smith, 2008).

Ions subjected to IM-MS separate based not only on mass-to-charge ratio (m/z) but also based
on their shape, or more specifically their rotationally averaged cross-sectional area termed a
‘collisional cross-section’ (CCS) (Wyttenbach et al., 1996). CCSs are energy and temperature
dependent measures of the gas-phase conformational state of ions and have been strongly
correlated to the areas derived from X-ray crystal structures when conditions are considered
native (Jurneczko and Barran, 2011). Data obtained using traditional drift tubes can be
assessed using the Mason-Schamp equation to directly determine CCSs of ions (McDaniel et
al., 1962), whereas TWIMS systems must make use of calibrants with known CCSs to
interpolate the CCS of unknown ions (Ruotolo et al., 2008b).

10

IM-MS has been particularly useful for the study of large macromolecular assemblies, as
there is now abundant evidence indicating that the binding interactions of large biological
molecular assemblies can be maintained in vacuo if the right conditions are met (Benesch et
al., 2007). By using IM-MS to measure the size of protein complexes and their corresponding
sub-complexes, researchers have been able to effectively produce and refine structural
models of macromolecular complexes that are difficult to study by standard techniques such
as X-ray crystallography. An example of this is in the study of molecular chaperones such as
the small-heat-shock proteins, which form large polydisperse oligomeric assemblies that
confound traditional structural analysis, but can be effectively resolved with MS and the
underlying structures can be examined with IM-MS providing constraint for in-silico
modelling (Baldwin et al., 2011).
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Figure 1.3: Ion mobility-mass spectrometry of protein assemblies. (A) Schematic showing the
general principle of ion mobility (IM) of ions. In this case a travelling-wave system is shown, where
gas-phase ions are carried by the travelling-wave potential against a countering inert gas-flow. Ions
separate based on their shape and size. (B) A typical ion chromatogram showing the measured arrival
time distributions of the ions being sampled, where larger ions take longer to traverse the cell and
therefore arrive later. Inset is a panel showing the MS –based deconvolution of a peak of mixed
species that share a similar arrival time but different m/z values. This can also be reversed, where
similar m/z values can be resolved using IM to determine different arrival times.

1.5

Collision-Induced Dissociation and Unfolding

Although native MS must be carefully performed to maintain native interactions, unfolding
and dissociating ions in the gas-phase can reveal much about their structure and oligomeric
composition. MS gives the user not only excellent separation of moderately heterogeneous
samples, but also unique capabilities that allow for further separation and analysis of specific
ions within mixtures. Integral to the investigation of protein complexes is an understanding of
12

their underlying composition as not all complexes are composed of homogenous subunits. A
common feature in all mass spectrometers is a collision-cell; a chamber in which ions can be
forced to undergo increasing collisions with an inert gas leading to the dissociation,
unfolding, and fragmentation of protein complexes dependent upon the amount of energy
input into the cell. Although this energy directed dissociation of heterogeneous protein
complexes is not generally correlated with solution-phase events, one can determine the
components of a heterogeneous complex with high accuracy and reliability via this method
(Sharon, 2010). In the gas-phase, collision-induced dissociation (CID) of multiply charged
protein complexes proceeds through pathways defined as symmetric and asymmetric
dissociation which is dependent upon the partitioning of charge after dissociation has
occurred. Symmetric dissociation results in fragment ions where charge is equal to the
proportion of mass represented by the ion (a dimer example = dimern+ = 2 × monomer(2/n)+),
whereas asymmetric dissociation results when a fragment ion of a complex carries a
disproportionate amount of charge after it has been dissociated (dimern+ = monomer>(2/n)+ +
monomer<(2/n)+). Asymmetric dissociation is the most typical form of dissociation that occurs
during CID-based studies (Felitsyn et al., 2001, Jurchen and Williams, 2003b, Versluis et al.,
2001), and is thought to be the consequence of the unfolding of a subunit within a complex,
which increases the accessible chargeable surface area, resulting in the migration of charge to
maintain a uniform charge density (Benesch et al., 2007, Benesch et al., 2006, Wanasundara
and Thachuk, 2007a). The asymmetric dissociation of complexes can be avoided by either
manipulation of ion charge (Bornschein and Ruotolo, 2015), or by utilising other activation
methods, such as surface-induced-dissociation (SID) where complexes are dissociated by
colliding with an inert, or functionalised, surface which results in a predominantly symmetric
dissociation pathway (Beardsley et al., 2009).
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In combination with tandem mass spectrometry (multiple mass spectrometers operating in
sequence), single ion populations can be selected and subject to collisions with increasing
energy, resulting in both collision induced unfolding (CIU) and CID. The advent of IM-MS
has allowed for more in depth studies into CIU and CID, where researchers have been able to
monitor both unfolding and dissociation, linking them within a kinetic framework that
defines the gas-phase dynamics of protein complexes. Recently, CIU was used to investigate
the gas-phase unfolding of monomers composed of 1 to 4 ubiquitin domains, as well as
cytochrome C, glutathione S-transferase, green-fluorescent-protein, and γD-crystallin. It was
determined that the gas-phase unfolding of these proteins was highly correlated to the number
of specific domains within their structure if the charge state chosen for examination was
below the average charge state produced by ESI (Zhong et al., 2014). Furthermore, it has also
been determined that CIU can be effectively used in measuring protein stability in the
presence of ligands and small molecules (Allison et al., 2015, Rabuck et al., 2013) which is
an important metric when developing organic molecules for the stabilisation of proteins
involved in misfolding-related diseases.
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Figure 1.4: A typical IM-MS/MS workflow for CID and CIU. (A) Samples are ionised and
detected by the first MS (MS1) which is used to isolate an ion-population by its m/z value. The
selected ion population traverses the collision-cell where increasing collisions with an inert gas can
dissociate and unfold proteins. The dissociated and/or unfolded proteins then traverse the IM-cell
where they are separated based on their CCS, after which they are detected by a second mass
spectrometer (MS2). (B) A basic mass spectra acquired from an IM-MS/MS experiment where the
selected ion (green) decreases in intensity relative to the product ions generated from CID (red and
blue) as collisional energy is increased. (C) The CIU fingerprint heat-map of an isolated ion shows
that as collisional energy is raised, the ion shows increased drift times, which correlate to increased
surface area. i.e. the ion is unfolding.

1.6

Misfolded and Unfolded Proteins

An increasing number of neurodegenerative diseases, such as Alzheimer’s disease,
Huntingtin, Parkinson’s disease, and amyotrophic lateral sclerosis, are associated with the
misfolding, unfolding, and subsequent aggregation of disease specific proteins. The
intracellular environment is tightly regulated to decrease the chance of protein misfolding or
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unfolding (Dobson, 1999). However, cells can still be subjected to stresses such as
temperature, pH change, and increased levels of oxidants, that can alter the normal
physiological conditions within the cell. When the physiological conditions in the
intracellular environment change, the stabilizing forces of hydrophobic interactions and
hydrogen bonds can be disrupted, leading to unfolding or misfolding (Carver et al., 2003,
Ecroyd and Carver, 2008). Protein unfolding describes the loss of native conformation in an
already folded protein, whereas protein misfolding describes the process of a newly
synthesized protein folding inappropriately into a non-native conformation. Protein
misfolding can result from mistakes during translation, unwanted interaction with metal ions,
and commonly, mutations within the amino acid sequence (Bross et al., 1999, Fink, 1998).
Since the native conformation and its resulting free energy is determined primarily by the
primary structure of a protein, genetic mutations that result in changes to the amino acid
sequence have a marked effect on the correct folding of the protein (Chiti et al., 2002,
Gregersen et al., 2006). When specific residues are mutated, they can have substantial effects
on the entire protein, such as decreasing net charge and increasing the number of exposed
hydrophobic residues (Chiti and Dobson, 2006). Two possible outcomes can be described by
the energy landscape model of protein folding, one representing correct folding regardless of
mutation, and the other representing mutations that have produced interactions that lead to a
structure with a lower free energy state than that of the native conformation (Clark, 2004,
Gregersen et al., 2006). If these unfolded or misfolded proteins persist in a cell and evade or
overwhelm the protein quality control mechanisms, there is a high chance of protein
aggregates forming (Carver et al., 2003, Dobson, 1999, Muchowski and Wacker, 2005).
The list of proteins involved in misfolding and disease is extensive (Chiti and Dobson, 2006)
and interestingly there does not seem to be a common structural theme of these
amyloidogenic proteins, as they can inhabit primarily α-helical, β-sheet, and intrinsically
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disordered native-folds. Typically, natively folded proteins mask their hydrophobic residues
in their interior to minimise unwanted interactions, however, misfolded proteins may expose
these residues which invariably increases their aggregation propensity and propensity for
potentially cytotoxic interactions in cells (Goldschmidt et al., 2010). It has been suggested
that misfolded proteins may inhabit conformations that expose hydrophobic patches or
inhabit dynamic molten-globule states that maintain a semblance of secondary structure but
no defined tertiary structure, allowing them to easily take part in intermolecular interactions
(Jahn and Radford, 2008). Recent work, using the amyloidogenic β2-microglobulin protein
that is involved in dialysis-related amyloidosis, has shown that a stable, but transiently
populated, state is almost exclusively responsible for aggregation in an in vitro system, and
that murine β2-microglobulin cannot undergo transition into this state (Karamanos et al.,
2016). Collectively, the evidence appears to point in a direction where misfolded states are
able to not only increase their propensity for intermolecular interactions, but also interact
through specific transient structures that lead to pathogenic aggregation.

1.4 Protein Aggregation

Protein aggregation occurs due to the inappropriate interaction of exposed hydrophobic
residues on separate misfolded proteins and can lead to two structurally based outcomes;
(i) disordered and (ii) ordered aggregation (Carver et al., 2003). Disordered aggregation leads
to the formation of amorphous aggregates that, if not cleared by intercellular quality control
mechanisms, precipitate irreversibly when they reach a certain size (Ecroyd and Carver,
2008). Ordered aggregation leads to the formation of amyloid fibrils, which are filamentous
structures that are rich in β-sheet (Dobson, 1999). Characterisation of the structure and
formation of amyloid fibrils has been the focus of intense research as they are a key
pathological feature of many neurodegenerative diseases (Chiti and Dobson, 2006). Amyloid
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fibrils are generic in structure, even though they are usually composed of different proteins
that are often not related. The fibril is generally an unbranched structure 7-12 nm in diameter
and hundreds of nanometres in length (Chiti et al., 1999, Serpell, 2000, Sunde et al., 1997).
The structure is a combination of 2-6 protofilament strands which are twisted around one
another in a helical arrangement (Dobson, 2004, Serpell, 2000).

Protofilaments are

predominantly composed of β-sheets forming β-strands that are perpendicular to the axis of
the fibril, giving a twisted appearance (Serpell, 2000, Sunde et al., 1997). These fibrils are
highly stable and resistant to cellular degradation processes due to the large amount of
hydrogen bonding between the β-strands, and low solvent accessibility to the fibril core
(Dobson, 2004, Ecroyd and Carver, 2008, Sunde et al., 1997).
Results from studies using thioflavin T (which binds to the β-strand motifs in fibrils) have led
to the assertion that amyloid aggregation obeys Boltzmann-sigmoidal kinetics where there is
a lag-phase, exponential growth phase, and plateau (Fig. 1.5 A). The molecular events
occurring during these phases are a topic of great interest, as understanding them is essential
to resolving the specific cytotoxic species that are responsible for disease. The lag-phase is
suggested as encompassing the unfolding of proteins, and their subsequent polymerisation
into aggregate nuclei, which is termed ‘primary nucleation.’ Fragmentation of these nuclei is
suggested to increases the number of interface points for monomer scaffolding, essentially
feeding back into the process until enough fibrillar species are present for a detectable
increase in aggregate abundance, i.e., the beginning of the elongation phase (Fig. 1.5 B)
(Knowles et al., 2014). Fibril formation ensues rapidly during the elongation phase (Chiti and
Dobson, 2006), where the same processes determining the lag-phase are measurable due to
the exponential increase in their occurrence (Knowles et al., 2014). For most amyloid
diseases, as fibrils composed of specific proteins grow in length they are likely to fragment
which increases the number of available ‘ends’ for monomers to template, a process which is
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defined as ‘fragmentation-controlled’ (Xue et al., 2008, Buell et al., 2014), although this is
not the case for the classical amyloid-β protein which seems to nucleate and elongate in vitro
under quiescent conditions in comparison to other amyloid proteins (Tiiman et al., 2013).
An apparent consequence of amyloid formation, within cells, seems to be the tangling of
fibrils, forming plaques or protein deposits (Dobson, 2004, Ecroyd and Carver, 2008, Serpell,
2000). It is as of yet definitively determined whether the primary toxic species in in amyloid
diseases are small soluble oligomers or fibrils. Oligomers have been highlighted for their
soluble nature which allows them to diffuse freely within cells to increase the potential for
cytotoxic interactions (Kayed et al., 2003, Lesne et al., 2006, Shankar et al., 2008), whereas
fibrils have been suggested as causing toxicity through disruption of cellular membranes
(Gharibyan et al., 2007, Pieri et al., 2006, Meyer-Luehmann et al., 2008), where their
cytotoxicity is greatly enhanced via fragmentation (Xue et al., 2009).
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Figure 1.5: The kinetics and processes of fibrillar aggregation. (A) The typical Boltzmannsigmoidal kinetics observed for fibrillary aggregation in the presence of thioflavin T, where τlag is the
lag-phase duration, elongation is the exponential growth phase, plateau is the saturation of
thioflavin T binding. (B) A basic schematic of fibrillar aggregation where unfolded monomers
associate into aggregate nuclei via primary nucleation. Additional monomers polymerise onto the
nuclei to either form mature fibrils or fragment into more nuclei, feeding back into the process.

1.5 Disease is Associated with Protein Aggregation
The formation of protein rich plaques and deposits is a characteristic of neurodegenerative
disease, but whether the aggregates themselves are the cause of pathology is still debated. It
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is suggested that the early structures of the aggregation cascade, such as prefibrillar
oligomers, are the most cytotoxic, and as such, are responsible for the onset of the disease
(Bucciantini et al., 2002, Dobson, 2004, Stefani and Dobson, 2003). Recent work has
identified small Amyloid-β and α-synuclein oligomers as potential diagnostic biomarkers
correlated with Alzheimer’s disease and Parkinsonism respectively (Hansson et al., 2014,
Hölttä et al., 2013). A primary hypothesis is that the toxicity observed in protein misfolding
diseases is the result of newly formed aggregates interacting inappropriately with cellular
machinery (Stefani and Dobson, 2003); however, the precise mechanism of toxicity is
unknown. Potential mechanisms by which these aggregates could be toxic include, inhibition
of the correct functioning of cellular machinery via inappropriate reactions, or physical
disruption of the cellular environment (Stefani and Dobson, 2003).
There is a lack of correlation between the amount of deposited protein and the severity of
disease in the case of most neurodegenerative disorders. Whilst there is evidence suggesting
that the amount of pathological TAR DNA binding protein-43 (TDP-43) aggregates in
amyotrophic lateral sclerosis patients is correlated with disease severity, it is difficult to
determine if these larger visible aggregate structures are the causative agent. It is thought that
the lack of correlation for most neurodegenerative diseases may be explained by the toxicity
of the prefibrillar aggregates (Stefani and Dobson, 2003). This is supported by the
consequences of the structural differences between oligomer and mature fibril, such as the
dramatically lower stability of oligomers and their smaller size allowing for higher mobility
in cells and tissue. It has also been suggested that the formation of amyloid fibrils and protein
deposits acts to remove the toxic prefibrillar aggregates from the cellular environment
(Lansbury, 1999, Soto and Estrada, 2008). The toxic oligomer hypothesis has implications in
all protein deposition associated neurodegenerative disease, signifying the importance of
understanding the specific aggregation related interactions within certain diseases. The failure
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of protein quality control is implicated as a major factor in neurodegenerative disease
(Yerbury et al., 2016), however, specific diseases are usually associated with specific
aggregating proteins. Alzheimer’s disease is associated with deposition of Amyloid-β, and
primarily manifests as a substantial loss of neurons throughout the cerebral cortex, consistent
with the observed memory deficiency of sufferers (Petersen, 2012). In contrast, Parkinson’s
disease is associated with α-synuclein aggregation, and loss of neurons in the substantia
nigra, responsible for movement control and initiation, consistent with the loss of motor
control (Beitz, 2014). Indeed, the differences in pathology and aetiology between
neurodegenerative diseases suggest different molecular causes are responsible for each
disease, and that a breakdown of protein quality control, whilst perhaps important, is not a
root cause. Amyotrophic lateral sclerosis is a prime example of the difficulty in determining
the molecular culprit of disease as it is associated with mutations in a wide range of genes,
and most cases are sporadic in nature.

1.6 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease initially presents as
muscle weakness that progresses to severe muscle paralysis in the patient. The paralysis
typically occurs first in the distal limbs and spreads rapidly throughout the body for 1-5 years,
after which respiratory failure leads to death (Pasinelli and Brown, 2006). The disease affects
the large neurons in the spinal cord, cortex and brain stem responsible for motor control,
leading to a common reference to the disease as ‘motor neuron disease’. The degeneration of
both upper and lower motor neurons is a key characteristic of the disease, leading to atrophy
of skeletal muscle as a result of denervation (Mitchell and Borasio, 2007). This degeneration
is observed to begin at a focal point in the central nervous system, after which it spreads
throughout the 3D anatomy of the nervous system, consistent with the progressive nature of
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the disease (Ravits and La Spada, 2009). ALS is the most prevalent motor neuron disease, has
an average age of onset of around 50-60 years, and risk of development increases with age
(Andersen and Al-Chalabi, 2011b). Lifetime risk (~1:300 to 1:400) is the most appropriate
measure of ALS frequency within the population, as most sufferers die soon after diagnosis,
leading to a seemingly low prevalence (Andersen and Al-Chalabi, 2011b).
The majority of ALS cases are sporadic (sALS) with no discernible cause of pathology;
however, inclusions composed of ubiquitinated and phosphorylated TDP-43 (TAR DNA
binding protein) have been associated with most disease cases (Mackenzie, 2007).
Approximately 10% of ALS cases are familial (fALS), as they are linked to autosomal
dominant mutations in several genes (including SOD1, TDP-43, FUS, C9orf72 and OPTN).
Within the fALS group, 20% of cases can be linked to mutations in the gene encoding the
SOD1 protein (Bruijn et al., 2004, Valentine et al., 2005). It is believed that due to the
similarity of the disease profiles between sALS and fALS, study of the more well understood
fALS cases will yield insight into sporadic ALS as well (Pasinelli and Brown, 2006).
However, the relevance of SOD1-associated fALS to sALS has recently been questioned (Liu
etal. 2009; Kerman etal. 2010).

1.7 SOD1 Structure and Function
Previously known as erythrocuprein, SOD1 is an antioxidant protein that resides within the
cytosol. SOD1 catalyses the dismutation of superoxide free radicals and is one of the body’s
prime defences against reactive oxygen species (McCord and Fridovich, 1969, Pasinelli and
Brown, 2006). The SOD1 protein is a homodimer composed of two polypeptides folded as
eight-stranded Greek key β-barrels. Each monomer is 153 amino acid residues in length and
in its native conformation contains both a zinc and copper atom (Fig. 1.6) (Cleveland and
Rothstein, 2001). The metal-binding region is encased by two large loops which are
23

important for the protein’s function. The loops are called the electrostatic and zinc loops and
both contribute to the viability of the metal binding region, but also to stability (Hough et al.,
2004). Each SOD1 monomer also has an intra-subunit disulfide bond (Cys57 – Cys146) that
is important in the stability of the dimer and the monomeric subunits (Arnesano et al., 2004,
Furukawa et al., 2004).

Figure 1.6: Crystal structure of SOD1 in its native conformation. SOD1 exists as a homodimer of
two 16 kDa subunits that adopt a Greek key β-barrel conformation. The copper atom (blue sphere) is
primarily coordinated by the electrostatic loop (blue), and the zinc atom (orange sphere) is
coordinated by the zinc-loop (orange). An intramolecular disulfide between Cys57 and Cys146 links
loop-IV with β-strand-VIII (PDB accession: 1HL5 – (Strange et al., 2003)).

The SOD1 dimer was initially found to be 32 kDa in size and to contain 0.34% copper by
weight (Markowitz et al., 1959). The copper is essential for the activity of SOD1 in its
superoxide scavenging role, as its removal was revealed to abolish activity in early studies
(McCord and Fridovich, 1969). The copper atom is able to react with the superoxide radicals
and produce molecular oxygen or hydrogen peroxide via two reactions dependent upon Cu
oxidation state:
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1. O2- + CuIIZnSOD → O2 + CuIZnSOD
2. O2- + 2H+ + CuIZnSOD → H2O2 + CuIIZnSOD
The hydrogen peroxide is subsequently converted to H2O by glutathione peroxidase
(Cleveland and Rothstein, 2001). Studies have highlighted the importance of a helper protein
called the human copper chaperone for SOD1 (hCCS), which recognizes newly synthesised
SOD1 and activates it by installing the copper ion and catalysing the oxidation of the
disulfide bond in the SOD1 monomers (Brown et al., 2004, Culotta et al., 1997, Furukawa et
al., 2004).
The superoxide scavenged by SOD1 is primarily a by-product of the molecular processes
taking place in the mitochondrion, such as oxidative phosphorylation (Pasinelli and Brown,
2006).

Reactive oxygen species produced by oxidative phosphorylation can cause

irreversible damage to cell membranes, proteins and DNA (Stadtman et al., 1992), signifying
the importance of SOD1 in cellular homoeostasis. It was suggested that mutations in SOD1
were responsible for the onset of fALS due to an impaired or complete loss of enzymatic
activity, leading to an increase in reactive oxygen species (Olanow, 1993). However,
research carried out on purified SOD1 in vitro and also on transgenic mice, where knocking
out SOD1 did not cause ALS symptoms, has indicated that a loss of enzymatic function is
not the cause of fALS (Bowling et al., 1993, Reaume et al., 1996, Rosen et al., 1993) but
rather suggests it is caused by a toxic gain of function (Reaume et al., 1996).
Furthermore, an in vitro study determined the relative enzymatic activity of various SOD1
mutants and analysed this against the mutant variants clinical pathology (age of onset, rate of
progression). No correlation was found between the enzymatic activity of the mutants and
fALS pathology, further suggesting that gained toxic properties are the main factor behind its
association with ALS (Cleveland et al., 1995). Perhaps the most substantial evidence is that
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mutant variants with full enzymatic activity still cause fALS (Borchelt et al., 1994). The
hypothesis linking loss of SOD1 activity to ALS was dealt a further blow when researchers
attempted to increase dismutase activity by increasing the expression of SOD1WT in mutant
SOD1 expressing mice. The increase in dismutase activity was found to have no effect upon
the progression of fALS (Bruijn et al., 1998) and one study found that an increase in human
SOD1WT expression accelerated the disease in mice (Jaarsma et al., 2008). In addition to this,
overexpression of SOD1 with mutated Cu-coordinating residues resulted in an aggressive
ALS phenotype in mice (Wang et al., 2003). Given that a loss of function in SOD1 activity is
not associated with ALS, research has focused upon the mutant variants and their possible
gain in toxic properties as a result of structural instability and aggregation.

1.8 SOD1 Stability
SOD1WT has been described as an incredibly stable protein in its fully metallated (two copper
and two zinc atoms), disulfide oxidised, and dimeric form (Valentine et al., 2005). Both
human and bovine SOD1WT proteins have exceedingly high thermodynamic stability, and are
resistant to proteolytic digestion with trypsin and aminopeptidase (Rodriguez et al., 2002,
Senoo et al., 1988). The remarkable stability of SOD1 is further demonstrated by its ability to
maintain its native conformation in concentrations of guanidine HCl as high as 3.2 M, as
measured by circular dichroism and tryptophan fluorescence spectroscopy (Mei et al., 1992,
Rumfeldt et al., 2006). Lindberg and colleagues argue that using measurements of stability of
the disulphide bonded holo-state are not valid owing to the unfolding process of this SOD1
form not being complete, and also show that the greatest effect of mutation on stability is
observed for the reduced apo-state. (Lindberg et al., 2002). Apart from the disulfide bond,
SOD1 is stabilised by a number of hydrogen bonds throughout the macromolecule.
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This exceptional stability is highly dependent upon the binding of the metal ions to the
protein, as the wild-type SOD1 apo-protein has a melting temperature of 52 ºC (Valentine et
al., 2005). Additional destabilisation is caused by the reduction of the intramolecular
disulfide, decreasing the melting temperature further to ~43 ºC and also effectively halving
the kinetic stability, as measured by guanidine HCL unfolding (Lindberg et al., 2002). The
relative importance of each metal ligand, with respect to stability is debatable, however, it is
clear from unfolding studies that both contribute significantly to stability (Kayatekin et al.,
2008, Lynch and Colón, 2006). The dependence of SOD1 stability on the coordination of the
metal ions indicates that mutations affecting the metal binding affinity of the protein would
have substantial effects upon stability. With a large number of mutations in SOD1 being
associated with fALS it is important to assess whether they affect the metal ion affinity of the
protein or not.

1.9 Mutations in SOD1
Over 183 different mutations in SOD1 have been identified and associated with fALS
(http://alsod.iop.kcl.ac.uk (Abel et al., 2013b) (see Fig. 1.7). Most of these mutations have
been identified as missense mutations, although deletions and truncations have also been
found. The mutations are not concentrated to specific regions of SOD1, but rather are spread
throughout the amino acid sequence, and all are able to alter the structure to varying degrees
(Cleveland and Rothstein, 2001) (Fig. 1.7). The mutations have been found to have diverse
effects upon the physical properties of the SOD1 protein, making it difficult to identify a
singular cause of toxicity. Effects can include a decrease or increase in thermostability
(Rodriguez et al., 2005, Shaw and Valentine, 2007), a lowering of affinity for copper and zinc
ions (Valentine et al., 2005), or inhibition of the intramolecular disulfide bond between
Cys57 and Cys146 (Hayward et al., 2002). SOD1 mutant variants that lose affinity for copper
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or zinc, or lose the intramolecular disulfide bond between Cys57 and Cys146, have been
found to have a lower conformational stability than SOD1WT, making them more prone to
aggregation (Arnesano et al., 2004, Valentine et al., 2005). The fALS mutant variants of
SOD1 have been separated into two classes based on biophysical studies of SOD1 activity,
metal content, and spectroscopic characteristics (Hayward et al., 2002, Tiwari and Hayward,
2003, Valentine and Hart, 2003). These classes are designated metal-binding region (MBR)
and wild-type-like (WTL) fALS mutant SOD1 proteins.

Figure 1.7: SOD1 monomer with ALS-associated point mutations. (A) Frequency of point
mutations across the SOD1 amino acid sequence. (B) Point mutations (red spheres) associated with
ALS are noted throughout the structure of SOD1 (PDB accession: 1HL5 – (Strange et al., 2003)).
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1.10 Metal Binding Region and Wild-Type Like SOD1 Mutants
The MBR class of SOD1 mutants are defined by mutations localized to the metal-binding
sites of the protein including the surrounding electrostatic and zinc loops. MBR mutations
have diverse effects upon the protein structure and activity. This is due to the direct
disruption of the metal coordinating amino acids that bind either zinc or copper, alteration of
the overall metal-binding affinity, or a substantial destabilization of the structure around the
metal-binding region (Valentine et al., 2005).
SOD1H46R has been studied in vitro where it was found that the native zinc binding site of the
protein is able to bind copper or zinc, but the native copper site no longer binds metal ions
(Liu et al., 2000). Studies involving transgenic rodents have been carried out with rats
expressing H46R (Nagai et al., 2001) and mice expressing a H46R/H48Q double mutation
(Wang et al., 2002). In both studies the rodents developed ALS-like symptoms, but the
disease progression was not as aggressive for SOD1H46R as it was for the SOD1 double
mutant. Indeed, in humans the SOD1H46R mutation results in ALS that has an average disease
progression of 17 years after diagnosis, much longer than other mutants, even those that are
WTL (Wang et al., 2008). This may be related to the curious observation that the H46R
substitution increases the stability of the disulfide reduced apo-state compared to SOD1WT,
indicating that destabilisation of this state may be linked to SOD1 pathogenesis (Rodriguez et
al., 2005). In contrast to the MBR mutants, WTL mutants are associated with correct metal
coordination and near SOD1WT activities, but can still contribute to disease.
The WTL mutant SOD1 variants have been researched in depth owing to the fact that even
though they still retain activity and stability similar to SOD1WT, they are implicated in fALS
cases. The thermostability of various WTL SOD1 mutants was assessed by comparing the
melting temperatures of mutant SOD1 to that of the wild-type (SOD1WT), with a report of a
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1-6°C drop in melting temperature across the mutants (Rodriguez et al., 2002). In addition,
the enzymatic activity of various WTL SOD1 mutants was compared to SOD1WT where the
results showed little distinction between the two (Lindberg et al., 2002). For example, a
biologically metallated SOD1A4V mutant isolated from both yeast (Goto et al., 2000) and
insect cells (Hayward et al., 2002) was shown to be appropriately metallated in addition to
having full enzymatic activity on a per copper basis. This combination of a relatively high
stability and little to no loss of enzymatic activity amongst the WTL SOD1 mutants makes a
cause of toxicity difficult to identify, at least in regards to natively folded SOD1 variants and
suggests, in conjunction with analysis of post-mortem tissue, that an off-folding pathway
leading to aggregation may play a role.
The high stability of SOD1 would infer that its aggregation propensity would be low,
however, SOD1 is associated with aggregates in motor neurons in ALS post-mortem tissue
(Forsberg et al., 2010). Several reasons have been suggested for the aggregation of SOD1,
including mutation or oxidative damage increasing the exposure of hydrophobic surfaces
(Munch and Bertolotti, 2010), and a destabilization of the dimer interface which increases the
propensity of dimer dissociation (Khare et al., 2006). Structural changes to SOD1 observed in
WTL mutants are not as substantial as the changes observed in MBR mutants, which should
suggest a lower propensity of WTL mutants to aggregate. This is not the case, however, as
both theoretical (Wang et al., 2008) and empirical studies (Prucendio et al., 2009) have
determined that aggregation propensity does not correlate to whether the mutant is MBR or
WTL.

1.11 SOD1 Aggregation
Electron microscopy imaging of protein inclusions harvested from ALS patients revealed that
they are distinct from amyloid, having an amorphous or granular structure (Kato et al., 2000)
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that does not stain with Congo red, and stains relatively weakly with Thioflavin S (Kerman et
al., 2010). However, recent research has suggested that although in vivo SOD1 deposits
appear to be amorphous by staining, at a molecular level there is a repetitive structure, as
determined by sequence level analysis using conformation specific antibodies in SOD1
transgenic mice (Bergh et al., 2015, Lang et al., 2015), and addition of SOD1G93A mouse
spinal cord homogenate to an in vitro aggregation assay showing a seeding effect (Chia et al.,
2010). If these structural elements exist in motor neurons from human SOD1-associated
fALS patients remains to be determined.
Although mutations in SOD1 are known to increase the aggregation propensity of the protein,
spontaneous aggregation of a fully metallated disulfide bonded ALS associated SOD1 variant
is yet to be observed. Initially, research into SOD1 aggregation utilised high temperatures,
extreme pH conditions, and organic solvents to induce aggregate assembly (Banci et al.,
2008, DiDonato et al., 2003, Stathopulos et al., 2003), conditions with little relevance to the
intracellular environment. Due to this, most modern SOD1 in vitro aggregation protocols rely
upon destabilising SOD1 via reduction of the disulfide and chelation of the metals, which are
events more likely to occur in the reducing chelating intracellular environment, as well as
agitation to increase the number of molecular contact events and therefore speed up the
process (Abdolvahabi et al., 2016, Chan et al., 2013, Chattopadhyay et al., 2008, Furukawa et
al., 2008, Roberts et al., 2013). Together this suggests that the immature form of SOD1,
without the stabilising post-translational modifications, may be a major vulnerable species
prone to aggregation and a primary template for SOD1 seeded aggregation. In the context of
typical amyloid aggregation kinetics (discussed in section 1.7), generally speaking SOD1
aggregation appears to follow amyloid like kinetics, although recent work has shown that the
formation of structured or unstructured aggregates is an entirely stochastic process dependent
upon the initial formation of primary aggregate nuclei (Abdolvahabi et al., 2016).
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1.12 Oxidatively induced damage and modification of SOD1
That SOD1 aggregates are found in both sALS and non-SOD1 associated fALS cases
(Forsberg et al., 2010), indicates that mutation is not necessary for SOD1 aggregation to
proceed. Furthermore, the use of novel antibodies raised against epitopes of misfolded
(protein that has folded into a non-native conformation) SOD1 has shown that misfolded
SOD1 can be found in sALS patients and fALS patients, and that overexpression of fALS
associated proteins such as TDP-43 and FUS in human neurons can induce SOD1 misfolding
(Bosco et al., 2010, Pokrishevsky et al., 2012b). Interestingly, the processes of misfolding
and aggregation appear to be specific to brain and spinal cord motor neurons (Rakhit et al.,
2007), even though SOD1 is ubiquitously expressed at high concentrations (Pardo et al.,
1995). One of the most studied factors that may be responsible for this is oxidative damage ,
which is thought to be associated with many neurodegenerative diseases, including ALS
(Jellinger, 2010). Oxidative stress is thought to play a role in many diseases, as a primary
cause, and also a contributing factor (Kennaway et al., 2005). Reactive oxygen species have
the capability to damage or modify proteins irreversibly, leading to changes in structure
and/or function (Sobott et al., 2002, Banci et al., 2014). A single point mutation is capable of
severely destabilising the structure of SOD1, and therefore oxidative damage may have the
potential to produce similar changes in structure. SOD1 is a prime target for oxidative
damage and modification due to its role of scavenging superoxide and catalysing the reaction
to transform it to hydrogen peroxide. Studies have shown that SOD1 can be oxidatively
damaged through reactions with hydrogen peroxide (McAlary et al., 2013b), hypochlorite
(Pokrishevsky et al., 2012b), peroxynitrite (McAlary et al., 2013a), bicarbonate (Coelho et
al., 2014), or fatty acid derived hydroperoxides (Appolinário et al., 2015) all of which can
potentially occur in vivo. SOD1 purified from human erythrocytes has been shown to be
oxidatively modified at the solvent exposed residue Cys111 to sulfonyl cysteine (C-SO2H)
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and sulfinyl cysteine (C-SO3H) (Fujiwara et al., 2007), modifications possible from reactions
with either superoxide anion or hydrogen peroxide (Forsberg et al., 2010), and identified on
SOD1 extracted from human post-mortem neural tissue (Auclair et al., 2014). Indeed,
SOD1WT at physiological concentration has been reported to misfold and aggregate in vitro
when oxidatively damaged potentially exposing hydrophobic regions responsible for toxicity
(Rakhit et al., 2004). Furthermore, oxidative damage may explain the selective neurotoxicity
of SOD1 in motor neurons as these cells are long lived, and where endogenous SOD1 may
persist for up to hundreds of days due to the slow transport from cell body to axon (Rakhit et
al., 2002). SOD1 having a long half-life in highly metabolically active motor neurons (Shaw
and Eggett, 2000) would strongly suggest that oxidative damage may be a factor in SOD1
associated ALS, as the protein would be more likely to accrue oxidative damage throughout
its long lifetime, leading to misfolding.
There is also evidence to suggest the protection of SOD1 from oxidative damage, by the
covalent binding of low molecular weight antioxidants, can contribute to SOD1 misfolding.
SOD1 purified from human erythrocytes has been found to be glutathionylated at Cys111
(Wilcox et al., 2009). Cys111 is close to the dimer interface of SOD1, and it has been shown
that non-covalent binding of either glutathione or cysteine to this residue can reduce the
stability of the SOD1 dimer leading to an increased population of monomers (Auclair et al.,
2013a, McAlary et al., 2013a, Redler et al., 2011). Glutathione is a tripeptide that protects
proteins from permanent oxidative damage by reversibly binding to free cysteine residues
(Townsend, 2007). It exists within cells primarily in its reduced form (GSH) at
concentrations of 1-10 millimolar (dependent upon tissue type) and is the major low
molecular weight antioxidant within the cellular environment (Schafer and Buettner, 2001).
Covalent binding of cysteine to Cys111 has been observed to occur on human SOD1 in
neural tissue extracted from both ALS patients and transgenic mice (Auclair et al., 2013b).
33

There is, as of yet, no evidence that SOD1 becomes glutathionylated in neural tissue, but
recent in vitro work performed on purified glutathionylated SOD1 showed that this
modification increased the reactivity of a disease associated epitope specific antibody (C4F6)
to SOD1 (Redler et al., 2014), suggesting that this modification, or other modifications
localised to Cys111 potentially contribute to SOD1 misfolding.

1.13 Prion-like properties of SOD1
Whilst it is possible that an increase in oxidative damage over time, or the presence of a
mutation or modification, may cause SOD1 to misfold into a toxic species, one might expect
these to consistently effect SOD1 throughout life, yet onset of ALS is typically 50-60 years of
age (Andersen and Al-Chalabi, 2011a). This infers either a sudden appearance of a
neurotoxic species or a decline in the ability of cells to process a consistently forming
neurotoxic species. The evidence for deposited protein observed in ALS patients, implicates a
decrease in the cellular proteostasis capacity of motor neurons; i.e. mutant SOD1 is
constantly expressed but the proteostasis machinery of the cell is acting to facilitate proper
folding, as well as degrade and clear misfolded and aggregated species of SOD1. However, a
decrease in proteostasis capacity does not sufficiently explain ordered spatiotemporal
progression of ALS pathology observed in patients. Recent work has suggested that
misfolded SOD1 may act similarly to prion protein (Ayers et al., 2014a, Bergh et al., 2015,
Grad and Cashman, 2014, Munch et al., 2011), Prion protein (PrP) is known to inhabit two
conformations; a benign physiological conformation (PrPc), and a disease-associated
conformation (PrPsc) that readily aggregates (Málaga-Trillo and Sempou, 2009). The PrPsc
form can recruit benign PrP and convert it to the disease-associated conformation (Riesner,
2003). Expression of the truncation mutant SOD1G127X and aggressive SOD1G85R mutant in
human neural cells has been shown to induce the misfolding of endogenous human SOD1WT

34

(Grad et al., 2011). Furthermore, this misfolded SOD1 can propagate intercellularly, similar
to PrP associated disease (Grad and Cashman, 2014), providing a potential explanation for
the ordered degeneration of motor neurons in SOD1 associated fALS.
A discrepancy still persists in relation to the curious differences in patient survival, where
particular fALS associated SOD1 mutants have a rapid disease progression and others don’t
(Wang et al., 2008). This has prompted a hypothesis by which different SOD1 mutations can
influence misfolding and/or aggregation, to result in variable structures that have different
propagation kinetics, and are correlated with differential survival times (Bergh et al., 2015,
Bidhendi et al., 2016). Indeed, the standard models of SOD1 associated fALS are mice
overexpressing SOD1G93A, SOD1G37R, or SOD1G85R, and it has been shown that injection of
spinal cord homogenate from SOD1G93A mice into the sciatic nerve of ALS inducible
SOD1G85R-YFP (yellow fluorescent protein) mice, produces an ALS pathology and
phenotype (Ayers et al., 2014a). However, injection of homogenate from SOD1G37R mice
does not induce an ALS pathology or phenotype, even though SOD1 G37R transgenic mice
develop the disease (Ayers et al., 2014a). Altogether, this supports the idea that separate
strains of misfolded or aggregated SOD1 can propagate intercellularly, and that different
misfolded or aggregate forms may dictate survival time (and potentially onset), making
identifying a therapeutic specific to SOD1-associated ALS a challenge.

1.14 Tryptophan-32 is implicated in SOD1-associated ALS
A striking observation in murine-based models of SOD1 misfolding and aggregation is that
endogenous murine SOD1 (mSOD1) does not co-aggregate with human SOD1 (hSOD1), or
react with misfolded SOD1 specific antibodies (Bergh et al., 2015, Grad et al., 2011). The
sequence identity of hSOD1 and mSOD1 is relatively high (83.3%), however, a region
corresponding to loop II and β-barrel III has a comparatively greater concentration of non35

conserved residues than the rest of the protein, and within this region is tryptophan-32 of
hSOD1 (Serine-32 in mSOD1) (Grad et al., 2011). Tryptophan is regarded as the amino acid
with the highest propensity to aggregate (Pawar et al., 2005), and indeed mutation of this
residue to a serine in SOD1 has been shown to reduce the binding affinity of misfolding
specific antibodies after passaging misfolded forms successively, thus blocking
intermolecular transmission (Grad et al., 2011). Trp32 is also identified as a site of oxidative
modification in hSOD1 extracted from human and mouse blood samples (Taylor et al., 2007),
further implying that oxidative damage may play a role in SOD1 associated ALS
pathogenesis. Mutation of this residue to a phenylalanine on a SOD1 G93A backbone was
shown to decrease the aggregation potential of SOD1 in cultured cells (Taylor et al., 2007).
The combination of Trp32 and oxidative damage strongly suggests that this residue may be
the common toxicity modulating feature across all SOD1 associated ALS cases, however
further study is necessary to determine if this is the case.

1.15 Aims and Objectives
Over 180 mutations in SOD1 are associated with fALS and the combined research into this is
extensive, yet the cause of toxicity and its determining factors are still unknown. It is clear
that protein aggregation is a hallmark of ALS and there is potential for SOD1 misfolding or
aggregation to be a common feature of all ALS cases, marking the cause of these processes as
a therapeutic target. Research into SOD1 stability has focused on metalation state and
disulfide status, owing to them imparting an exceptional stability to the native conformation.
However, there are still gaps in knowledge pertaining to the effect of mutation on these
features and subsequent aggregation in the context of mutation specific patient survival, and
the common identified aggregation modulating feature W32. Therefore, the subsequent work
detailed within this thesis investigates:
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The gas-phase directed dissociation and unfolding of fALS associated SOD1 variants



The effect of glutathionylation on the dimer dissociation of fALS associated SOD1
variants



The structural consequences of disulfide reduction and metal chelation, as well as
their relationship with aggregation of fALS associated SOD1 variants



The effect of a W32S substitution on the aggregation of fALS associated SOD1
variants
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2. General Materials and Methods
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2.1 General Materials
Details of general buffer compositions are listed in Appendix A

2.2 Bacterial culture methods
2.2.1 Basic Escherichia coli culture
Escherichia coli (E. coli) containing plasmid DNA for DNA purification (E. coli DH5α) or
protein expression (E. coli Bl21(DE3)) were grown on Luria-Bertani (LB)-agar plates
containing either 100 µg/mL ampicillin, or 50 µg/mL kanamycin, overnight at 37 °C. Liquid
E. coli cultures were grown using a single colony from LB-agar plates in LB media
containing either 100 µg/mL ampicillin or 50 µg/mL kanamycin, overnight with shaking at
180 rpm at 37 °C.

2.3 Plasmid DNA purification
2.3.1 Plasmid extraction and purification for bacterial expression
Plasmid DNA for bacterial expression was extracted and purified using the GeneJET Plasmid
Miniprep Kit (ThermoFisher Scientific, USA). Bacterial cultures were grown, as stated in
2.2.1, in 10 mL of LB media. Cells were pelleted via centrifugation (6 200 × g, 10 min) and
resuspended in 250 µL of the resuspension solution (with added RNase A) and transferred to
a microfuge tube. After cells were resuspended, 250 µL of lysis solution was added and the
cells mixed by inverting the tube four times. Cell lysis was typically achieved in 4 min, after
which 350 µL of neutralization solution was added and mixed by inverting the tube 4 times.
Immediately after mixing, the cell debris and chromosomal DNA was pelleted via
centrifugation (16 000 × g, 10 min) and supernatants were transferred to the supplied
GeneJET spin columns and centrifuged (8 000 × g, 1 min). Spin columns with bound plasmid
DNA were washed twice with 500 µL of wash solution via centrifugation (8 000 x g, 1 min).
Elution of the plasmid DNA was achieved by adding 50 µL of elution buffer to the spin
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column and incubating at

room temperature for

2 min before centrifugation

(8 000 × g, 1 min) into a sterile microfuge tube.

2.3.2 Plasmid extraction and purification for mammalian expression
Plasmid DNA for mammalian expression was extracted a purified using the CompactPrep®
Maxi Plasmid Kit (Qiagen, Germany) using the manufacturer’s instructions and buffers (all
buffers for this section were supplied by the manufacturer). Briefly, bacterial cultures were
grown, as stated in 2.2.1, in 100 mL of LB media. Cells were pelleted via centrifugation
(6 200 x g, 10 min) and resuspended in 5 mL of buffer P1. After cells were resuspended,
5 mL of buffer P2 was added and cells were mixed thoroughly by inverting the tube 6 times,
following which cells were incubated for 3 min at room temperature. After incubation, 5 mL
of buffer S3 was added to the cell lysate, which was mixed immediately by inverting the tube
6 times, and centrifuged (20 000 × g, 30 min at 4 °C). Following centrifugation, the
supernatant was transferred to clean tubes and centrifuged again (20 000 × g, 15 min at 4 °C).
Following this, 5 mL of buffer BB was added to the supernatant and mixed via inverting
tubes 6 times. Supernatants were transferred to the supplied CompactPrep columns with
attached tube extenders and supernatant was passed through the columns via gravity flow.
Following this, 700 µL of buffer PE was added to the columns and they were centrifuged
(8 000 × g, 1 min), the flow through was discarded, and the columns centrifuged again
(8 000 × g, 1 min). Plasmid DNA was eluted by addition of 200 µL of buffer EB to the
columns, which were incubated for 1 min, followed by centrifugation (8 000 × g, 1 min) into
sterile microfuge tubes.
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Table 2.1: Plasmid constructs used throughout this project. Plasmid constructs are separated into
‘bacterial expression’ and ‘mammalian’ expression vectors, and further separated by the final amino
acid residue substitutions made to SOD1, and fluorescent tag. Sources of plasmids are listed with
corresponding references. Those noted as “commercial” were designed in-house and generated using
commercial services with sequencing to confirm correct mutation. Bacterial expression proteins were
also analysed by mass spectrometry to confirm correct mutation.

Bacterial expression vector
pACA forward yCCS hSOD1

Contains genes for the expression of both yeast CCS and human SOD1
under a lac operon. The antibiotic resistance is Ampr.

Variants used in study
SOD1-Wild type
SOD1-A4V
SOD1-G37R
SOD1-H46R
SOD1-G85R
SOD1-D90A
SOD1-G93A
SOD1-E100G
SOD1-I112T
SOD1-A140G
SOD1-V148G
SOD1-W32S
SOD1-G93A-W32S
SOD1-V148G-W32S

Source
Oliveberg group (Stockholm,
Sweden)
In-house
In-house
In-house
In-house
In-house
Oliveberg group (Stockholm,
Sweden)
In-house
In-house
In-house
In-house
In-house
In-house
In-house

Reference
(Lindberg et al., 2002)
(Lindberg et al., 2002)
-

Mammalian expression vector
pEGFP-N1

Contains multiple cloning site prior to the EGFP gene which has been
modified for mammalian expression. The antibiotic resistance is Kmr.

Variants used in study

Source

EGFP(vector)
SOD1-Wild type-GFP
SOD1-Wild type-tdTomato
SOD1-A4V-GFP
SOD1-A4V-tdTomato
SOD1-G37R-GFP
SOD1-H46R-GFP
SOD1-G85R-GFP
SOD1-G85R-tdTomato
SOD1-D90A-GFP
SOD1-G93A-GFP
SOD1-G93A-tdTomato
SOD1-V148G-GFP
SOD1-V148G-tdTomato
SOD1-W32S-GFP
SOD1-A4V-W32S-GFP
SOD1-G85R-W32S-GFP
SOD1-G93A-W32S-GFP
SOD1-V148G-W32S-GFP

Clontech, USA
Turner group (Melbourne,
Australia)
In-house
In-house
In-house
In-house
Hatters group (Melbourne,
Australia)
Hatters group (Melbourne,
Australia)
In-house
In-house
Turner group (Melbourne,
Australia)
In-house
In-house
In-house
In-house
In-house
In-house
In-house
In-house

Reference
(Turner et al., 2005)
(Turner et al., 2005)
Unpublished
Unpublished
(Turner et al., 2005)
-
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2.4 Generation and transformation of expression stocks
2.4.1 Preparation of electro-competent E.coli
Single colonies of E. coli grown on an LB-agar plate with no antibiotics were used to
inoculate 10 mL of LB media and grown overnight as described in 2.2.1. The overnight
cultures were used to inoculate 1 L of LB media which was grown at 37 °C with shaking at
180 rpm until an optical density (OD600) 1.0 was reached. The cells were pelleted via
centrifugation (6 200 × g, 10 min) kept at 4 °C for the rest of the protocol. The cell pellet was
resuspended in 80 mL of ice cold sterile dH2O and pelleted again via centrifuge
(6 200 × g, 10 min), this was repeated twice. Cell pellets were then resuspended in 80 mL of
ice cold 10% glycerol and pelleted again as before. Following the final wash, the cells were
resuspended in 2 mL of ice cold 10% glycerol (v/v) and snap frozen in liquid nitrogen for
storage at -80 °C.

2.4.2 Preparation of chemically-competent E.coli
Single colonies of E. coli grown on an LB-agar plate with no antibiotics were used to
inoculate 10 mL of LB media and grown overnight as described in 2.2.1. The overnight
cultures were used to inoculate 1 L of LB media which was grown at 37 °C with shaking at
180 rpm until an optical density (OD600) 0.35 was reached, after which the cells were
immediately incubated in an ice water bath. From this point all materials and buffers were
chilled on ice. Cells were harvested by centrifugation (6 200 × g, 10 min at 4 °C), following
which they were resuspended and washed in 400 mL of sterile ice cold 100 mM MgCl2. The
washed cells were pelleted via centrifugation (3 000 × g, 10 min at 4 °C), followed by
resuspension and washing in 200 mL of sterile ice cold 100 mM CaCl2. The recently washed
cells were incubated for 20 min on ice, after which they were harvested via centrifugation
(3 000 × g, 10 min at 4 °C) and the pellet resuspended in 50 mL sterile ice cold 85 mM CaCl2
15%

glycerol

(v/v).

Resuspended

cells

were

harvest

via

centrifugation
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(1 000 × g, 15 min at 4 °C), resuspended in 2 mL of sterile ice cold 85 mM CaCl2
15% glycerol (v/v), aliquoted, and snap frozen in liquid nitrogen for storage at -80 °C.

2.4.3 Transformation of electro-competent E. coli
Electro-competent E.coli were transformed using a Bio-Rad Gene Pulser electroporator (BioRad, USA) according to the manufacturer’s instructions. Transformation mixtures consisted
of 50 ng of plasmid DNA in 50 µL of competent cells (DH5α or BL21(DE3) cells) in an ice
cold electroporation cuvette. The electroporator was set to 2.5 kV, 25 µ FD, and 200 Ω. After
electroporation, cells were transferred to 500 µL of LB media and incubated for 1 h at 37 °C
with shaking at 180 rpm. Aliquots of 100 µL and 300 µL were spread onto LB-agar plates
containing the appropriate antibiotics and incubated overnight at 37 °C.

2.4.4 Transformation of chemically-competent E. coli
Chemically-competent E.coli stocks were defrosted on ice and 50 ng of plasmid DNA was
added and gently mixed, following which cells were incubated on ice for 30 min. Cells were
then subject heat-shock (42 °C) for 45 sec and immediately placed onto ice for 5 min. After
the ice incubation, cells were diluted to 500 µL with LB media and incubated for 1 h at 37 °C
with shaking at 180 rpm. Aliquots of 100 µL and 300 µL were spread onto LB-agar plates
containing the appropriate antibiotics and incubated overnight at 37 °C.

2.4.5 Generation of glycerol stocks of transformed cells
Single colony of transformed E.coli was picked from plates and grown overnight in 10 mL of
LB media containing the appropriate antibiotic resistance as stated in 2.2.1. Overnight
cultures were used to inoculate (1/100 dilution v/v) 10 mL of LB media containing
appropriate antibiotics and the OD600 monitored until 0.5. Once at OD600 0.5, 750 µL of
bacterial suspension was mixed with 750 µL of sterile 40% glycerol (v/v) 2% casamino
acids (w/v) in a cryovial. Cryovials were snap frozen in liquid nitrogen and stored at -80 °C.
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2.5 SOD1 bacterial expression and purification
2.5.1 SOD1 bacterial expression
The basis for the protocols describing SOD1 expression and purification have been
previously published (Lindberg et al., 2002). For the purpose of generating destabilised
mutants, modifications were made to the protocol. Initial 20 mL LB media starter cultures
containing appropriate antibiotics were inoculated with a single colony of transformed pACA
forward yCCS hSOD1 BL21(DE3) E.coli and grown overnight at 37 °C with shaking at 180
rpm. Each 20 mL overnight starter culture was used to inoculate 1 L of main culture (2x LB)
with carbenicillin (Cb) added to a final concentration of 100 µg/mL. Main cultures were
grown at 37 °C with shaking at 180 rpm until an OD600 of 0.5 was reached. In the case of
mutant variants SOD1A4V, SOD1G85R and SOD1G85R-W32S, main cultures were grown until an
OD600 of 0.25, after which they were moved to 18 °C until they reached an OD600 of 0.5. At
OD600 0.5 isopropyl β-D-1thiogalactopyranoside (IPTG), CuSO4, and ZnSO4 were added to
final concentrations of 0.5 mM, 3 mM, and 40 µM respectively, as well as the addition of
further Cb to a final concentration of 150 µg/mL. After induction, cultures incubated at 18 °C
with shaking overnight. Following overnight expression, bacterium were harvested via
centrifugation (6 200 × g, 10 min at 4 °C) and resuspended in ice cold 50 mM Tris-base
(pH 7.4) (25 mL per litre of main culture). Samples were lysed by applying the bacterial cell
suspension 2 times to an Avestin EmulsiFlex-C5-Homogeniser (ATA Scientific, Australia) at
120 000 kPa. Cellular debris was removed from the lysate via centrifugation
(40 000 × g, 20 min at 4 °C). The cleared lysate was then subject to heat denaturation by
incubation in a water bath at either 65 °C (Wild type), 60 °C (Mutants), or 55° C (SOD1 A4V,
SOD1G85R).

Precipitate

was

cleared

from

the

lysate

via

centrifugation

(40 000 × g, 20 min at 4 °C). At this point mutants SOD1A4V and SOD1G85R, were
concentrated using a stirred filtration cell (Millipore, USA) with Ultracel® 10 kDa
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ultrafiltration disc membranes to a volume of approximately 15 mL after which they were
subject to size exclusion gel-filtration chromatography (see section 2.5.2 below). Other SOD1
mutant preparations had their volumes measured and (NH4)2SO4 was added stepwise with
mild stirring at 4 °C until a final concentration of 60% (w/v) was reached, after which the
samples were incubated for 2 h at 4 °C with constant stirring. Following incubation,
precipitated protein was cleared via centrifugation (40 000 × g, 20 min at 4 °C) and
(NH4)2SO4 was added to a final concentration of 90% (w/v) and samples were incubated
overnight at 4 °C with stirring. Following overnight incubation, the precipitated protein
fraction containing SOD1 was harvested via centrifugation (40 000 × g, 20 min at 4 °C) and
the pellets were rinsed with dH2O and resuspended in 2 mL of 50 mM Tris-base 150 mM
NaCl (pH 7.4) per 1 L of main culture. Resuspended pellets were filtered through a 0.22 µm
filter and either immediately subject to gel-filtration chromatography (see section 2.5.2
below) or snap frozen in liquid nitrogen for subsequent purification.

2.5.2 SOD1 purification via gel-filtration and ion-exchange chromatography
SOD1 samples that were (NH4)2SO4 precipitated, or filtrator concentrated, were injected onto
a Hiload 16/600 Superdex™-75 prep-grade column equilibrated in 50 mM Tris-base 500 mM
NaCl (pH 7.4) at volumes no more than 4% total column volume (120 mL). The protein was
eluted at a flowrate of 1 mL/min and collected in fractions of 1 mL volume. Fractions
containing SOD1 were determined by SDS-PAGE (see section 2.5.3 below) and pooled. The
pooled eluent was transferred to Snakeskin® pleated dialysis tubing (3 500 MWCO)
(ThermoFisher Scientific, USA) and dialysed at 4 °C with stirring into 20 mM Tris-base
(pH 8.0). The dialysed sample was then loaded onto a HiPrep™ DEAE FF 16/10 anionexchange column equilibrated in 20 mM Tris-base (pH 8.0). After the protein was loaded, the
column was washed with two column volumes of 20 mM Tris-base (pH 8.0) and the protein
eluted with a gradient from 0-200 mM NaCl across 240 mL at a flow rate of 2 mL/min.
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Fractions containing pure SOD1 were determined by SDS-PAGE (see section 2.5.3 below),
concentrated using Vivaspin™ 20 centrifugal concentrators (10 000 MWCO), and frozen at 20 °C in aliquots for later use. Impure fractions were pooled and frozen at -20 °C for further
purification via use of the above methods.

2.5.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SDS-PAGE analysis was used routinely to analyse and confirm protein expression and
purification. Resolving gel components were generated by pouring Acrylamide gel mixtures
ranging from 7-12% acrylamide (v/v) into a MINI PROTEAN® system (Bio-Rad, USA) and
overlaying with 70% ethanol. Resolving gels were allowed to set for 30 min, after which the
overlayed 70% ethanol was removed by absorption into filter-paper. A 4% stacking gel mix
was then overlayed, and a comb inserted to form wells. The stacking gel was allowed to set
for 30 min. Gels to be stored for later use were wrapped in wet paper towel and plastic wrap,
and stored at 4 °C for a maximum of two days. Protein samples were mixed with an
appropriate volume of reducing “sample” buffer, and boiled for 5 min. Samples were loading
into wells and the gel was run at 150 V in 1 × SDS running buffer, until the dye front ran off.
Protein bands were visualised by incubation in Coomassie stain solution 1-24 h with shaking
(50 rpm). Gels were destained using rapid de-stain solution until protein bands were resolved.
Protein bands of interest were identified using Precision Plus Protein™ dual colour standards
(Bio-Rad, USA) as a reference.

2.5.4 Native PAGE
Native PAGE was used to assess SOD1 oligomeric distribution. Either a 10% acrylamide gel
(generated as per section 2.5.3), or an Any-kD™ Mini-PROTEAN® TGX Stain-Free™
(Bio-Rad, USA) was set up for electrophoresis in a MINI PROTEAN® system (Bio-Rad,
USA). Protein samples were mixed with an appropriate amount of native PAGE loading
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buffer and dispensed into wells, with the gel being run at 100 V at 4 °C for 210 min in
25 mM Tris-base 192 mM Glycine (pH 8.3). In-house 10% gels were stained using
Coomassie. Stain-Free™ gels were analysed using a Gel Doc™ EZ System (Bio-Rad, USA).
Stain-Free™ gels were placed onto the stain-free tray with a thin layer of dH2O, and activated
for 5 min prior to final imaging. Quantification and analysis of gel bands was performed
using ImageJ software (Abramoff et al., 2004).

2.5.5 Protein quantification
Owing to the removal of tryptophan-32 in some of our SOD1 variants, and the generation of
structurally destabilised variants of SOD1, we typically determined protein concentration
using BCA protein assay (Sigma Aldrich, USA). A 25 µL sample of each protein sample
(diluted if necessary) was added, in triplicate, to a 96-well microtitre plate. Bovine serum
albumin (BSA) standards of known concentrations (0–2 mg/mL), in the same buffer as the
samples to be determined, were also added to the plate in triplicate. The reaction was initiated
by addition of 196 µL of reagent A, and 4 µL of reagent B to each well. Plates were gently
agitated to ensure proper mixing of reagents, after which they were incubated at 37 °C for
30 min. Following incubation, plates were analysed using a POLARstar Omega Plate Reader
Spectrophotometer (BMG Labtech, Germany) using absorbance at 560 nm. Protein
concentrations were interpolated from a BSA standard curve. Protein quantification was also
determined via molar absorption, analysed using a UV mini 1240 UV/Vis spectrometer
(Shimadzu, Japan) when appropriate. Briefly, SOD1 samples were diluted in appropriate
buffer and 100 µL was loaded into a quartz cuvette which was read using a UV/Vis
spectrophotometer zeroed to the appropriate buffer at wavelength of 265 nm. Concentration
was determined using a coefficient of 18 700 M-1cm-1 (Stansell and Deutsch, 1966).
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2.5.6 Buffer exchange of proteins
Purified SOD1 and commercial proteins were buffer exchanged, by either gel-filtration
chromatography or spin columns, into appropriate buffers prior to certain analyses. Gelfiltration buffer exchange was achieved using either a HiLoad™ Superdex™-75 10/300 GL
or HiLoad™ Superdex™-200 10/300 GL (GE Life Sciences, USA). Protein samples were
injected onto the column, equilibrated with appropriate buffer, and eluted at a flow rate of
0.5 mL/min. Spin column buffer exchange was achieved using Vivaspin™ (500 or 20)
centrifugal concentrators (10 000 MWCO). Protein samples were aliquoted into the
concentrators and concentrated via centrifuge (8 000 × g, 10 min). The buffer to be
exchanged into was added to the max volume of the concentrator unit and centrifuged again
(8 000 × g, 10 min). This process was repeated 3 times prior to removing the protein sample
for subsequent experimentation.

2.6 Mass spectrometry
2.6.1 General mass spectrometry apparatus and settings
A SYNAPT® G1 High Definition MS™ mass spectrometer (Waters, UK), in positive ion
mode, with a nano-electrospray source was used for all mass spectrometry based experiments
in this work. All nano-capillaries were created in-house from borosilicate capillaries
(100 mm length, 1.0 mm outer diameter, 0.78 mm internal diameter) (Harvard Apparatus,
USA) using a P-97 Flaming/Brown Micropipette Puller (Sutter Instrument, USA), at a
pressure of 85, with a three step method ((i) Pull = 0, Velocity = 6, Time = 45, Heat = 585
(ii) Pull = 0, Velocity = 6, Time = 45, Heat = 585 (iii) Pull = 120, Velocity = 100,
Time = 100, Heat = 585). Pulled capillaries were gold-coated using a K500X sputter coater
(Quorom Tech., UK) at 50 mA for 2 min. The parameters used for all mass spectrometry
based experiments were generally the same unless stated otherwise elsewhere. All native
mass spectrometry protein samples were analysed in 200 mM NH4OAc (pH 6.8) unless stated
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otherwise. All spectra were externally calibrated using a solution of 10 mg/mL caesium
iodide in 50% n-propanol. All spectra were analysed and processed using MassLynx 4.1
software (Waters, UK) and other programs where stated.
Table 2. 2: General system parameters for the SYNAPT G1 HDMS.

Parameter

Experimental Setting

Capillary voltage
Sampling Cone
Extraction Cone
Source Temperature
Low Mass Resolution
High Mass Resolution
Trap Collision Energy
Transfer Collision Energy
Trap Gas Flow
Source Gas Flow
Detector
Backing Pressure
Trap Pressure
Time-of-Flight Pressure

1.52 (kV)
80 V
4.0 V
25 °C
4.7
15.0
6V
4V
2.9 mL/min
1 mL/min
1800 V
4.0e0 mbar
1.21e-1 mbar
8.41e-2 mbar

2.6.2 Denatured mass spectrometry and zip-tip protocol
In order to assess the extent of modification on the purified SOD1 in this work, acid
denaturing mass spectrometry was performed either through direct addition of acid and
denaturant, or through a zip-tip protocol. Proteins buffer exchanged into 200 mM NH4OAc
(pH7.0) (as per section 2.5.7) were denatured by the addition of acetonitrile and formic acid
to final concentrations of 49% and 1% respectively. Following denaturing, 2 µL of sample
was loaded into a gold-coated borosilicate capillary and nano-electrosprayed into the mass
spectrometer. Protein samples in salt based buffers were desalted using ZipTip®C18 tips
(Millipore, USA) prior to denaturing mass spectrometry. Zip-tips were wetted with a solution
of 100% MeOH and equilibrated with a solution of 1% formic acid, before aspirating the
protein sample at least 5 times into the tip. Following binding of the protein sample, the ziptip was washed by aspirating 1% formic acid at least 5 times. Protein was eluted from the tip
using a solution of 1% formic acid 70% acetonitrile. A volume of 2 µL of the eluted protein
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sample was loaded into a gold-coated borosilicate capillary and analysed by mass
spectrometry.

2.6.3 Dimer dissociation constant determination
Solution phase dimer dissociation constants were determined by methods previously
published (Rose et al., 2011). SOD1 variants, at concentrations ranging from 20 – 0.6 µM
were nano-electrosprayed and an acquisition range of m/z 1000 – 5000 was analysed.
Dissociation constants were determined using the integrated peak areas of the ions detected.
The total monomer abundance was defined as IM, total dimer abundance defined as ID, and
the sum of both previous values equalled total signal, which was defined as ITS.
𝐼𝑀 + 𝐼𝐷 = 𝐼𝑇𝑆
The proportion of monomer signal (PM) was determined by dividing monomer abundance
(IM) by total signal (ITS).
𝐼𝑀
= 𝑃𝑀
𝐼𝑇𝑆
The concentration of monomer at equilibrium ([M]eq) was determined by multiplying the
proportion of monomer signal (PM) by the total protein concentration in µM as determined by
UV/VIS spectroscopy or BCA ([Po])
𝑃𝑀 × [𝑃𝑜 ] = [𝑀]𝑒𝑞
The concentration of dimer at equilibrium ([D] eq) is defined as:
( [𝑃𝑂 ] − [𝑀]𝑒𝑞 )
2

= [𝐷]𝑒𝑞
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The KD of dimer dissociation was derived from the gradient of plotting [D]eq against ([M]eq)2.
In each case at least 5 data points were plotted with repeat experiments being performed if the
line of best fit gave least-squares-regression, r2 = < 0.75. At least n = 3 nano-electrosprays
were performed at each concentration for each SOD1 variant.

2.6.4 Tandem mass spectrometry
Protein samples buffer exchanged (as per section 2.5.6) into 200 mM NH4OAc (pH 7.0) had
their concentration determined (as per section 2.5.6) prior to all mass spectrometry
experiments. SOD1 samples were diluted to a concentration of 7.5 µM, and 2 µL was loaded
into gold-coated borosilicate capillaries. Samples were nano-electrosprayed and acquired in a
mass range of m/z 1000 – 5000 with a scan time of 2 seconds. Tandem mass spectrometry
(MS/MS) was used to isolate specific ions, by limiting the peak window, for subsequent
collisional activation. Gas phase unfolding and dissociation were promoted by raising the
voltage of the Trap cell, typically from 6 – 100 V in 5 V increments. In cases where MS/MS
was coupled with ion mobility, the MS/MS parameters remained consistent but particular
system parameters were changed (see section 2.6.4 and table 2.3 below).

2.6.5 Ion mobility - mass spectrometry
Ion mobility-mass spectrometry (IM-MS) was used to determine the collision cross sections
(CCS) of SOD1 variants, and to monitor dissociation and unfolding of ions in the gas phase.
System parameters were similar to above (Table 2.2), with exceptions that were based on
(Ruotolo et al., 2008a) (Table 2.3).
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Table 2.3: Ion mobility system settings for the SYNAPT G1 HDMS. Shown are parameters that
were changed for IM-MS.

Parameter

Experimental Setting

Trap DC Entrance
Trap DC Bias
Trap DC Exit
Trap Manual Control
Trap Wave Velocity
Trap Wave Height
IMS Manual Control
IMS Wave Velocity
IMS Wave Height
Transfer Wave Velocity
Transfer Wave Height

5.0
22.0
5.0
ON
250 m/s
0.2 V
ON
250 m/s
3.0 V
200 m/s
8.0 – 10.0 V

Calibrants for CCS area determination were horse heart myglobin and cytochrome c (SigmaAldrich, USA). Calibrants were resuspended into a solution of 50% MeOH and 2% acetic
acid in dH2O, and diluted to a concentration of 10 µM. Each calibrant was
nano-electrosprayed separately at IM wave heights of 8, 9, and 10 V. Calibrants were made
fresh and sprayed every day that CCS experiments were being performed. SOD1 variants that
had their CCS areas determined were diluted to a concentration of 10 µM prior to
nano-electrospray. MassLynx (Waters, UK) and DriftScope (Waters, UK) software was used
to analyse the ions and determine ion drift time. Calibration curves were generated from the
drift times of the calibrants, and SOD1 drift times were interpolated from a standard curve of
the calibrant CCS areas (Appendix C).

2.7 SOD1 unfolding and aggregation
2.7.1 Thioflavin T based aggregation assays
Purified SOD1 variants were buffer exchanged into 1 × PBS (pH 7.4) (section 2.5.7) prior to
all aggregation assays. Prior to incubation at 37°C, the final reaction mixture was 30 µM
SOD1, 20 mM DTT, 5 mM EDTA, 10 µM thioflavin T (ThT) in 1 × PBS (pH 7.4). Reaction
mixtures were vortexed for 5 sec, and 50 µL per well was aliquoted into 384-well clear
bottomed plastic plate (Greiner, Germany). Loaded plates were incubated inside a
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POLARstar Omega Plate Reader Spectrophotometer (BMG Labtech, Germany) at an internal
temperature of 37 °C and incubated for 20 min to equilibrate, following which the plates
were covered with adhesive film. Plates were shaken at 300 rpm, in a double-orbital pattern,
for 330 sec at the start of a 900 sec cycle, for at least 200 cycles. ThT was excited at 450 nm
and its emission read at 480 nm using the bottom optic of the plate reader. Seeded
aggregation assays were carried out similarly, with the exception that the reaction mixture
was 30 µM SOD1, 10 mM DTT, 1 mM EDTA, 10 µM ThT, in 1 × PBS (pH 7.4). Seeded
assays also contained 0.3% (w/w) of total protein as seed from a previous aggregation assay.
The kinetics of aggregation were analysed using derivation of the equation for the
Boltzmann-sigmoidal curve. The main parameters used in this equation are final fluorescence
(Ff), initial fluorescence (Fi), time to half maximal fluorescence (t50), and the slope of the
curve (k). From this equation we could determine lag-phase and fibril elongation rate. The
equations are as follows based on previous work (Nielsen et al., 2001)
The equation of the Boltzmann curve is given as:
𝐹 = 𝐹𝑖 +

(𝐹𝑓 − 𝐹𝑖 )
1+𝑒

(𝑡50 −𝑡)
𝑘

The slope of the line at any point is:
(𝑡50 −𝑡)
(𝐹𝑓 − 𝐹𝑖 )
𝑘
×
𝑒
𝑑𝐹
𝑘
=
(𝑡50 −𝑡) 2
𝑑𝑡
(1 + 𝑒 𝑘 )

When t = t50 (i.e. the inflexion point, when the elongation rate is maximal), the elongation
rate is:
𝑑𝐹
=
𝑑𝑡

(𝐹𝑓 − 𝐹𝑖 )
× 𝑒0
𝑘
(1 + 𝑒 0 )2

=

(𝐹𝑓 − 𝐹𝑖 )
4 ×𝑘
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The lag phase is when
{

(𝐹𝑓 − 𝐹𝑖 )
} × 𝑡50 + 𝑏 = 𝐹𝑖
4×𝑘

To solve for b, at t50 (i.e. the mid-point between Ff and Fi):
𝐹𝑡50 =

𝑏= {

(𝐹𝑓 − 𝐹𝑖 )
2

(𝐹𝑓 − 𝐹𝑖 )
(𝐹𝑓 − 𝐹𝑖 )
}− {
} × 𝑡50
2
4×𝑘

So, substituting b into equation (ii):
𝐹𝑖 = {

(𝐹𝑓 − 𝐹𝑖 )
(𝐹𝑓 − 𝐹𝑖 )
(𝐹𝑓 − 𝐹𝑖 )
} × 𝑡𝑙𝑎𝑔 + {
}− {
} × 𝑡50
4×𝑘
2
4×𝑘

Solving for tlag:
4 × 𝑘 × 𝐹𝑖 = {(𝐹𝑓 − 𝐹𝑖 ) × 𝑡𝑙𝑎𝑔 } + {2 × 𝑘 (𝐹𝑓 − 𝐹𝑖 )} − {(𝐹𝑓 − 𝐹𝑖 ) × 𝑡50 }
(𝐹𝑓 − 𝐹𝑖 ) × 𝑡𝑙𝑎𝑔 = 4 × 𝑘 × 𝐹𝑖 + {(𝐹𝑓 − 𝐹𝑖 ) × 𝑡50 } − {2 × 𝑘 (𝐹𝑓 − 𝐹𝑖 )}
𝑡𝑙𝑎𝑔 =

4 × 𝑘 × 𝐹𝑖
+ 𝑡50 − {2 × 𝑘 }
(𝐹𝑓 − 𝐹𝑖 )

2.7.2 Transmission electron microscopy
A volume of 2 µL of aggregated SOD1 from plate reader based aggregation assays (section
2.7.1) was loaded onto a carbon coated 400 mesh Nickel TEM grid (ProSciTech, Australia).
Loaded samples were then diluted with 10 µL of 0.22 µm filtered milli-Q H2O and left to
stand for 1 min. Grids were then dried with fine fibre blotting paper by dabbing the side
gently. The addition of milli-Q and drying was repeated three times, after which 10 µL of
2% uranyl acetate (w/v) was added and left to stand for 1 min. Uranyl acetate was dried off
the grid gently with blotting paper, and the grid was left to air dry, upside down, for 5 min
before being stored. Grids were stored at room temperature in sealed plastic container.
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Prepared grids were imaged at the Australian Institute of Innovative Materials using a JEOL
JEM-2011 transmission electron microscope (JEOL, Japan). Images were processed using
Image J software (Abramoff et al., 2004).

2.7.3 Generation of destabilised conformations of SOD1
Purified SOD1 variants were buffer exchanged into 1 × PBS (pH 7.4) (section 2.5.7) and
diluted to 30 µM, after which DTT and EDTA were added to concentrations of 20 mM and
5 mM respectively. Samples were incubated at 37 °C for 2 hours and then concentrated using
Vivaspin™ 500 centrifugal concentrators (10 000 MWCO) at 4 °C. Concentrated samples
were diluted to 100 µ and loaded onto a Hiload Superdex™-75 10/300 GL column (GE Life
Sciences, USA) equilibrated in 200 mM NH4OAc (pH 7.0). The samples were injected and
eluted at 0.5 mL/min with 0.5 mL fractions being collected. Volumes of 10 µL from each
fraction containing protein were pooled to create a sample representative of the total
conformational distribution of destabilised SOD1. All destabilised SOD1 was quantified via
BCA (section 2.5.6) and subject to native mass spectrometry (section 2.6.1) on the day of
generation.

2.8 Secondary tissue culture and fluorescent imaging
2.8.1 Preparation of NSC-34 cells
Mouse neuroblastoma/motor neuron hybrid cells (NSC-34) (Cashman et al., 1992) were
cultured in Dulbecco’s modified Eagles medium-F12 (DMEM-F12) (Invitrogen, Australia),
supplemented with 10% (v/v) heat inactivated foetal bovine serum (FBS) (Bovogen
Biologicals, Australia). In order to passage and plate cells, they were washed once with
DMEM-F12 and treated with 0.25% Trypsin, 0.02% EDTA (Sigma-Aldrich, Australia) to lift
off the adherent cells. The cells were pelleted via centrifugation (500 × g, 5 min) and
resuspended in pre-warmed DMEM-F12, supplemented with 10% FBS. Following washing,
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plates and chamber-slides were seeded at a confluency of 40% and cultured at 37 °C in a
humidified incubator with 5% atmospheric CO2 for 24 h prior to transfection.

2.8.2 Transfection of NSC-34 cells
NSC-34 cells were transfected, 24 h post-plating into either multi-well plates or chamberslides, using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer’s
instructions. Lipofectamine 3000 reagent was added to pre-warmed DMEM-F12 to a
concentration of 6% (v/v). P3000 reagent and plasmid DNA were added to a separate
DMEM-F12 volume to concentrations of 4% (v/v) and 20 ng/µL respectively. The
DNA/lipofectamine complex was generated by mixing one volume of 6% (v/v) lipofectamine
in

DMEM-F12,

with

one

volume

of

DNA/P3000

mix

in

DMEM-F12.

The

DNA/lipofectamine mixture was incubated for 30 min at room temperature, after which it
was dispensed onto cultured cells. For cells that were co-transfected, the total amount of
DNA was halved between plasmid constructs. After 24 h incubation, transfection was
assessed using an Eclipse TE2000-E fluorescent microscope (Nikon, Japan).

2.8.3 Laser scanning confocal imaging
All cell imaging was performed using a Leica TCS SP5 Confocal microscope (Leica,
Germany). Cells were imaged live in 5% atmospheric CO2, with the incubation unit set to a
temperature of 37 °C. For all confocal experiments, the argon laser power was at 20%, with
the DPSS 561 nm, and HeNe 633 nm lasers being turned on when necessary. All greenfluorescent protein (EGFP) tagged constructs were excited with 10% laser power at 488 nm
and emission was analysed from 507-550 nm. TdTomato protein tagged constructs were
excited with 7% laser power at 561 nm and emission was analysed from 581-700 nm. Images
were acquired using or a HCX PL APO 63.0 × 1.20 water immersion objective, using PMT
detectors, with a pin-hole of 100 µm.
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2.8.4 Z-stack imaging for inclusion quantification
To quantify inclusion formation of our SOD1 fluorescent constructs, z-stacks of transfected
cells were acquired. Cells were cultured (section 2.8.1) into µSlide 8-well chamber slides
(Ibidi, Germany) and transfected with either EGFP or tdTomato fluorescent SOD1 constructs
(section 2.8.2). Imaging was performed 48 h post-transfection using a HCX PL APO 63.0 ×
1.30 water immersion objective. Z-stacks series were acquired at 512 × 512 pixels, laser
scanning speed 400 Hz, line and frame averaging = 1, where each image was a 400 – 500 nm
slice of the z-axis. At least five z-stack series were acquired per well of a chamber slide,
accounting for at least 100 transfected cells imaged per well. Z-stacks were processed into a
single image using LAS-AF Lite software (Leica, Germany), where cells containing
inclusions were determined by the presence of bright fluorescent puncta in the cytoplasmic
region greater than 2 µm in diameter

2.8.5 Dual colour transfection for in cell aggregation seeding analysis
In order to examine the ability of SOD1 variants to template onto aggregates in a cellular
context, NSC-34 cells were cultured (section 2.8.1) in µSlide 8-well chamber slides (Ibidi,
Germany) and transfected with both EGFP and tdTomato fluorescent SOD1 constructs
(section 2.8.2). tdTomato-SOD1 fusions are less likely to aggregate than EGFP fusions, likely
due to the larger size of the fusion protein (Fig. 5.1 B). As a result, we used EGFP as a nonaggregating control, and in our analyses, tdTomato constructs were defined as the template
for the aggregation of SOD1-EGFP variants. Co-transfected cells were identified by the
presence of both EGFP and tdTomato fluorescent signal. Individual co-transfected cells were
magnified and imaged at 1024 × 1024 pixels, laser scanning speed 1000 Hz, line averaging 1,
using frame by frame sequential scanning with averages calibrated to minimise bleed-through
of EGFP emission reading into the tdTomato emission window. Both EGFP and tdTomato
channels were gain adjusted in over-glow mode to avoid saturation of the images acquired.
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Images were processed for analysis using LAS-AF Lite software (Leica, Germany), and
image analysis was performed using Image J software (Abramoff et al., 2004). Using Image
J, the area within a cell that was composed of aggregated SOD1 was determined by setting a
‘max entropy’ threshold in the tdTomato channel, followed by then applying this selected
area to the green channel and measuring the pixel area (AP) and mean pixel intensity (IP)
of both channels. The AP and IP of the diffuse fluorescent protein was determined in the
tdTomato channel, and applied to the EGFP channel, by setting the maximum threshold to
the value of the minimum threshold determined for the aggregated fluorescent protein,
followed by setting the minimum threshold to a value that selected the cell cytoplasm.
Using AP and IP values for both diffuse and aggregated protein, in both the EGFP and
tdTomato channels, we determined the ratio of EGFP to tdTomato signal that was
aggregated per cell.
Firstly, since intracellular SOD1 aggregates are noted to be porous (Farawell et al., 2015,
Matsumoto et al., 2006, Matsumoto et al., 2005), corrected aggregate fluorescence intensity
(Aggregated IC) was determined by subtracting the diffuse mean pixel intensity (Diffuse IP)
from aggregated mean pixel intensity (Aggregated IP).

1.

(𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝑃 ) − (𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝐼𝑃 ) = 𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝑃 (𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝐶 )

Total aggregated signal (SA) was determined by multiplying the corrected aggregated
fluorescence intensity (Aggregated IC) by the aggregated pixel area (Aggregated AP).

2.

(𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐼𝐶 ) × (𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝐴𝑃 ) = 𝑇𝑜𝑡𝑎𝑙 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝑆𝑖𝑔𝑛𝑎𝑙 (𝑆𝐴 )

Total diffuse signal (SD) was determined by multiplying the mean diffuse fluorescence
intensity (Diffuse IP) by the diffuse pixel area (Diffuse AP).
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3.

(𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝐼𝑃 ) × (𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝐴𝑃 ) = 𝑇𝑜𝑡𝑎𝑙 𝐷𝑖𝑓𝑓𝑢𝑠𝑒 𝑆𝑖𝑔𝑛𝑎𝑙 (𝑆𝐷 )

Total cell fluorescence signal (SC) was determined by the addition of total diffuse signal (SD)
and total aggregated signal (SA).

4.

𝑆𝐷 + 𝑆𝐴 = 𝑇𝑜𝑡𝑎𝑙 𝐶𝑒𝑙𝑙 𝑆𝑖𝑔𝑛𝑎𝑙 (𝑆𝐶 )

The proportion of aggregated fluorescent signal (PA) was determined by dividing the total
aggregated signal (SA) by total cell fluorescence signal (SC).

5.

𝑆𝐴
= 𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 (𝑃𝐴 )
𝑆𝐶

The proportion of aggregated EGFP (EGFP PA) was then divided by the proportion of
aggregated tdTomato (tdTomato PA) to determine the ratio of EGFP to tdTomato
fluorescence signal that was contributing to the intracellular aggregates.

6.

(𝐸𝐺𝐹𝑃 𝑃𝐴 )
= 𝑅𝑎𝑡𝑖𝑜 𝑜𝑓 𝐸𝐺𝐹𝑃 𝑡𝑜 𝑡𝑑𝑇𝑜𝑚𝑎𝑡𝑜 𝑎𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑
(𝑡𝑑𝑇𝑜𝑚𝑎𝑡𝑜 𝑃𝐴 )
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3. SOD1 in vacuo Dissociation and
Unfolding

*Note: This chapter is written in a style that makes it stand-alone and ready for publication, as a
consequence there is some repetition with the Introductory Chapter 1.
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3.1 Introduction
The structures of protein assemblies are increasingly being interrogated using native mass
spectrometry (MS). When optimised to maintain a native-like state, this technique can reveal
attributes of protein complexes such as oligomeric distribution, topology, and protein-protein
interactions, even in complex systems (Bich et al., 2010b, Daniel et al., 2002, Hilton and
Benesch, 2012, Mehmood et al., 2015, Smith and Zhang, 1994). This is further enhanced
with the use of tandem mass spectrometry (MS/MS), in which discrete ions can be isolated
and subjected to collision-induced dissociation (CID) (Benesch et al., 2006), thereby
providing insight into the underlying composition of narrow m/z (mass to charge) regions
within multi-component spectra. Ion mobility-mass spectrometry (IM-MS) makes analysis
three dimensional by determining ion drift-time, which is correlated with the collisional
cross-section of the ion, providing constraints for downstream in silico modelling of oligomer
packing (Hall et al., 2012). IM-MS is also useful for analysing the induced unfolding of
biological molecules in vacuo, either in the absence or presence of binding partners (Hopper
and Oldham, 2009). In native protein mass spectrometry, charge is added to solvent exposed
basic amino acids, typically via electrospray ionisation (ESI), where proteins in a volatile
buffer are subjected to high voltage to create an aerosol. The aerosol droplets containing the
protein progressively evaporate with the final evaporation leaving behind charge on the
protein to generate a gas phase ion (Nguyen and Fenn, 2007). ESI is described as a ‘soft
ionisation’ technique owing to the small amount of fragmentation that occurs to analytes,
making it especially useful for the study of multimeric protein complexes (Hilton and
Benesch, 2012). Most identified proteins exist as components of a complex in vivo and it is
important for structural and functional analysis to dissociate these complexes into subunits to
characterize them (Kuriyan and Eisenberg, 2007).

In MS based-assays, dissociation is

typically achieved in vacuo, where charged ions of protein assemblies are subject to
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increasing energy to promote dissociation into subunits. Dissociation of a complex is defined
as asymmetric when a small subunit or monomer, carrying a high proportion of charge
relative to their mass, is ejected from the protein complex (dimern+ = monomer>(n/2)+ and
monomer<(n/2)+). Dissociation is defined as symmetric when the proportion of charge on
fragment ions is equal to the proportion of mass it represents (dimern+ = 2 × monomer(2/n)+);
i.e. in the case of dimern+, the monomer charge state distribution will be unimodal and
centred on monomer(2/n)+, but if asymmetrical it will lead to bimodal distribution of charge
states. In the asymmetric model, the disproportionately high charge on the ejected monomer
has been explained as a consequence of unfolding during dissociation in the gas phase.
Unfolding of a subunit in a multimeric complex increases the surface area on the subunit to
balance the charge to surface area distribution, a result of an increase in the number of
chargeable sites accessible to the existing charges on the ion. (Benesch et al., 2007, Benesch
et al., 2006, Wanasundara and Thachuk, 2007b). Asymmetric dissociation is typical of most
multimeric protein complexes (Felitsyn et al., 2001, Jurchen and Williams, 2003a, Versluis et
al., 2001). Another proposed model for the asymmetry observed during dissociation is
explained by Coloumbic repulsion, where the charges on each subunit in a complex repulse
each other. In this model, the charges on subunits exist in an equilibrium state where total
charge of the complex is divided amongst subunits, and the complexes with the most unequal
charges are thought to present a higher barrier to dissociation, dependent upon charge isomers
and charge migration during unfolding (Sinelnikov et al., 2007, Wanasundara and Thachuk,
2007a).
If we wish to interrogate the utility of gas phase dissociation in biomolecular analyses, we
need to first broaden our understanding of the mechanisms of this process. Recently, Zhuang
and colleagues investigated the in vacuo unfolding and dissociation of bovine superoxide
dismutase-1 (SOD1) (Zhuang et al., 2014), postulating that dissociation and unfolding in
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vacuo, could be used to analyse disease-associated mutants of human SOD1. SOD1
misfolding and aggregation is involved in the neurodegenerative disease amyotrophic lateral
sclerosis (ALS), as evidenced by a misfolded conformation specific antibody being
immunoreactive to SOD1 in both sporadic ALS and SOD1-associated familial ALS postmortem tissue (Bosco et al., 2010). Taken together, these data suggest that SOD1
conformation may play a role in the toxicity responsible for motor neuron death.
SOD1 is a 32 kDa homodimeric enzyme that converts superoxide to either O2 or H2O2
(McCord and Fridovich, 1969). Each SOD1 monomer contains a catalytically active copper
atom, a zinc atom, and an intramolecular disulfide bond that links loop-IV with β-strand-VIII
(Fig. 3.1). These post-translational modifications impart a high level of stability to the
protein, making it resistant to proteolytic digestion (Senoo et al., 1988) and heat denaturation
(Rodriguez et al., 2002). Protein inclusions composed of SOD1 and soluble misfolded
SOD1, have been observed in both sporadic and SOD1 familial patients (Bosco et al., 2010,
Forsberg et al., 2010, Pokrishevsky et al., 2012b), pointing to a putative common pathway
responsible for toxicity whereby both the wild-type and mutant variants assume a common
misfolded and/or aggregated conformation. Research has historically been focused on
disease-causing SOD1 mutants, of which there are over 183 linked to the familial form of
ALS (fALS) (http://alsod.iop.kcl.ac.uk (Abel et al., 2013a). These mutations are found
throughout the SOD1 primary structure and result in variation in protein stability (Khare et
al., 2006), post-translational modification states (Arnesano et al., 2004, Goto et al., 2000,
Hayward et al., 2002), and even disease progression (Wang et al., 2008). A suggested
pathway through which SOD1 may cause ALS is that structural destabilisation (via mutation,
metal deficiency, disulfide reduction) leads to increased abundance of SOD1 monomers,
which are increasingly prone to misfolding and subsequent aggregation (Rakhit et al., 2004).
It is currently unclear if toxicity can be attributed to misfolded SOD1 monomers, small
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oligomers, or larger SOD1 aggregates; however, it is evident that misfolding precedes
aggregation.

Figure 3.1: SOD1 showing mutation locations and post-translational modification. The native
structure of the SOD1 homodimer is reliant upon the correct coordination of Zn2+ (brown sphere) in to
the zinc loop, and Cu2+ (light blue sphere) into the electrostatic loop, as well as the formation of an
intramolecular disulfide bond (black) between C57 and C146. The mutations examined here were
chosen due to variable effects upon SOD1 structural stability, including destabilisation of the dimer
interface (A4V-grey and V148G-orange), destabilisation of monomeric structure (G37R-red, D90Adark blue, G93A-green), perturbation of copper binding (H46R-magenta). Disease severity of these
mutants ranges from 0.9 – 17.6 years on average post-diagnosis (Wang et al., 2008).

As stated previously, Zhuang and co-workers (2014) have reported on the in vacuo
dissociation and unfolding of bovine SOD1 using IM-MS to examine the ion species
generated from increasing acceleration potentials in CID (Zhuang et al., 2014). IM-MS has
also been performed on SOD1 purified from sporadic ALS patient erythrocytes, showing that
sporadic patients had increased SOD1 monomer abundance compared to healthy controls
(Borges-Alvarez et al., 2012). In this work, we used MS/MS, and IM-MS, coupled with CID
to gain an understanding of how the in vacuo environment affects SOD1 quaternary and
tertiary structure with respects to in vacuo dissociation models, and how this relates to
disease. To this end, we performed the above techniques on a set of recombinantly expressed
SOD1 ALS-associated variants (Fig. 3.1) chosen for their differential effects upon the
stability of the SOD1 dimer, monomer and metal-binding. The results demonstrate that
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collision-induced dissociation and unfolding of the SOD1 dimer and monomer in vacuo
follows a symmetrical pathway for the most part, with the exception of SOD1G37R, which
presents a more asymmetric dissociation. We find this is at odds with the conformational
changes, observed using IM-MS, in the dimer over increasing acceleration potentials.
Analysis of a heterodimer, composed of SOD1WT and SOD1G37R, suggested that, in the case
of SOD1, charge partitioning seems to be uncoupled from the unfolding of subunits in the
dimer. This suggests an allosteric effect of the SOD1G37R mutant is largely affecting its
interesting in vacuo properties. Furthermore, we did not observe substantial differences in
dimer dissociation or unfolding, of our SOD1 variants, when compared to previously
published solution-phase work, suggesting that in vacuo dissociation and unfolding is not
reflective of the solution states of SOD1.

3.2 Results
3.2.1 Tandem mass spectrometry (MS/MS) of SOD1 variant dimers
It has been previously established that when SOD1 is subjected to collisional activation, the
abundant dimer 10+ and 11+ ions (denoted as D10+ and D11+ from hereon) dissociate
primarily into monomer ions of charge states 5+ and 6+ (denoted as M 5+ and M6+ from
hereon) (Zhuang et al., 2014). The M6+ and M5+ product ions can overlap with D12+ and D10+
ions respectively, since, for example, the m/z of M5+ is the same as D10+ (twice the mass and
twice the charge). To overcome this we employed MS/MS, with a peak window centred on
the unique D11+ ion at m/z ~2900. By increasing the acceleration potential into the “Trap”
collision cell, we prompted the dissociation of D11+ into product ions ranging from M4+ to
M7+ (Fig. 3.2). Considering charge conservation, the dissociation of D11+ into these
monomeric ions indicates that SOD1 can dissociate via two routes, resulting in either M5+
and M6+ (termed symmetric dissociation considering non-integer charge states are
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impossible), or M4+ and M7+ (asymmetric dissociation). Across the acceleration ramp, D11+
of each SOD1 variant decreased in relative abundance (Fig. 3.3 A). Application of a
logarithmic function (log values of the abundances measured in Fig. 3.3 A) to these data
showed that the dissociation of the D11+ ion was biphasic, with two separate rates of
dissociation, where phase 1 was from 6 – 70 V, and phase 2 was from 70 – 100 V (Fig. 3.3
B). Comparing the rates of dissociation in the two phases separately, revealed significant
differences between some of the SOD1 variants when compared to SOD1WT (Fig. 3.3 C and
D). However, these differences are at odds with previously well-established SOD1 dimer
dissociation work in solution, for example, SOD1A4V (dimer dissociation constant = ~1 µm)
is well known to have an increased dimer dissociation propensity when compared to SOD1WT
(dimer dissociation constant = ~10 nM) (Doucette et al., 2004, Ray et al., 2004, Redler et al.,
2011), yet here we see no significant difference in dissociation between SOD1A4V and
SOD1WT in either phase. This highlights the difference between the gas phase and solution
phase dynamics, where the apparent effect of mutation is not the same, most likely due to the
change in physical forces that direct the non-covalent interaction between subunits.
The biphasic dissociation of our SOD1 variants were consistent with the dissociation through
the two observed routes, where in phase 1 (0 – 70 V) we observed primarily M5+ and M6+
product ions, but in phase 2 we saw an increase in M4+ and M7+ ions (Fig. 3.4 B).
Interestingly, we observed a substantially increased relative abundance of the M 7+ and M4+
ions for SOD1G37R at high acceleration potentials (Fig. 3.4 A). When comparing the ratio of
M6/5 ions to the ratio of M7/4 ions, we observed that from 65 – 100 V SOD1G37R, had a
substantially increased abundance of M7/4 ions, suggesting that a higher abundance of
SOD1G37R dimers are following the asymmetric dissociation pathway during phase 2. X-ray
crystallography of SOD1G37R has suggested that dimers of this variant can be composed of
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asymmetrically folded subunits, and that the monomer is more flexible than that of SOD1 WT
(Hart et al., 1998).

Figure 3.2: MS/MS dissociation profile of the D11+ ion of SOD1WT. Increasing acceleration
potentials (collision energy; CE) prompted the dissociation of the D11+ ion into species M4+, M5+, M6+,
and M7+. Oligomeric size is denoted by the ellipsoids (1 = monomer, 2 = dimer), and charge state by
the accompanying number.
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Figure 3.3: In vacuo dimer dissociation of SOD1 variants analysed by IM-MS/MS. The unique
D11+ ion of each SOD1 variant was selected using MS/MS and subject to increasing accelerating
potentials (collision energy) in the Trap. (A) The relative abundance (as determined by peak area) of
the D11+ ion decreased for all SOD1 variants as acceleration potential was raised. The relationship was
similar for all SOD1 variants, although a difference in rate for SOD1G93A and SOD1V148G was
apparent. (B) Application of a logarithmic function (log of the percentage values in panel A) to the
dissociation curves revealed two discreet linear relationships for the dissociation of the D11+ ion,
indicating that it was biphasic. (C) Plotted dissociation rates of the first phase of dissociation showed
significant differences in the dissociation rate of SOD1H46R, SOD1D90A, SOD1G93A, and SOD1V148G
when compared to SOD1WT. (D) Plotted dissociation rates of the second phase of dissociation showed
significant differences in the dissociation rate of SOD1H46R and SOD1G93A when compared to
SOD1WT. Error bars represent SD of the mean of at least 3 nano-electrosprays. Statistical significance
was determined using a non-paired t-test, (* = P < 0.05).
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Figure 3.4: MS/MS of D11+ resulted in the evolution of four main product ions. The D11+ ion was
dissociating into either M6+ and M5+, or M7+ and M4+. (A) Base peak (BP) normalised mass spectrum
of the m/z region where the M7+ ion was evolving at 80 V acceleration potential, showing the
substantially higher relative abundance of SOD1G37R. (B) Plotting the ratio of M7/4 to M6/5 shows that
from 60-100 V acceleration potential, the abundance of the M7+ and M4+ ions increases substantially
for SODG37R compared to other variants. (C) Plot showing the mean monomer charge state across
acceleration potentials where SOD1G37R presents a higher mean charge state from 70 – 100 V.

3.2.2 Ion mobility-mass spectrometry of SOD1 variants
The advent of ion mobility analysis coupled to mass spectrometry has provided another
mechanism to investigate biomolecular ions, as collisional cross-sections (CCS) can be
determined by the relative drift times of ions. In order to investigate if there were any
differences in the unfolding of our SOD1 variants in vacuo, we employed IM-MS with
increasing acceleration potentials to induce unfolding and dissociation. The main ion species
arising, at low acceleration potential, from our IM-MS analysis were D11+ and D10+
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(Fig. 3.6 A), indicating that under IM conditions the charge state distribution of SOD1 was
not significantly altered. The IM-MS of SOD1, under low acceleration potential, showed ion
drift times that were typical of folded conformers, as there was only one drift time population
per ion species (Fig 3.6 B) (conformers are labelled with oligomeric state [M = monomer,
D = dimer], charge, and subscript = conformer, i.e. D11+
[2] is the second conformer to evolve
from the dimeric 11+ charge state ion). When acceleration potential was increased, evolution
of new conformers for all of the ions was observed (CCS values in Tables 3.1 and 3.2). Of
interest was the D11+ ion which transitioned into two conformers, with higher drift times, as
11+
11+
acceleration potential was increased (D11+
[1] > D [2] > D [3] at respective drift times of 9 > 11.5 >

13.2 ms) (Fig 3.6 C). As stated previously, there is signal overlap between SOD1 dimers and
monomer products. As such, we were unable to reliably identify the existence of particular
conformers in both the D12+ and D10+ m/z regions. Due to this signal overlap we once again
focused our analysis on the D11+ ion.
Table 3.1: The interpolated CCS (Å2) values of monomeric conformers of SOD1 variants
determined using IM-MS. Calibration curves were generated using cytochrome c and myoglobin,
and SOD1 CCS values were interpolated from these curves (calibration curves can be found in
appendix C)
8+

8+

7+

7+

Variant

M[1]

M[2]

M[1]

M[2]

WT
A4V
G37R
H46R
D90A
G93A
V148G

957 ± 90
969 ± 88
969 ± 75
957± 99
969 ± 86
969 ± 82
957 ± 80

1292 ± 122
1321 ± 112
1315 ± 126
1303 ± 118
1351 ± 115
1363 ± 125
1351 ± 120

970 ± 70
954 ± 72
954 ± 65
964 ± 80
987 ± 76
954 ± 79
975 ± 70

1243 ± 116
1254 ± 120
1243 ± 126
1264 ± 110
1286 ± 107
1307 ± 131
1259 ± 124
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Table 3.2: The measured CCS (Å2) values of dimeric conformers of SOD1 variants determined
using IM-MS. (calibration curves can be found in appendix C)
Variant
WT
A4V
G37R
H46R
D90A
G93A
V148G

9+

9+

10+

10+

10+

11+

11+

11+

12+

12+

D[1]

D[2]

D [1]

D [2]

D [3]

D [1]

D [2]

D [3]

D [1]

D [2]

1478 ±
120
1499 ±
110
1505 ±
125
1446 ±
127
1434 ±
114
1499 ±
118
1505 ±
120

1761 ±
136
1787 ±
132
1751 ±
140
1787 ±
129
1763 ±
139
1716 ±
138
1763 ±
119

1393 ±
121
1397 ±
115
1437 ±
118
1370 ±
119
1357 ±
126
1423 ±
129
1397 ±
122

1728 ±
134
1729 ±
133
1703 ±
129
1729 ±
140
1729 ±
141
1796 ±
137
1716 ±
135

1995 ±
147
1958 ±
150
1944 ±
142
1958 ±
143
1944 ±
148
1987 ±
148
1958 ±
140

1347 ±
121
1397 ±
115
1354 ±
129
1339 ±
120
1296 ±
126
1339 ±
118
1354 ±
119

1727 ±
129
1714 ±
124
1714 ±
120
1728 ±
118
1714 ±
134
1771 ±
132
1692 ±
120

1956 ±
137
1958 ±
148
1944 ±
144
1958 ±
141
1944 ±
135
1987 ±
139
1958 ±
146

1331 ±
122
1279 ±
112
1293 ±
123
1357 ±
122
1365 ±
128
1350 ±
114
1350 ±
119

1491 ±
140
1499 ±
150
1478 ±
145
1478 ±
143
1485 ±
136
1513 ±
138
1485 ±
133
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Figure 3.5: IM-MS chromatogram of SOD1 under different acceleration potentials. SOD1
variants were subject to IM-MS with increasing acceleration potentials in the Trap to prompt
unfolding and dissociation. (A) Typical native spectrum of SOD1WT with ellipsoids representing the
oligomeric state (1 = monomer, 2 = dimer) with charge states above. The maxima observed on the
10+ and 11+ labelled peaks are representative of glutathionylation state (discussed later in section
4.2.3). (B) IM chromatogram of SOD1WT at an acceleration potential of 15 V, showing singular
conformers for each ion. (C) IM chromatogram of SOD1WT at an acceleration potential of 50 V,
showing the evolution of multiple conformers at each charge state. Conformers are labelled with
Oligomeric state (M = monomer, D = dimer) charge, and subscript = conformer, i.e. D11+
[2] is the
second conformer to evolve from the dimeric 11+ charge state ion.

Using a combination of MS/MS and IM-MS, we monitored the change in drift time for the
D11+ ion as a function of acceleration potential to generate CIU fingerprints using CIUSuite
(Eschweiler et al., 2015) (Fig 3.7),as well as measurements of standard deviation between
nano-electrospray replicates (Fig 3.8).From these fingerprints it was apparent that the D11+
ion species of all of our SOD1 variants shared similar unfolding pathways, with the exception
of SOD1G37R, which preferentially remained in the D11+
[2] conformer state at high accelerating
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potentials, rather than transition to the D11+
[3] state. To further analyse differences in the SOD1
variants CIU fingerprints, we utilised the CIUSuite ‘compare’ feature which generates heat
maps, where differences between fingerprints are colour coded, and root-mean-square
deviation (RMSD) values. All SOD1 variants CIU fingerprints were compared to SOD1WT
(Fig 3.9) showing low RMSD values with the exception of SOD1G37R which gave a value
approximately 4 times that of the other SOD1 variants (SOD1G37R = 19.99%, average of other
variants = 5.88 %). The heat map of SOD1WT and SOD1G37R showed that SOD1G37R was
WT
remaining in the D11+
was
[2] conformation throughout the acceleration ramp, whereas SOD1

transitioning to the D11+
[3] conformation. An IM-MS study performed with bovine SOD1
showed similar results to most of the SOD1 variants examined here, where the bovine D11+
transitioned into three conformers with increasing accelerating potential (Zhuang et al.,
2014). The authors described the three diferent conformers as the result of the fold of the
monomeric subunits, which suggests in our case D11+
[1] is a dimer with two folded subunits,
11+
D11+
[2] may be a dimer with one unfolded (or less compact) subunit, and D [3] may be a dimer

where both subunits are unfolded. However, it is possible that only one subunit in the dimer
is transitioning through multiple conformational states. This, like the dissociation data
presented earlier, suggests that in vacuo dynamics are having a significant effect upon both
unfolding and dissociation pathways, as one would expect dissociation to occur prior to
unfolding of both monomers in a dimer when in solution.
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Figure 3.6: Mean CIU fingerprints for the D11+ ion of SOD1 variants. The conformational change
of D11+ in response to increasing acceleration potentials was monitored using IM-MS and plotted as a
heat-map using CIUSuite. All SOD1 variants showed similar gas phase unfolding, transitioning
11+
11+
G37R
through 3 conformers (D11+
, which transitioned
[1] , D [2] , and D [3] ) with the exception of SOD1
primarily into the D11+
[2] conformer. All unfolding plots are averages of 3 separate nano-electrosprays.
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Figure 3.7: The standard deviation of CIU fingerprints of the D11+ ion of SOD1 variants. Using
CIUSuite it was possible to determine the standard deviation between replicates for each SOD1
variant. Deviation was minimal in each case with the exception of SOD1G37R. This data was generated
from 3 separate nano-electrosprays.
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Figure 3.8: The difference in the mean CIU fingerprint between SOD1 variants and SOD1WT.
The average CIU fingerprint of each SOD1 variant (blue) was compared to the SOD1WT (red)
fingerprint to determine differences in CIU. Root-mean-square deviation was calculated to determine
difference showing that SOD1G37R was the most different (RMSD = 19.99 %). The differences were
G37R
apparent with SOD1WT inhabiting the D11+
inhabited the D11+
[3] conformer, whilst SOD1
[2] conformer
for the majority of the acceleration ramp.
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When comparing the unfolding rates of D11+, we observed that all SOD1 variants showed
11+
similar rates of transition from D11+
[1] to D [2] (Fig 3.7), suggesting that mutation was having

little effect upon the unfolding of a single SOD1 subunit within a dimer. Conversely, the
11+
relative abundances of the D11+
[2] and D [3] conformers (Fig. 3.10 B and C, respectively) showed

that SOD1G37R was behaving differently. SOD1G37R preferred to remain in the D11+
[2] state
across the acceleration ramp, whereas the other SOD1 variants transitioned rapidly into the
D11+
[3] state. This suggests that the unfolding of a second subunit, or increased unfolding of a
single subunit, in a SOD1G37R dimer is not occurring, and that the dimer is potentially
dissociating prior to, or concomitantly with, the secondary unfolding event. After examining
the dimer, we performed the same analysis on the solution M7+ ion (therefore we did not use
MS/MS) to determine if there were signficant differences in the in vacuo unfolding of the
solution-phase monomer (Fig 3.7 D). There were no observable differences between the
7+
SOD1 variants in terms of M7+ abundane as it transitions to M[2]
over increasing acceleration

potentials, again suggesting that in vacuo dynamics are overpowering the effect of mutation.
For example, SOD1D90A has a destabilised tertiary structure but not quaternary structure
(Lindberg et al., 2005), yet in our assay the unfolding of monomeric SOD1D90A required
energies similar to that of monomeric SOD1WT to induce unfolding.
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Figure 3.9: In vacuo unfolding of the D11+ ion and M7+ ion for all SOD1 variants. (A) The
11+
11+
relative abundance of the D11+
[1] conformer, compared to the abundance of the D [2] and D [3]
conformers, decreased across the acceleration series, with all SOD1 variants showing a similar
relationship. (B) The relative abundance of D11+
[2] showed a similar relationship for all SOD1 variants,
with the exception of SOD1G37R, increasing in abundance until 40 V in the Trap, after which relative
abundance decreased. SOD1G37R showed no decrease in relative abundance across the acceleration
series, rather an increase in abundance plateauing at 60 V in the Trap. (C) The relative abundance of
G37R
D11+
which plateaued at
[3] increased to ~80% for all SOD1 variants, with the exception for SOD1
7+
~20%. (D) The relative abundance of the M[1]
conformer decreased across the collision series in a

similar relationship for all SOD1 variants. Error bars represent SD of the mean of 3 separate nanoelectrosprays.

3.2.3 Analysis of a SOD1WT/G37R heterodimer
The previous analyses highlighted SOD1G37R as a clear outlier, compared to other variants,
especially when considered in the light of current models of in vacuo dissociation and
unfolding. In simple terms, current models of in vacuo unfolding and dissociation suggest
that the more unfolding there is in a protein multimer, the more asymmetric the dissociation
of the multimer will be (Wanasundara and Thachuk, 2009). In order to more accurately
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determine the differences in dissociation and unfolding of SOD1 G37R, we generated a
SOD1WT/G37R heterodimer by mixing both variants at equal concentration (10 µM) and
incubating the mixed sample at 37 °C overnight to ensure sufficient subunit exchange had
taken place before performing similar analysis to that described above. Since mixing of
SOD1WT and SOD1G37R generates heterodimer as well as homodimers of both variants (Fig.
3.10 A), we again utilised MS/MS to isolate the D11+ ion, focusing on the heterodimer peak at
m/z ~2915, and subjected it to increasing accelerating potentials. We first assessed the
symmetry of dissociation by comparing the ratio of M7/4 to M6/5 dimer, observing that the
dissociation was closer to the symmetrical dissociation of SOD1WT than that of SOD1G37R
(Fig 3.10 B). This suggests that the asymmetry of the SOD1G37R dimer dissociation is reliant
upon both subunits having an arginine at position-37. The SOD1WT/G37R heterodimer can
dissociate through four main routes dependent upon the monomer and charge composition
(WT6+/G37R5+, G37R6+/WT5+, WT7+/G37R4+, G37R7+/WT4+) (Fig 3.10 C). Plotting the
relative abundance of these dissociation routes revealed a preference for the symmetric
pathway, indicating that a single SOD1G37R subunit does not affect the dissociation route.
Although the dissociation of the SOD1WT/G37R heterodimer was similar to SOD1WT, we
observed differences in the unfolding of the D11+ ion. The SOD1WT/G37R heterodimer still
proceeded to evolve the three main D11+ conformers across acceleration potentials
11+
(Fig. 3.11 A), with the D11+
[2] and D [3] conformers being abundant from approximately 35 and

45 V acceleration potential respectively (there was low standard deviation between repeats –
11+
Fig. 3.11 B). The D11+
[2] and D [3] conformers both remained abundant across the acceleration

ramp, indicating that the in vacuo unfolding of the SOD1WT/G37R heterodimer was a mix of
11+
both SOD1WT and SOD1G37R unfolding dynamics. By comparing the ratio of D11+
[3] to D [2] ,

we can determine the similarity of the unfolding dynamics between homodimer and
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heterodimer. The SOD1WT/G37R heterodimer unfolding was much closer to that of the
SOD1WT homodimer (Fig. 3.11 C and D), however, there were significant differences
between each variant at 70 V accelerating potential (Fig 3.11 E). These unfolding data, in
conjunction with the dissociation symmetry data, suggest that the effect of the SOD1 G37R
subunit on the heterodimer unfolding is independent of charge as we still observe a high
abundance of D11+
[2] conformer, yet no significant difference in dissociation symmetry when
compared to a SOD1WT heterodimer.

Figure 3.10: IM-MS/MS analysis of a SOD1WT/G37R heterodimer. (A) MS/MS selection of the
SOD1WT/G37R heterodimer. (B) The ratio of M7/4 to M6/5 shows that the charge partitioning of the
heterodimer is closer to that of a SOD1WT homodimer than a SOD1G37R homodimer. (C) The four
dissociation routes (black = WT6+/G37R5+, blue = G37R6+/WT5+, grey = WT7+/G37R4+, red =
G37R7+/WT4+) by which the heterodimer can dissociate reveal that no particular dissociation channel
is favored. Error bars represent SD of the mean from 3 nano-electrosprays.
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Figure 3.11: IM-MS/MS analysis of a SOD1WT/G37R heterodimer. (A) The mean CIU finger print of
D11+ of the SOD1WT/G37R heterodimer. (B) The standard deviation between replicates of the
SOD1WT/G37R heterodimer. (C) The difference in CIU fingerprint between a SOD1WT homodimer
(blue) and a SOD1WT/G37R heterodimer (red). (D) The difference in CIU fingerprint between a
11+
SOD1G37R homodimer (blue) and a SOD1WT/G37R heterodimer (red). (E) The ratio of D11+
[2] to D [3]
showing that the D11+ ion of the heterodimer unfolds with a relationship closer to SOD1WT than
SOD1G37R. All data were averaged from 3 separate nano-electrosprays of different samples, error bars
represent SD of the mean.
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Owing to the substantial difference in the dissociation and unfolding profile of SOD1 G37R
compared to all other variants we next examined the packing of the dissociated monomer ions
across acceleration potentials to determine if there were any differences. Using the CIUSuite
compare function we quantified where the differences were for each variant compared to
SOD1WT. We found a major difference when comparing the SOD1 WT and SOD1G37R M7+
ions, where SOD1G37R presented a more compact dissociation product, as measured by the
drift time (SOD1G37R = 10.3, SOD1WT = 11.2) (Fig 3.12). Further analysis, comparing the
drift times of the SOD1WT and SOD1G37R M7+ ions dissociated from the SOD1WTéG37R
heterodimer showed similar results, where the SOD1G37R ion was more compact than the
corresponding SOD1WT ion in the same assay (Fig. 3.12). Quantification of this was carried
out and it was observed that there was no difference between mean RMSD values for each
monomer ion dissociated from each variant (Fig. 3.13 A, C, and E), and no difference
between all replicates when comparing the M5+ ion from each variant against SOD1WT (Fig.
3.13 B). Only a small difference was observed for the M6+ ion when SOD1G93A was
compared to SOD1WT (Fig. 3.13 D), however a large difference in RMSD was observed for
the M7+ ion for only SOD1G37R (Fig. 3.13 F). These results taken in conjunction with the
different unfolding and dissociation of SOD1G37R indicate that this variant is dissociating
prior to unfolding in this CID-CIU assay.
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Figure 3.12: The difference in the compactness of the dissociating M7+ ion during IM-MS/MS
analysis. The average CIU fingerprint of the dissociated M7+ from each variant (blue) was compared
to the SOD1WT (red) fingerprint to determine differences in the packing of dissociated monomer ion.
Root-mean-square deviation was calculated to determine difference showing that SOD1G37R was the
most different (RMSD = 15.16 %), having a more compact ion at ~10.3 ms drift time across
acceleration potentials.
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Figure 3.13: Analysis of the differences between replicates and variants for the dissociated
monomeric conformers. (A) The variance in replicates for the dissociated M5+ conformer showing
minimal difference for all variants. (B) The difference between WT and other variants for the
dissociated M5+ conformer (black dotted line = total average across all variants). (C) The variance in
replicates for the dissociated M6+ conformer showing minimal difference for all variants. (D) The
difference between WT and other variants for the dissociated M6+ conformer where only G93A was
significantly different (black dotted line = total average across all variants). (E) The variance in
replicates for the dissociated M7+ conformer showing minimal difference for all variants. (F) The
difference between WT and other variants for the dissociated M7+ conformer where G37R and H46R
were both significantly different (black dotted line = total average across all variants). When
comparing to WT, means were calculated by comparing all replicates on a single basis (3x3 replicates
= 9 data points). Significance was determine by students t-test against the total average (*** = P
<0.001, * = P < 0.01).
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3.3 Discussion
In the present study, we have investigated the gas phase dissociation and unfolding of several
ALS-associated SOD1 variants. Our data clearly show that CID-directed dimer dissociation
of SOD1 in vacuo does not reflect its solution-state dissociation dynamics regardless of
mutation. Previous work has determined the dimer dissociation constants of several SOD1
variants, finding specific mutants to have significantly altered dissociation constants
compared to the wild-type (Byrstrom et al., 2010, Khare et al., 2004, Redler et al., 2011).
Here, our CID-based dissociation of SOD1 dimers did not correlate with the substantial
differences between variants that have been previously observed in solution. For example, the
dimer dissociation constant of SOD1A4V was found to be ~ 1 µM, as determined by analytical
size-exclusion chromatography (Redler et al., 2011), compared to a value of 10 nM for
SOD1WT as determined by analytical ultracentrifugation (Doucette et al., 2004). The
usefulness of MS, coupled with analyses that are performed in the gas-phase, to study protein
structure and dynamics in a manner relevant to disease, therefore, is model/protein specific.
Solution methods that measure equilibrium dissociation constants may themselves require
different observation conditions that affect equilibrium. In an MS/MS experiment, in the
absence of solvent, the mechanism of dissociation may be different from those which occur
in solution. In the context of the SOD1 dimer, the driving force behind dimer association is
reported to be hydrophobic interaction, as well as electrostatic attraction between subunits
(Mozo-Villarías et al., 2014). It is known that forces that affect the non-covalent binding of
proteins can be modified in the absence of bulk-solvent, leading to a decrease or loss of
hydrophobic interaction (Bich et al., 2010a), and an increase in the strength of polar and
electrostatic forces (Sharon and Robinson, 2011). From the work presented here, it is clear
that in the case of SOD1, the structural perturbations caused by mutations that destabilise the
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dimer are overwhelmed by the strengthening of the polar and electrostatic interactions
between subunits in vacuo.
The substantial difference in tertiary and quaternary structural stabilities observed in solution
between SOD1 mutants (Byrstrom et al., 2010, Doucette et al., 2004, Khare et al., 2004,
Redler et al., 2011) lead to the hypothesis that MS might be useful to detect these variations,
however, there was no real difference observed in gas phase dissociation and unfolding
between most of the SOD1 mutants. However, it was observed that the D11+ ion of SOD1G37R
presented a significantly more asymmetrical dissociation relative to the other SOD1 variants.
From the analysis of the SOD1WT/G37R heterodimer, one could expect the SOD1G37R subunit
to be disproportionately abundant in the M7+ population owing to the existence of one more
basic residue compared to SOD1WT. Our data shows that this is not the case, suggesting that
charge isomers are not driving unfolding, or that a salt bridge is forming so that the residue
that it pairs with is not available for neutralisation. This also infers that the asymmetry stems
not from a change in the formal charge, but rather allosteric effects that modify the dimer
interface.
IM-MS can determine CCS values that reflect the packing of the native protein conformation.
There were no significant differences in CCS values between our SOD1 variants, with and
without accelerating potential. The SOD1 monomer, in its metal bound disulfide bonded
form, is a constrained and rigid structure. Given the tight packing of SOD1, in conjunction
with the dehydration/collapsing effect of the in vacuo environment, and the relatively low
resolution of IM-MS, we expected no measurable difference in CCS between the variants.
Instead, the main utility of IM-MS in the current work comes from the additional separation
provided by the drift time dimension. By separating the variants, not only using m/z ratio, but
also by CCS, conformational changes provoked by collisional activation were interrogated.
The energy of activation required to transition the monomeric and dimeric ions into their
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more unfolded conformations was effectively the same for all SOD1 variants tested. This
further supports the idea that the effect of mutation on structure is being overshadowed by in
vacuo forces in the work presented here. The transition of the D11+ ion to multiple unfolded
states has been reported previously by Zhuang and colleagues (Zhuang et al., 2014) when
they were performing similar IM-MS analysis on bovine SOD1. They proposed a model of
SOD1 in vacuo destabilisation involving the unfolding of a single subunit in a dimer to
11+
generate D11+
[2] followed by unfolding of the second subunit to generate D [3] as accelerating

potential increases. Dissociation of the dimer can occur from any point along this model. Our
results are in agreement with this model, with the exception of SOD1G37R.
When the results from both the MS/MS and IM-MS experiments are considered, SOD1G37R
stands as a curious outlier with respect to current models of in vacuo dissociation, due to its
asymmetry and unfolding. The inability to inhabit the D11+
[3] state suggests that the dimer is
dissociating prior to unfolding of the second subunit. One would expect this difference in
dissociation state to be reflected in the observed effect of acceleration potential on dimer
dissociation, however, this was not the case. One might also expect that since SOD1 G37R did
not unfold to the same extent as the other variants, that it might present a much more
symmetrical dissociation, but again we observe the opposite. Wanansundara and Thachuck
(2009) suggested that when dimer charge partitioning is symmetric, there is minimal
structural change to monomers prior to dissociation, and that the asymmetric partitioning of
charge results in the more charged monomer unfolding at a lower energy prior to
dissociation. We have observed the opposite here, with SOD1G37R, suggesting that current
modelling may not apply to all proteins. The heterodimer analysis further supports our
postulation of allosteric effects, with the apparent lack of dissociation asymmetry coupled
with the high abundance of D11+
[2] across acceleration potentials.
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Overall, our results show that the in vacuo dynamics of ALS-associated SOD1 variants do
not reflect observations based on dissociation constants measured in the solution phase.
Although native-like protein structure can be retained during ESI-MS, any analysis directed
in vacuo, such as CID or IM-MS, must be performed carefully to ensure relevance when
making comparisons to the solution-state interactions that are associated with disease. The
most interesting data produced, involved the decoupling of dissociation asymmetry and
protein fold in vacuo, suggesting that distribution of charge across a protein multimer alone
may not dictate dissociation characteristics. Regardless of the biological relevance, the ability
to separate and resolve samples based upon m/z and cross-sectional size provides an
invaluable tool for the analysis of heterogeneous samples as evidenced by our ability to
resolve the SOD1WT/G37R heterodimer, and determine its in vacuo dissociation and unfolding
dynamics.
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4. Glutathionylation and Dimer
Dissociation of SOD1
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A sub-set of the data presented in this chapter has been peer reviewed and published in
Scientific Reports (SOD1WT, SOD1A4V, SOD1G37R, SOD1H46R, SOD1D90A, SOD1G93A, and
SOD1V148G data set) and re-edited to encompass new data (SOD1G85R, SOD1G93D, SOD1E100G,
SOD1I112T, and SOD1A140G data set).
Reference:
McAlary, L., Yerbury, J.J., Aquilina, J.A. (2013). “Glutathionylation potentiates benign
superoxide dismutase 1 variants to the toxic forms associated with amyotrophic lateral
sclerosis”. Scientific Reports 3, 3275-80. doi:10.1038/srep03275

4.1 Introduction
Approximately one in five cases of familial amyotrophic lateral sclerosis (fALS) is associated
with naturally occurring mutations in the gene encoding superoxide dismutase-1 (SOD1).
Currently, 183 mutations have been identified and are spread throughout the SOD1 amino
acid sequence (http://alsod.iop.kcl.ac.uk (Abel et al., 2013b). Many of these mutations confer
a significant level of instability to the native homodimer (Hough et al., 2004), which may
ultimately lead to unfolding and the formation of insoluble cytoplasmic aggregates – a
hallmark of SOD1 associated fALS pathology. Concomitant with this, recent evidence has
suggested that the aggregation or misfolding of wild-type SOD1 is involved in some cases of
the considerably more prevalent sporadic ALS (Bosco et al., 2010, Forsberg et al., 2010,
Pokrishevsky et al., 2012b).
Existing evidence suggests that dissociation of the native homodimer is a key step in the
aggregation pathway of SOD1, as SOD1 monomers with various post-translational
modification states have been identified as common misfolding intermediates (Rakhit et al.,
2004, Svensson et al., 2010). This mechanism of aggregation is supported by the
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extraordinary difference in the dissociation constant (KD) reported for the fALS associated
SOD1A4V variant dimer (~1 µM) compared to that of SOD1WT (~10 nM) (Doucette et al.,
2004, Redler et al., 2011); i.e. the dissociation of SOD1A4V into monomers is approximately
100 times more facile at concentrations found in vivo. Furthermore, chemical cross-linking of
the aggregation prone SOD1A4V monomers, can prevent its aggregation in vitro (Ray et al.,
2004). Similarly, cross-linking experiments performed on other SOD1 variants was shown to
confer greater thermostability (Auclair et al., 2010).
A compounding factor in SOD1 dissociation is the post-translational modification (PTM) of
cysteine at position-111 (Cys111) by the ubiquitous antioxidant glutathione, a modification
that has been previously identified in SOD1 purified from human erythrocytes (Wilcox et al.,
2009). Although it has been questioned whether this PTM occurs naturally in neuronal tissue
or rather is an artefact of purification methodology (Auclair et al., 2014). Regardless, the high
concentration of glutathione within tissue (0.5 - 10 mM) (Schafer and Buettner, 2001), and
the innate antioxidant activity of SOD1, identifies glutathione as a possible PTM of SOD1.
Cys111 is proximal to the dimer interface and, not surprisingly, the introduction of a
glutathione moiety has been shown to augment dissociation (Redler et al., 2011), as well as
increase the immunoreactivity of antibodies that recognise misfolded SOD1 (Redler et al.,
2014).
In this work we assess the effect of glutathionylation of Cys111 on the native homodimer of
multiple fALS associated SOD1 variants, comparing the dissociation of the dimer to the
reported patient survival times. We report that level of glutathionylation of Cys111 was
variable across the recombinantly produced SOD1 variants, and that it was consistent with
increased dimer dissociation, showing a stronger correlation with reduced patient survival.

91

4.2 Results
4.2.1 Assessment of modification to recombinant SOD1
We first assessed the modification states of our SOD1 variants after purification using acid
denaturing mass spectrometry, finding that all of our SOD1 variants were glutathionylated to
some extent, and that, for the most part, it was a major modification for all SOD1 variants.
We observed for each variant that the full-length protein mass was consistent with metal-free
disulfide oxidised SOD1 based upon a mass difference of -2 Da which is typically associated
with the loss of hydrogen from two sulfhydryl groups. Previously, it has been shown that
glutathionylation of SOD1 purified from E. coli can occur at all cysteine residues (Cys6,
Cys57, Cys111, and Cys146), as detected by mass spectrometry (Furukawa et al., 2004). We
observed only one peak corresponding to the addition of a single glutathione (+305 Da) for
each SOD1 variant. We deduce this to be glutathionylation of Cys111 based upon the
oxidation of the disulfide (Cys57 and Cys146), and the method by which we express and
purify SOD1 resulting in a natively folded product where Cys6 is not solvent accessible
(Strange et al., 2003). Other modifications were observed consistently on each SOD1 variant
but they were not evident on glutathionylated-SOD1 (gsSOD1), indicating that these
modifications were occurring to Cys111, which would be protected by addition of a
glutathione moiety. Due to this, and for the purpose of the analysis, we term any SOD1
protein species not glutathionylated as unmodified-SOD1 (uSOD1). Modifications to SOD1
were identified by mass difference (Table 4.1), as has been used previously to identify the
sulfinic (+32 Da) and sulfonic (+48 Da) acid modifications in vitro (Fujiwara et al., 2007)
and in vivo (Choi et al., 2005). Another major modification was the peak corresponding to
+119 Da, which is consistent with cysteinylation, a modification previously observed
(Auclair et al., 2013b). The modifications of -18 and -36 Da are typically consistent with
dehydration, however, since they only occurred to Cys111 these identifications are tentative
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and by mass and chemistry we suspect -18 Da as S-gamma-glutamyl from cysteine, and -36
as dehydroalanine from cysteine. This conversion of a cysteine to dehydroalanine is known to
be induced by heat (Wang et al., 2010), and may occur during the purification of SOD1,
where temperatures of 55 – 65 °C are used to partially clear the bacterial lysate containing
SOD1 (section 2.5.1).
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Figure 4.1: Mass transforms showing the modification states of recombinant SOD1. SOD1
variants were incubated in 2% formic acid 49% acetonitrile and 49% 200 mM NH 4OAc for up to an
hour before being nano-electrosprayed. Mass differences are shown in daltons and FL = full length
unmodified SOD1 and GS = glutathionylated SOD1. Peaks with similar mass differences are
observed across all SOD1 variants (-36, -18, +16, +32, +48, +119) but these modifications are not
observed to occur to glutathionylated SOD1, indicating that these are modifications to Cys111.
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Table 4.1: Major modifications to SOD1 detected by acid denaturing mass spectrometry. SOD1
variants were incubated for up to 1 hour in a buffer of 2% formic acid, 50% acetonitrile, and 50%
200 mM NH4OAc before being nano-electrosprayed.

Mass difference (Da)
-36
-18
+16
+32
+48
+119
+305

Identification
Dehydroalanine from cysteine
S-gamma-glutamyl from cysteine
S-OH on cysteine
S-O2H on cysteine
S-O3H on cysteine
Cysteinylation
Glutathionylation (GS)

4.2.2 Glutathionylated SOD1 is disproportionately monomeric
Following our determination of the percentage of SOD1 that was glutathionylated for each
variant, we investigated whether gsSOD1 was disproportionately monomeric. To this end we
performed mass spectrometry optimised to gentle conditions in the absence of denaturant to
maintain the native fold, and compared the relative abundance of uSOD1 and gsSOD1 that
was monomeric for each variant. The charge state distribution of the monomers observed for
each SOD1 variant were conserved to the 8+ and 7+ charge states, typical of what was
previously observed (section 3.2.2, Fig. 3.4). The peaks corresponding to gsSOD1 were
readily apparent for each variant, and in all cases, with the exception of SOD1D90A,
SOD1E100G and SOD1V148G, gsSOD1 appeared to be highly abundant (Fig. 4.2). By
integrating the peak areas of uSOD1 and gsSOD1, from our acid denatured mass
spectrometry (Fig. 4.1), we were able to determine the percentage of each SOD1 variant that
was glutathionylated (Fig: 4.3). We compare total gsSOD1 to the relative abundance of
gsSOD1 within the native monomer ions, finding that in all cases the level of monomeric
gsSOD1 was disproportionately greater than the total percentage of gsSOD1, indicating that
glutathionylation was associated with monomerisation.
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Figure 4.2: Native spectra of SOD1 monomer ions showing high relative abundance of gsSOD1.
SOD1 variants were nano-electrosprayed under gentle conditions to assess modification state of the
solution monomer ions. We found that gsSOD1 was highly abundant in the monomer ions detected
for native SOD1 (M8+ = ~ m/z 2000, M7+ = ~ m/z 2300). Each spectrum is representative of 3 nanoelectrosprays.
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Figure 4.3: Monomeric gsSOD1 abundance is disproportionately greater compared to total
abundance of gsSOD1. Comparison of percentage of SOD1 that is glutathionylated (measured from
the acid denatured mass spectrometry) and SOD1 monomer that is glutathionylated (from native mass
spectrometry). The comparison shows, that in all cases, there is a higher abundance of gsSOD1
monomer relative to the total gsSOD1 abundance. Error bars represent SD of the mean of 3 separate
dilutions of sample.

4.2.3 Glutathionylation increases the dimer dissociation constant of SOD1
The observation that gsSOD1 was disproportionately monomeric as detected by mass
spectrometry, and the fact that previous work has suggested that glutathionylation of SOD1 at
Cys111 enhances dimer dissociation (Redler et al., 2011), prompted us to investigate the
dimer dissociation of a range of SOD1 variants in the context of glutathionylation. Mass
spectrometry is useful for the assessment of non-covalent protein-protein interactions as the
mass resolution provides a means by which to separate and analyse differentially modified
protein species. With this in mind, SOD1 dimers could be comprised of two unmodified
monomers (uSOD12), one unmodified monomer and one glutathionylated monomer
(uSOD1:gsSOD1), or two glutathionylated monomers (gsSOD12) (Fig. 4.4). The resolution
provided by native mass spectrometry was different for each SOD1 variant, even when they
were measured at similar system parameters, which implies that certain mutants may
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desolvate more efficiently. Due to the necessity of maintaining system parameters, we
theoretically determined, by expected masses, the areas under the peak that corresponded to
uSOD12, uSOD1:gsSOD1, and gsSOD12 (Fig. 4.4).
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Figure 4.4: Native spectra of the SOD1 dimer. SOD1 variants were nano-electrosprayed at a
concentration of 5 µM under gentle conditions optimised to maintain native interaction. It was
observed that the main dimer peaks were at 10+ (~3250 m/z) and 11+ (~2950 m/z) charge states. The
resolution of differential glutathionylation states on these peaks was variable, and seemed to be
associated with the extent of glutathionylation within the sample, as well as the overall dimer KD
determined i.e., The greater the effect of glutathionylation on KD, the less gsSOD1 existed as dimer to
measure.

A dilution series of SOD1 variants was prepared ranging from 20 µM to 620 nM and mass
spectrometry was used to determine the relative abundance of all species present in solution.
As a result, it was possible, by plotting the proportion of monomer vs total concentration
(Fig. 4.5), to calculate discreet dimer dissociation constants for uSOD12 and gsSOD12.
Owing to the differences in resolution between SOD1 variants, we elected to determine areas
under the peaks as corresponding to uSOD12, uSOD1;gsSOD1, or gsSOD12 based upon
expected mass. Unlike the homodimers, which dissociate into their respective and unique
monomer pairs, products of the heterodimer (uSOD1:gsSOD1) contributed to both
populations of monomer, and were not so readily estimated. In an effort to account for
monomers originating from the mixed dimer, we monitored the decline in uSOD1:gsSOD1
ion intensity with successive dilution, and subtracted an equivalent quantity from each
monomer signal. Although imprecise, we believe this correction attenuated, to some extent,
the confounding effects of the mixed dimer species.
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Figure 4.5: Glutathionylation of SOD1 increases dimer dissociation propensity. Successive
dilution of SOD1 variants prior to mass spectrometry resulted in an increase in monomeric signal as
SOD1 concentration decreased. In all cases, uSOD1 (red) monomer abundance was less than that of
gsSOD1(blue) at all concentrations. Variants with only uSOD1 plots were not sufficiently
glutathionylated for accurate measurement. Error bars represent SEM of 3 dilutions and nanoelectrosprays.
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Table 4.2: Dimer KD’s of uSOD1 and gsSOD1 variants as measured by mass spectrometry.
SOD1 variants dimer KD’s were determined as previously described (Rose et al. 2011). Linear
regression plots, from which KD’s were calculated, can be found in Appendix C.

Variant
uSOD1 KD
(nM)
gsSOD1 KD
(nM)
Variant KD
(nM)
uSOD1 KD
(nM)
gsSOD1 KD
(nM)

WT

A4V

G37R

H46R

G85R

D90A

9±1

1100 ± 100

10 ± 1

30 ± 4

8±2

25 ± 4

34 ± 5

9600 ± 900

60 ± 9

97 ± 16

-

-

G93A

G93D

E100G

I112T

A140G

V148G

12 ± 1

54 ± 8

7±2

32 ± 3

86 ± 8

271 ± 40

160 ± 32

395 ± 48

-

622 ± 85

661 ± 81

-

All uSOD1 variants, except uSOD1G85R and uSOD1E100G, had dimer KD values greater than
that of uSOD1WT (9 ± 1 nM), implying that single residue substitutions are sufficient to
disturb the quaternary structure. uSOD1G85R (8 ± 2 nM) and uSOD1E100G (7 ± 2 nM) both had
dimer KD values that were not significantly different to that of SOD1WT suggesting similar
quaternary dynamics between these variants. The most substantial augmentations were
observed for uSOD1A4V (1.1 ± 0.1 µM) and uSOD1V148G (271 ± 40 nM), being approximately
112-fold and 28-fold greater than uSOD1WT respectively (Fig. 4.6 A). SOD1A140G showed an
interesting difference with an 8.9-fold change, which was unexpected due to the location of
this mutation being localised to loop-VII which is distal from the dimer interface. The
changes in dimer KD in the other variants ranged from 0.8 to 5.6-fold, which, whilst
appreciable, were not as substantial as SOD1V148G or SOD1A4V. Assessment of the foldchange in dimer KD between uSOD1 and gsSOD1 for each variant showed that
glutathionylation of Cys111 was substantially increasing dimer dissociation (Fig. 4.6 B),
consistent with previous work (Redler et al., 2011). The fold-changes in KD values were
different for each variant, with the greatest difference being that of SOD1 I112T (19.6-fold
change), which is suggestive of cross-talk between mutated residues, Cys111, and dimer
interfacing.
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Figure 4.6: Fold change in dimer KD induced by mutation and glutathionylation. (A) The foldchange in dimer KD of uSOD1 variants compared to uSOD1WT. (B) The fold change in dimer KD when
comparing uSOD1 to gsSOD1 in variants that were sufficiently glutathionylated.

The fact that monomeric SOD1 is associated with aggregation implicates the monomer as a
potential toxic form or intermediate. Owing to this, we sought to determine if there was a
plausible link between patient survival and the dimer KD determined here (Fig. 4.7). To
achieve this, the log of the KD value of each mutant was plotted against mean disease
duration (Wang et al., 2008) (Fig. 4.7). We found that there was a weak correlation between
dimer dissociation rates and disease duration for all uSOD1 variants (r2 = 0.12 for all
variants, r2 = 0.18 for the subset that were sufficiently glutathionylated to enable analysis)
(Fig. 4.7 A and B). In comparison, the dissociation rate specific to gsSOD1 had a much
stronger, although still weak, correlation with disease duration (r2 = 0.49), suggesting that
perhaps modification of the Cys111, in this case glutathionylation, may play a role in the
augmentation of monomerisation and subsequent destabilisation of SOD1 thought to
contribute to disease severity.
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Figure 4.7: Dimer dissociation of gsSOD1 has a stronger correlation with patient survival than
uSOD1. (A) Plot of log uSOD1 (KD/nM) against the mean disease duration of the variant showing a
weak correlation (r2 = 0.12). (B) Plot of log uSOD1 (KD/nM) against mean disease duration of
variants that had their corresponding gsSOD1 dimer KD values determined, showing a weak
correlation (r2 = 0.18). (C) Plot of log gsSOD1 (KD/nM) against mean disease duration showing a
stronger correlation than uSOD1 (r2 = 0.49).

4.3 Discussion
Post-translational modifications are important features to consider when examining
biophysical characteristics and dynamics of proteins. Our mass spectrometry-based analysis
identified several modifications that occurred to recombinantly expressed SOD1 that
appeared to be localised to residue Cys111. Cys111 has been identified as a site of oxidative
modification previously (Choi et al., 2005, Fujiwara et al., 2007), and the modifications we
observed were in agreement with past work. Although we report on the dimer KD of what we
here refer to as unmodified SOD1, it is clear from our denaturing mass spectrometry that
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there is a great extent of modification included within this defined population, and these
modifications may have potentially augmented the uSOD1 dimer KD reported here.
It is well documented that patients suffering from SOD1-associated fALS have variable
survival times (Wang et al., 2008), dependent upon the particular amino acid substitution.
Our analysis of the dimer KD of the uSOD1 variants and their corresponding mean disease
durations produced weak a correlation, however the correlation was appreciably increased
when examining the dimer KD of gsSOD1 variants, inferring that glutathionylation is a
potential modifier of SOD1-associated ALS. An interesting observation was that specific
SOD1 variants with stable quaternary structures but rapid disease progression, such as
SOD1G93A (KD = 12 nM, disease duration = 2.2 years) and SOD1 I112T (KD = 32 nM, disease
duration 0.9 years), had substantial increases in dimer KD when glutathionylated (~13-fold
and ~20-fold respectively). This effectively highlights the importance of understanding the
effects of post-translational modifications on proteins in regards to biophysical
characterisation. Our data can be used to reframe the idea that there is a relationship between
dimer KD and disease progression: i.e., it is not only the dimer KD of ALS-associated SOD1
variants that may influence the rate of disease progression, but potentially the extent of
glutathionylation and the dimer KD of the glutathionylated species. Glutathionylation,
however, is not a requirement for pathogenicity, as sequence modification alone of SOD1A4V
and SOD1V148G cause ~110-fold and ~30-fold increases in dimer KD over SOD1WT
respectively. These mutations are located deep within the inter-subunit cleft, where small
molecular volume changes are able to disrupt the dimer interface leading to more facile
dissociation (Perry et al., 2010).
In contrast to Val148 and Ala4, Gly37 and Gly93 are spatially remote to the dimer interface,
being situated in the β3/β4 Greek key loop and the β5/β6 inter-strand loop respectively. It is
notable that the Gly37 and Gly93 loops are proximal to each other and the Leu38 cork, while
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Cys111 is within the β6/β7 Greek key loop at the opposite end of the β-barrel. Prior to
glutathionylation, the G37R and G93A mutations impart a somewhat negligible effect upon
the KD of SOD1; i.e., in isolation, these mutations appear not to be significantly destabilising
to natively folded SOD1. Rather, it is the synergy of glutathionylation and point mutation at
the β-barrel ‘poles’ that accounts for the significantly higher KD of a multitude of individual
variants in a unique allosteric-like fashion. Even though the work presented here implicates
post-tranlsational modification to C111 as a possible disease modifier, it is interesting to note
the existence of the C111Y mutation that is reported to have high penetrance for ALS(Eisen
et al., 2008). We would postulate that the C111Y mutation would act much in the same
fashion as other SOD1 mutations, lowering the structural stability of the folding states,
increasing the propensity for pathogenic aggregation. Indeed, in cell-culture models of SOD1
aggregation a SOD1C111Y mutant shows a high aggregation propensity comparative to a
SOD1C111S mutant (Karch and Borchelt, 2008). Taken together, these data are consistent with
the contemporary notion of SOD1 dimer dissociation being a major factor in SOD1associated fALS, and therefore requires further examination. We
Specifically, it is proposed that the toxicity of a specific variant of SOD1 is a biophysical
consequence of either, (i) a potent destabilising mutation such as A4V, or (ii) modification of
Cys111, including glutathionylation as studied here, in a weak or non-destabilising mutation
such as G93A. Indeed, oxidation of Cys111 has been observed in sporadic ALS in the
absence of SOD1 mutation (Auclair et al., 2014). In each scenario there is an increase in the
abundance of monomer, which is more susceptible to misfolding into toxic conformations
compared to the dimer (Rakhit et al., 2004, Svensson et al., 2010). If the cellular clearance
rate of misfolded SOD1 is inadequate, increasingly frequent hydrophobic interactions
ultimately give way to aggregation, forming larger structures that stress the cellular
machinery (Weisberg et al., 2012). Many neurodegenerative diseases, including ALS, are
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also associated with oxidative stress (Barber and Shaw, 2010), which in turn can lead to an
up-regulation of glutathione (Dalle-Donne et al., 2007) increasing the likelihood of gsSOD1.
Indeed, an increase in GSH levels has been observed in ALS patient CSF (Tohgi et al., 1999),
marking glutathionylation as a potential modifier of SOD1-associated ALS pathogenesis.
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5. Aggregation and Unfolding of SOD1
variants
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5.1 Introduction
Amyotrophic lateral sclerosis (ALS) is a disease characterised by the progressive
degeneration of both upper and lower motor neurons, ultimately resulting in death. The
symptoms of ALS typically manifest in people aged 55-65 years, with younger patients rarely
being identified (Gordon, 2011). Post-diagnosis, the average disease duration is
approximately 3 years, although patients suffering different familial variants can have shorter
and longer durations. Genetic studies of ALS patients have revealed that 90% of cases are
sporadic (sALS) and the remaining 10% of cases are familial (fALS) (Renton et al., 2014).
Several of the fALS associated genes (TDP-43, C9orf72, FUS, ALS2) have roles in the
biogenesis and trafficking of RNA species, and another clear grouping are associated with
protein degradation (CCNF, VCP, SQSTM1, UBQLN2, OPTN, TBK1); most are also linked
to frontotemporal dementia (Peters et al., 2015). The first fALS linked gene discovered, and
most studied, is the gene encoding superoxide dismutase-1 (SOD1) which is only associated
with a pure motor neuron disease phenotype.
SOD1 is a cytosolic 32 kDa homodimeric enzyme that catalyses the dismutation of oxygen
radicals to either molecular oxygen or hydrogen peroxide (McCord and Fridovich, 1969).
Each subunit contains a catalytically active copper ion, a zinc ion, and an intramolecular
disulfide bond. These post-translational modifications confer substantial stability to the native
fold of SOD1, endowing it with resistance to heat denaturation and maintenance of catalytic
activity in denaturing conditions (Rodriguez et al., 2002, Senoo et al., 1988). Zinc binding
occurs spontaneously following synthesis and folding, whereas copper binding and disulfide
bond formation are mediated by association with the copper-chaperone for SOD1 (Furukawa
et al., 2004, Rae et al., 2000). Currently, there are known to be over 180 natural mutations
that

can

occur

within

the

SOD1

sequence

that

are

associated

with

fALS

(http://alsod.iop.kcl.ac.uk - (Abel et al., 2013b). These mutations occur throughout the SOD1
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structure, and all have the ability to destabilise the native fold, leading to an increased
propensity to misfold and/or aggregate (Byrstrom et al., 2010, Khare et al., 2006, Munch and
Bertolotti, 2010). Owing to the high number of mutations associated with SOD1 fALS, and
the fact that a misfolded/aggregated wild-type SOD1 species has been found associated with
sALS (Bosco et al., 2010), it has been suggested that there is a common toxic form that exists
for all SOD1 variants, although it is yet to be elucidated.
Metal coordination and disulfide bond formation are important for stability of SOD1 tertiary
and quaternary structures (Hayward et al., 2002, Lynch et al., 2004, Svensson et al., 2010,
Tiwari and Hayward, 2003), and their absence has been shown to increase the aggregation
propensity of SOD1 (Arnesano et al., 2004, Ding and Dokholyan, 2008). From this, it has
been inferred that an immature/unfolded conformation(s) of SOD1 is responsible for
aggregation. Investigation of these possible unfolded SOD1 conformations has been difficult
due to the heterogeneity of non-native protein structures. High resolution analyses, such as Xray crystallography, are impeded by the existence of disordered protein regions that can
assume multiple conformations (Banci et al., 2009), and typical separation techniques such as
size exclusion chromatography (SEC) do not provide sufficient resolution to separate
different conformations for downstream analysis (Hong et al., 2012), although use of smallangle X-ray scattering coupled with SEC can provide valuable insight into the structural
plasticity of proteins in solution by separating different conformers and oligomeric states
(Furukawa et al., 2015, Wright et al., 2011, Wright et al., 2016). Nuclear magnetic resonance
(NMR) spectroscopy has been used to great extent on disordered SOD1, monitoring
unfolding, refolding, and even identifying a zinc-deficient form of SOD1 proposed as a
precursor to the toxic species (Luchinat et al., 2014, Szpryngiel et al., 2015). Although NMR
analysis is an extremely useful tool in structural biology, it requires high concentrations of
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protein (0.1-3 mM), which can lead to undesirable artefacts, especially in the case of proteinprotein interactions.
In comparison, native mass spectrometry (MS) is a powerful tool for the analysis of
structurally heterogeneous protein samples as it allows for the separation of different protein
species based upon mass, charge, and drift time when coupled to ion mobility (IM-MS)
(Mehmood et al., 2015), allowing for the resolution of species in solution at variable
concentrations. This study details the use of native MS to investigate the possible
misfolded/unfolded conformations SOD1 can occupy when metal binding and disulfide
bonding are disrupted, and the relationship of these species to SOD1 aggregation. We first
determined if there was a correlation between isolated recombinant protein aggregation and
cellular aggregation of different SOD1 variants, focusing on the EGFP fusion proteins
(described in table 2.1 and section 2.8). Next we attempted to assess the oligomeric state of
our SOD1 variants under similar aggregation conditions, finding that SOD1 variants had
differential mobility in both SEC and native PAGE. This was followed by native MS
analysis, as well as IM-MS to separate and analyse the variably destabilised SOD1 species.
Our observations indicate that the oligomeric state of the SOD1 variants was primarily
monomeric and that the monomer assumed 3 conformations based upon mass-to-charge
distributions. The relative abundances of the conformations were dependent upon the SOD1
variant being analysed.

5.2 Results
5.2.1 Cellular and isolated protein aggregation of SOD1 variants
It has been established that SOD1 variants expressed in cultured cells have differing
propensities to aggregate (Turner et al., 2005). This variation in aggregation may offer an
explanation to the large disparity in average length of disease duration between SOD1
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mutations. We first sought to determine the aggregation propensities of our chosen SOD1
variant EGFP fusion proteins in cultured cells using microscopy. To this end, mouse
neuroblastoma/motor neuron hybrid cells (NSC-34) (Cashman et al., 1992) were transfected
with SOD1-EGFP and imaged 48 hours post-transfection, to count the number of transfected
cells that formed inclusions. We observed that variants SOD1A4V, SOD1G37R, SOD1G85R,
SOD1G93A, and SOD1V148G had significantly increased populations of transfected cells
containing inclusions when compared to SOD1WT (Fig. 5.1 A, B). In contrast, there was no
statistical significance between SOD1WT and the variants SOD1H46R and SOD1D90A (Fig. 5.1
B). We also generated tdTomato fusions of select variants (SOD1A4V, SOD1G85R, SOD1G93A
and SOD1V148G) and assessed the inclusion formation of these constructs. The tdTomato
fusion proteins generally showed a decrease in numbers of cells with inclusions when
compared to the corresponding EGFP fusion (Fig. 5.1 C). This observed difference in
inclusion formation is most likely due to the difference in size between EGFP (~29 kDa) and
tdTomato (~59 kDa).
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Figure 5.1: SOD1 variants have differential aggregation propensities in NSC-34 cells. Cells were
imaged 48 h post-transfection and the number of transfected cells containing inclusions was counted.
(A) Representative images of NSC-34 cells transfected with SOD1WT, SOD1A4V, SOD1G37R, and
SOD1G93A showing cells containing bright puncta that were determined to be inclusions. (B) Manual
counting of images showed that SOD1 variants had differential aggregation propensities when
expressed in NSC-34 cells. Significance is determined against SOD1WT-EGFP. (C) Comparison of
inclusion formation 48 h post-transfection between EGFP (green) and tdTomato (red) SOD1 fusion
proteins normalised to the EGFP inclusion count to allow comparison of differences. Error bars
represent SD of the mean from 3 separate transfections on different days. Statistical significance was
determined via a one-way ANOVA with a Tukey’s multiple comparison post-test (*** = P < 0.001,
** = P < 0.01, * = P < 0.05, ns = non-significant).

Following from this, we sought to assess if there was a correlation between isolated
recombinant protein aggregation and aggregation in cells. We based our aggregation assay of
isolated protein on previous work (Furukawa et al., 2008), making use of DTT (to reduce the
intramolecular disulfide) and EDTA (to chelate Cu and Zn), as well as shaking, to promote
aggregation of the SOD1 variants, as spontaneous aggregation of holo-SOD1 is yet to be
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observed. Aggregation was measured via thioflavin T fluorescence, which has been used as a
measure of amyloid formation and is thought to fluoresce when it binds to the β-sheet
structure characteristic of amyloid. The variants SOD1WT, SOD1G37R, SOD1H46R, SOD1D90A,
SOD1G93A and SOD1V148G were chosen for the remainder of this work owing to their high
purification yield and variable patient survival time (SOD1G37R = ~17, SOD1H46R = ~17.6,
SOD1D90A ~8, SOD1G93A ~3.1, SOD1V148G = ~2.1 years) (Wang et al., 2008). The aggregation
propensities differed between SOD1 variants (Fig. 5.2 A and B), with SOD1V148G, SOD1G93A,
SOD1G37R, and SOD1D90A obeying Boltzmann-sigmoidal kinetics typical of fibrillar
aggregation. SOD1 aggregation is noted to be a highly stochastic process, with large variance
between technical and biological replicates (Abdolvahabi et al., 2016); however, a
comparison of the rates of fibril elongation (measured as change in ThT fluorescence) (Fig.
5.2 C) between two assays here showed that inter-assay variation was minimal with the
exception of SOD1G93A. SOD1WT and SOD1H46R did not fit standard fibrillar aggregation
kinetics, and as such analysis of the fibril elongation phase was not performed on these
variants. Rather, SOD1WT and SOD1H46R did not seem to aggregate at all under our assay
conditions (20 mM DTT, 5 mM EDTA 1 ×PBS 37 °C, shaking agitation), suggesting either
resistance to the initial denaturing event or aggregation proceeding down an amorphous
pathway not recognized by ThT. For the most part, our assays suggested that propensity to
aggregate was dependent upon mutation, and when we plotted the relative final fluorescence
of each SOD1 variant in first isolated aggregation assay (Fig. 5.2 A) against the inclusion
formation data from transfected mammalian cells (Fig 5.2 D) we observed a relatively weak
correlation (r2 = 0.6). However, if we omit SOD1G37R as an outlier, due to its interestingly
high propensity to form inclusion in cells comparative to its patient survival time, the
correlation is much stronger (r2 = 0.86). We also plotted the lag-phase of aggregation against
the percentage of cells with inclusions (Fig. appendix-C 5) finding a plausible correlation (r2
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= 0.83), however there were only 4 data points in this analysis, and it would be greatly
benefitted by expanding the number of mutants investigated. These data taken together
suggest that in our case, with the exception of SOD1G37R, aggregation propensity of isolated
SOD1 can predict its cellular aggregation. The two models of aggregation (isolated protein
and cellular) were also compared with regards to the variable disease duration observed in
SOD1-associated fALS patients. Plotting the maximum relative ThT signal against SOD1
mutant disease duration showed a relatively strong correlation of r2 = 0.77, however when
plotting the number of cells with inclusions against disease duration the r 2 value of 0.16 was
much weaker.
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Figure 5.2: SOD1 aggregation and its relationship with disease progression. (A) and (B)
Aggregation of SOD1 was promoted with DTT, EDTA, with shaking at 37 °C, and was monitored by
ThT fluorescence. Dotted lines represent SEM of 4 technical replicates. (C) Plotting the slope of the
elongation phase, of the variants that had a sigmoidal fit with an r2 > 0.8, showed that inter-assay
variations in aggregation were low with the exception of SOD1G93A. (D) Plotting the max
fluorescence of each variant in assay A against the previously shown intracellular aggregation data
gave an r2 value of 0.60 (solid line) for our SOD1 variants. The r2 value was 0.86 (dotted line) when
SOD1G37R was omitted from the data. (E) Plotting maximum ThT signal vs disease duration gives a
moderately strong r2 value of 0.77. (F) Plotting the number of cells with inclusions against disease
duration gives a relatively weak r2 value of 0.16. Error bars represent SD of mean for cells containing
inclusions and SEM for 4 technical replicates of aggregation assay A for ThT signal.
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5.2.2 Solution analysis of SOD1 denaturation and aggregation
Since our the protein aggregation assay relied upon disulfide reduction and metal chelation to
aggregate SOD1, we attempted to assess the consequences of these reactions on the initial
oligomeric distribution of SOD1 structure using native PAGE. SOD1 variants were subject
to aggregation conditions similar to that of our isolated protein assay (30 µM SOD1, 20 mM
DTT, 5 mM EDTA in 1 × PBS) and aliquots were taken and flash frozen in liquid nitrogen
for subsequent native PAGE. Native PAGE of our variants at a concentration of 15 µM
resolved SOD1WT, SOD1H46R, and SOD1D90A into clear monomer and dimer populations (Fig.
5.3). The monomeric population of SOD1WT and SOD1H46R decreased as aggregation
proceeded, whereas SOD1D90A had both its monomer and dimer populations decrease as
aggregation proceeded, indicating the dimer was dissociating into monomers, or that the
dimer was taking part in aggregation. Interestingly, we observed no separate monomer or
dimer populations for SOD1G37R, SOD1G93A, or SOD1V148G. Rather, the bands seem to
indicate that a large proportion of the protein remained dimeric as aggregation proceeded, but
the intensity of these bands decreased substantially as aggregation progressed. In particular,
SOD1G37R showed a substantial difference compared to SOD1WT as there was a large
proportion of protein that had a lower mobility when compared to the dimer band, suggesting
the presence of larger oligomeric species. Apparent aggregation (indicated by the red band
above gel), identified by the presence of protein in the stacking gel or by streaked high
molecular weight protein species was observed for all variants at 24 and 48 hours. SOD1D90A
had substantial abundance of high molecular weight species at 4 hours and onwards, at odds
with the previous aggregation assay data, although this difference maybe due to the kinetics
of both systems (eppendorf tube vs microplate well), or the stochastisty of protein
aggregation, i.e. fibrillar vs amorphous aggregation, as well as potentially capturing
oligomers that eventually give way to ThT postivie fibrils. Native PAGE has been used
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previously to investigate the electrophoretic mobility of SOD1 variants following disulfide
reduction (Tiwari and Hayward, 2003), where it was proposed that increased mobility was
most likely a result of metal loss, and retarded mobility was most likely a result of a
conformational change in the protein structure. It is clear that aggregation was occuring for
each of the SOD1 variants, however we could not accurately quantify aggregation nor
determine aggregate morphology (amorphous or fibrillar) using this assay.
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Figure 5.3: Native-PAGE of SOD1 variants under aggregation conditions. SOD1 variants were
subject to aggregation conditions and aliquots were taken and snap frozen in liquid nitrogen for native
PAGE. Ellipsoids denote oligomeric state (1 = monomer, 2 = dimer) and the red line indicates
fractions where protein remains in the stacking gel, indicating large oligomers or aggregates.
SOD1WT, SOD1H46R, and SOD1D90A showed the expected monomer dimer distribution, however
SOD1G37R, SOD1G93A, and SOD1V148G did not. The 0 time point is shown only for SOD1WT as all
variants shared the same profile at this point.
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The apparent structural heterogeneity, induced by DTT and EDTA treatment across SOD1
variants, likely arising from differential oligomeric distributions, metallation states, and
disulfide statuses, prompted a secondary approach. We elected to use analytical SEC after a
2 hour incubation in DTT and EDTA, in order to simultaneously investigate oligomeric
distribution and desalt samples for native mass spectrometry. We observed that the elution
profiles of the SOD1 variants corresponded closely to the mobility observed for each variant
at the 2 hour time point of the native PAGE assay (Fig. 5.4), suggesting similar changes were
detected by each technique. The dimer and monomer populations were, again, apparent for
SOD1WT, SOD1H46R and SOD1D90A, with the dimer eluting at ~12.5 mL, and the monomer at
~14.3 mL. However, the elution profile of the DTT/EDTA-treated SOD1 dimer was distinct
to the primarily dimeric non-treated controls (~13.6 mL), indicating a change in the
hydrodynamic volume of the SOD1 dimer. This shift to a lower elution volume was observed
for all SOD1 variants, with SOD1G37R, SOD1G93A and SOD1V148G having major elution peaks
at ~12.5 ml, but no peak at ~14.3 mL in contrast to SOD1WT, indicating a lack of monomer.
Interestingly, SOD1G37R showed substantial protein at the void volume indicating the
presence of oligomeric species with masses greater than or equal to ~100 kDa (S-75 10/300
GL column). SOD1G93A, SOD1V148G, and to a lesser extent SOD1D90A showed the presence of
oligomeric species with peak shoulders ranging from ~ 9 to 11 mL. The high abundance of
oligomeric species observed, after only 2 hours, is most likely due to the effects of
concentrating the protein prior to analytical SEC, however it is interesing to note the
differences between SOD1 variants. The analytical SEC, in conjunction with the native
PAGE analysis, suggest that after a 2 hour treatment with DTT and EDTA, SOD1 undergoes
a conformational change that affects the hydrodynamic volume and the packing of the
protein. It is well known that changes to the structure of molecules can make SEC data
ambiguous (Hong et al., 2012), potentially making the interpretation of these data
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complicated. Due to this, native mass spectrometry analysis was performed on fractions
eluted from analytical SEC assays.

Figure 5.4: Analytical size-exclusion chromatography of SOD1 variants. SOD1 variants were
incubated at 37 °C, in 1 × PBS, with 20 mM DTT and 5 mM EDTA, for 2 hours. After incubation,
samples were concentrated at 4 °C to 450 µM in a volume of 100 µl and loaded onto an analytical S75 column equilibrated in 200 mM NH4OAc, and eluted at 0.5 ml/min into 0.5 ml fractions. Black is
control SOD1 which was not incubated in the presence of DTT or EDTA. Blue is SOD1 +DTT
+EDTA, which showed different elution profiles for all SOD1 variants, with the peak at ~12 mL
being labelled ‘peak 1’ and the peak at ~14 mL being labelled ‘peak 2’. Inset above each
chromatogram is native PAGE of the 2 hour incubation time point.
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5.2.3 Native mass spectrometry analysis of DTT/EDTA-treated SOD1 variants
The previous native PAGE and analytical SEC assays indicated the presence of high
molecular weight oligomeric species, as well as SOD1 dimer and monomer populations. In
addition, a potential change in conformation was observed as the dimer peak had a lower
elution volume after treatment. Native mass spectrometry (MS) can be used to
simultaneously investigate this dynamic system in simple experiments, giving high-resolution
mass data that can be used to determine modification states (disulfide status, metal binding,
oxidative modification). MS was used to analyse the main peaks eluting from the analytical
SEC from figure 5.4 (MS analysis in Fig. 5.5 and 5.6), finding that in the case of SOD1 WT,
(Fig. 5.5 A and B) the oligomeric distribution in the mass spectra matched the oligomeric
state determined from the SEC (i.e. the peak at 12.5 mL = dimer and the peak at 14.3 mL =
monomer). The charge state distributions of both monomer and dimer in this assay were
similar to that observed previously for native SOD1 variants (dimer 9 – 12+, monomer 7 –
8+) (McAlary et al., 2013a); however, there was a relatively high abundance of monomer in
peak 1 of DTT/EDTA-treated SOD1WT from the analytical SEC (dimer = 76.5%, monomer =
23.5% of signal) (Fig. 5.5 A), and also a low abundance of dimer present in the monomer
peak (dimer = 5.6%, monomer = 94% of signal) (Fig. 5.5 B). The presence of monomer in
the dimer peak maybe, at least partly, attributed to the effect of diluting the protein from an
original concentration off the column to a concentration of 10 µM for analysis, as well as
overlap of monomer and dimer populations as baseline resolution was not achieved during
SEC separation. Analytical SEC of SOD1G93A resulted in only one major peak from
DTT/EDTA treatment at 12.5 mL (peak 1), consistent with the elution of the DTT/EDTAtreated SOD1WT dimer peak (Fig. 5.4). However, when this was analysed via MS, it was
observed that a substantially higher abundance of monomer ranging from charge states 7+ to
21+ was present (Fig. 5.5 C). Figure 5.6 shows that this broad monomeric charge state
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distribution was also observed in the ~12 mL peak for SOD1G37R (peak 1), the ~14.2 mL peak
for SOD1D90A (peak 2), and the ~12.1 mL peak for SOD1V148G (peak 1), although each
presented different relative abundances of the highly charged monomer ions (9 – 21+). The
charge state distribution of proteins in mass spectrometry is dependent upon conformation
(Prakash and Mazumdar, 2005), and the presence of these highly charged monomeric ions is
indicative of a variably unfolded protein in the solution phase, due to greater access of
solvent to chargeable sites during ionisation. SOD1 contains 23 basic amino acids (His = 8,
Lys = 11, Arg = 4), and when recombinantly expressed and purified from E. coli, the
methionine at position 1 is cleaved but the N-terminus is not acetylated (see section 4.2.1 and
(Leinweber et al., 2004), meaning it can theoretically carry 23 positive charges if fully
unfolded. Figure 5.5 C shows a maximum of 21 charges applied to SOD1G93A, and even in
the case of SOD1G37R (Fig. 5.6), which has 24 chargeable sites, we only see a maximum of 21
charges, indicating that 2 (3 for SOD1G37R) of the basic amino acids are masked from
protonation.
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Figure 5.5: Native mass spectrometry of peaks from analytical SEC. Fractions from peaks were
subject to mass spectrometry under gentle conditions (section 2.6.1). (A) Spectra of the first eluting
peak of SOD1WT (~12.5 mL) showing dimer (black labels) as the most abundant species with an
appreciable abundance of monomer (grey labels). The charge state distribution was typical of a
natively folded SOD1WT. (B) Spectra of the second eluting peak of SOD1WT (~14.3 mL) showing the
major species as monomeric SOD1 at charge states 7+ and 8+, with a low abundance of dimer. (C)
Spectra of the major peak of SOD1G93A (~12.5 mL) showing a high abundance of monomer ranging
from charge states 7+ to 21+, with a low abundance of dimer. This broad charge state distribution is
indicative of the monomer inhabiting several conformations. The SOD1WT spectra also contained
highly charged monomer signal but it is not visible due to low abundance. Similar spectra from other
variants are shown in figure 5.6.
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Figure 5.6: Native mass spectra of peaks from analytical SEC. Other SOD1 variants were subject
to analysis similar to that in Figure 5.5. Each variant had unique spectral profiles, with SOD1 G37R
presenting the most abundant and highly charged monomeric distribution. The first eluting peak of
SOD1H46R (~12.5 mL) showed a population of trimer (red labels) ranging from 13+ to 15+ charge
states.
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To further investigate the effect of DTT/EDTA-treatment on the SOD1 variants, MS coupled
with ion mobility (IM-MS) was used to determine the drift times of ions, where these drift
times are correlated with the collisional cross-section of the ion. The IM-MS analysis
revealed that the ions carrying lower charge were unfolding in vacuo, suggesting that they
were maintaining their solution phase conformation for the most part. This is evidenced by
the existence of low charge monomers (7-8+) partitioning to two populations in the drift-time
7+
8+
dimension (M[2]
and M[2]
) (Fig. 5.7). The monomer ions that had larger collisional cross-

sections (more unfolded; defined by their increased drift times) ranged from 7 – 11+ across
all SOD1 variants, however the abundance of these conformers was different for each variant.
The monomeric fraction from analytical SEC of SOD1WT (taken from a different assay to
what is shown in Fig 5.5) showed that the monomer fraction of SOD1WT is capable of
unfolding in solution, as indicated by the highly charged monomer (Fig. 5.7 A), although the
unfolded species was at a very low abundance (4.3%). This is similar to the presence of
unfolded monomer in the monomeric fraction of SOD1D90A suggesting that the unfolding
may occur spontaneously after analytical SEC. SOD1H46R and SOD1D90A (Fig. 5.7 C and D
respectively) showed monomeric conformers of similar drift time to that of SOD1WT,
although the M9+ ion did not evolve a third conformer in the case of SOD1H46R. This is most
likely due to the different relative abundances of ions detected for each SOD1 variant. In
agreement with previous spectra, SOD1G37R, SOD1D90A, and SOD1V148G (Fig. 5.7 B, E, and F
respectively) all produce a monomeric ion ditribution ranging from 7 – 21+, with several
conformers arising in the 7 – 11+ ion range. Interestingly, the highly charged monomer ions
(12-21+) showed only one conformer, for all SOD1 variants, at relatively low drift times.
Owing to the high charge applied to these monomer species during ionisation, we expect this
difference to be an in vacuo collapse of the solution unfolded monomer conformer, as
opposed to the in vacuo unfolding we are observing for other monomer ions. From this we
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can determine that the monomer ions ranging from 7 – 11+ have maintained some structure
after DTT/EDTA treatment, and that 12 – 21+ ion are representative of a highly unfolded
monomer. However, even though the system parameters used are gentle, in vacuo forces are
still quite harsh and we may not be observing a true reflection of the solution cross-section of
the high charged monomer ions because they may unfold/collapse in the time between
electrospray and detection.
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Figure 5.7: IM-MS of DTT/EDTA treated SOD1 showing different conformers evolving at each
charge state. (A) Mass spectrum and IM chromatogram of SOD1WT monomer fraction after
incubation in DTT/ EDTA treatment. (B) IM-MS of SOD1G37R after DTT/EDTA treatment. (C) IMMS of SOD1H46R after DTT/EDTA treatment. (D) IM-MS of SOD1D90A after DTT/EDTA treatment.
(E) IM-MS of SOD1G93A after DTT/EDTA treatment. (F) IM-MS of SOD1V148G after DTT/EDTA
treatment. For all IM chromatograms the monomer charge states have the various conformers arising
7+
identified by dotted white lines and labels (i.e. the M[2]
denotes the second conformer of the 7+ charge
state monomer).
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5.2.4 Mass spectrometry of SOD1G37R oligomers
The elution profile of SOD1G37R, from analytical SEC, showed a large abundance of protein
in the void volume, indicating high molecular weight oligomeric species. In order to identify
oligomeric species mass spectrometry was performed on the void volume fraction as well as a
second analytical size exclusion analysis with freshly prepared DTT/EDTA treated SOD1 G37R
using an S-200 column (1.3 MDa exclusion limit). The S-200 SEC of SOD1G37R (Fig. 5.8 A)
showed a primary elution peak for DTT/EDTA treated SOD1G37R at ~15.6 mL compared to
the untreated control SOD1G37R at ~16.5 mL. This lower elution volume was consistent with
the peaks observed in the S-75 SEC (Fig. 5.4). The absorbance at 280 nm was broad ranging
from 8 – 21 mL, with 8 – 14 mL corresponding to high molecular weight species, and 18 – 21
mL likely corresponding to residual DTT from the treatment (MS of this peak showed no
protein signal – not shown). To identify the main components of the major peak
(marked by *) from the S-200 analysis, mass spectrometry was performed on this fraction
(Fig. 5.8 B), which showed the charge state distribution, of primarily monomeric SOD1G37R,
similar to that observed from the S-75 SEC (Fig. 5.6). The fractions at lower elution volumes,
containing oligomeric SOD1G37R, were also subject to MS, however low signal was acquired,
most likely due to the very low abundance of the oligomers present. To overcome this, the
void volume fraction of the SOD1G37R S-75 SEC analysis was subject to MS. We observed a
broad distribution of oligomers ranging from 1 to 12 subunits (Fig. 5.8 C), with the monomer
being the most abundant species, indicating that the oligomers eluted from the column were
highly labile. Generation of a theoretical mass spectrum containing the potentially identified
species allowed for the correct assignment of each ion species (Fig. 5.8 D). We plotted the
abundance of each oligomer to determine if there was a pattern in the dynamics of
oligomerization, observing that the large oligomers were assembling in patterns of 4 subunits,
as shown by oligomers composed of 4, 8, and 12 subunits being relatively abundant, and no
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7, 9, 10, or 11 subunit oligomers being detected (Fig. 5.8 E). Since the monomer and dimer
ions detected from this fraction were showing a charge state distribution typical for SOD1
(monomer = 7-8+, dimer = 9-12+), we plotted the average charge of each oligomeric state
against the number of subunits in that oligomer finding that the charge added per subunit
addition was consistent at ~2 charges per subunit added to the complex, indicating that the
oligomers were forming in an ordered fashion (Fig. 5.8 F).
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Figure 5.8: Oligomeric distribution of DTT/EDTA treated SOD1G37R. (A) SOD1G37R
(blue = DTT/EDTA treated, black = control) was subject to analytical SEC using an S-200 column
showing the elution of large molecular weight species (arrows above trace are protein standards). (B)
Mass spectrometry of the peak from the S-200 SEC showing the broad charge state distribution
observed previously for DTT/EDTA treated SOD1G37R. (C) Mass spectrometry of the void volume
peak from the S-75 SEC showing the broad oligomeric distribution of SOD1G37R from this column
fraction (oligomers are colour-coded to corresponding peaks). (D) A theoretical mass spectrum of the
SOD1G37R showing the expected location of observed peaks allowing for the deconvolution of
overlapping peaks. (E) The relative abundance of each SOD1G37R oligomer (colours match those in
panel C) showing that oligomerization was mostly proceeding through the addition of 4 subunits (1 >
4 > 8 > 12). (F) The relationship between the average charge and the number of subunits in an
oligomer was consistent (r2 = 0.99).
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5.2.5 Determination of the abundances of unfolded SOD1
Due to the broad elution profiles of our DTT/EDTA treated SOD1 in analytical SEC, and the
IM-MS analysis revealing the existence of different conformational and oligomeric species, it
was necessary to normalise the conformational and oligomeric distributions to include a
broad picture of the effect DTT/EDTA treatment. This was achieved by pooling all fractions
from analytical SEC containing protein (determined by absorbance at 280 nm) into a single
fraction, and diluting it to a concentration of 10 µM (determined by BCA) for subsequent MS
analysis. This allowed for direct comparison of the relative abundances of charge states, and
oligomeric distributions for each variant.
It was observed, in the pooled fractions of each SOD1 variant that the major species was
monomeric, ranging from charges of 7+ to 21+ (Fig. 5.9), as previously observed (Fig. 5.5
and 5.6). The dimer abundance was substantially decreased in all cases, compared to previous
spectra that were acquired from peak 1 in analytical SEC. This indicates that the pooling and
dilution of the samples from analytical SEC resulted in dissociation of the dimer. In the case
of SOD1G37R (Fig. 5.9 B), there was no evidence of any oligomeric species, even though
fractions thought to contain them were included into the pooled sample. This is most likely
due to a combination of the biases involved in mass spectrometry based analyses such as this,
where system parameters determine sensitivity at specific mass ranges, and the previously
observed labile nature of the oligomers. In contrast to previously acquired spectra from
fractions corresponding to peaks in the analytical SEC (Fig. 5.5 and 5.6), it was observed that
highly charged monomer was present for all SOD1 variants, although at different abundances
for each SOD1 variant. SODWT, SOD1H46R, and SOD1D90A (Fig. 5.9 A, C, and D
respectively) showed relatively low abundances of highly charged SOD1 monomer, instead
the major ion species was the monomeric 8+ charge state. SOD1 G37R, SOD1G93A, and

139

SOD1V148G (Fig. 5.9 B, E, and F respectively) had considerably increased relative abundances
of highly charged monomeric species, in comparison to the typical 7+ and 8+ monomeric
charge states.
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Figure 5.9: Mass spectra of pooled column fractions of DTT/EDTA-treated SOD1 variants.
Fractions, across the elution profile, containing SOD1 were pooled, diluted to a concentration of
10 µM, and subject to mass spectrometry. (A) SOD1WT showing a high abundance of monomer (grey
labels) compared to dimer (black labels). Inset is an expansion of the high charged 10 – 21+ monomer
ions, normalised to the 10+ ion intensity. (B) SOD1G37R spectrum showing that highly charged
monomer is the major species present. (C) SOD1H46R showing a primarily low charged monomeric
distribution. Inset is an expansion of the high charge region normalised to the 9+ ion intensity. (D)
SOD1D90A showing that the most abundant ion species is the 8+ charge state with low abundance of
highly charged monomer. Inset is an expansion of the high charged region, normalised to the intensity
of the 16+ ion. (E) SOD1G93A showing a substantial abundance of high charged monomer. (F)
SOD1V148G showing a substantial abundance of high charged monomer.
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Since charge state is affected by conformation (Prakash and Mazumdar, 2005), analysis of
the modification states, including metal binding, disulfide status, and oxidative modification,
of select monomeric charge states (8+ = M8+, 10+ = M10+, and 14+ = M14+) and the 11+ dimer
charge state (D11+) was carried out (Fig 5.10). As shown in figure 5.10, across all monomeric
charge states, no evidence of any bound metals was observed with the exception of dimeric
SOD1WT (Fig. 5.10 D). Indeed, analysis of M8+ for each SOD1 variant revealed that the major
species within that charge state had a mass consistent with disulfide reduced apo-SOD1,
designated E,E,SH (E for empty metal binding site, SH for intact, reduced cysteines).
Figures 5.10 A and E are SOD1WT (15804 Da reduced, 15802 Da intact disulfide) and
SOD1G93A (15818 Da reduced, 15816 Da intact disulfide) respectively. If either copper or
zinc were present we would expect mass changes of +63 Da and +65 Da respectively. Other
major species within M8+ were determined, by mass, to be an addition of sodium (+22 Da)
and a +60 modification that is potentially both sodium and potassium, based on the
incubation of the protein sample in 1 × PBS during DTT/EDTA treatment, however, this is
uncertain. Interestingly, the major species in both the 10+ and 14+ monomeric charge states
of SOD1WT was a mass of 15768 Da, which is a loss of 36 Da from reduced apo-SOD1WT. As
stated previously in section 4.2.1, a mass changes of -18 Da and -36 Da are potentially
successive dehydration (-18 = 1 dehydration, -36 = 2 × dehydration), however it could also
represent S-gamma-glutamyl (-18 Da) from cysteine and dehydroalanine from cysteine
(-36 Da). Conversion of cysteine to a dehydroalanine can proceed through heat induced
β-elimination of the sulphur (Wang et al., 2010), which is possible here due to the protocol
used for purification utilising heat to denature contaminating proteins from bacterial lysate
(65 °C for SOD1WT, 55 °C for SOD1 mutants). The M10+ charge state of SOD1WT also
showed another modification that was +100 Da of the mass of reduced apo-SOD1WT that is of
unknown origin. The SOD1WT M14+ ion also displayed two peaks that did not match any
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masses that correspond to known modifications (Fig 5.10 C). Although the dimer was at
relatively low abundance in the MS assay, there was sufficient signal and resolution to
distinguish peaks corresponding to differential metalation states for SOD1 WT (E,E = empty ,
Cu,E = copper only, Cu, Zn = copper and zinc) of disulfide reduced SOD1 (Fig. 5.10 D).
Interestingly, a dimer composed of reduced apo-SOD1WT was observed, however, it was at an
extremely low abundance compared to all species in the spectra. The major species for the
M8+, M10+, and M14+ ions of other SOD1 variants were also reduced apo-forms where the
most abundant modifications were the addition of sodium adducts (Fig. 5.10 E). The sodium
adducts were confined to low charged monomer ions in the case of each variant. In
comparison, the higher charged monomer ions showed little to no sodium binding. This
suggests that the lower charge states are potentially binding sodium via the maintenance of
structural features, even after extensive desalting via column chromatography, which is
consistent with lower charged ions being more structured than their higher charged
counterparts. Alternatively, more highly charged ions are less likely to pick up adventitious
sodium owing to electrostatic repulsion.
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Figure 5.10: Identification of protein species across the oligomeric and charge state distribution
of DTT/EDTA-treated SOD1. (A) The M8+ ion of SOD1WT showing that the most abundant species
at that charge state is reduced apo-SOD1 (E,E,SH). (B) The M10+ ion of SOD1WT showing the major
species as being a mass change of -36 Da on reduced apo-SOD1. (C) The M14+ ion of SOD1WT
showing the most abundant species is, again, -36 Da from the reduced apo-SOD1. (D) The D11+ ion of
SOD1WT showing a wide distribution with peaks consistent with different metalation states ranging
from completely apo ((E,E)(E,E)) to completely metallated ((Cu,Zn)(Cu,Zn)). All of the masses were
consistent with reduced SOD1. (E) The M8+ ion of SOD1G93A showing the major species is apo
reduced with subsequent peaks being sodium adducts. The M10+ ion of SOD1G93A showing the major
species as reduced apo-SOD1G93A.

Following the analysis and identification of protein species evident from a close inspection of
different monomer ions, it was determined that there were three main monomeric
conformations that were being detected by MS. These conformations were termed compact,
intermediate, and unfolded due to the major species across the monomeric ions being reduced
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apo-SOD1 for all variants i.e. no holo-SOD1 was observed. It was also based on the Gaussian
distribution of peaks (Fig 5.11 A and B) where we determined the relative abundance of each
peak and plotted the abundance of each charge state. From these Gaussian fits it was possible
to determine the relative abundance of each conformation for all SOD1 variants (Fig 5.11 C).
We found that SOD1WT, SOD1H46R and SOD1D90A monomers primarily inhabited the
compact conformation, with much lower abundances of intermediate and unfolded
conformations. SOD1G37R, SOD1G93A, and SOD1V148G had far higher abundances of
intermediate and unfolded monomer, compared to SOD1WT, and out of the three variants,
only SOD1G37R showed a higher abundance of unfolded monomer compared to compact
monomer. Since SOD1 aggregation has been previously proposed to be dependent upon the
amount of unfolded/destabilised protein (Byrstrom et al., 2010), the relative ThT intensity
from previous aggregation data (Fig. 5.2 A) was plotted against the percentage of monomer
that was destabilised (sum of intermediate and unfolded abundances). The correlation was
relatively weak (r2 = 0.31), however when SOD1G37R was omitted from the linear fit, the
correlation became much stronger (r2 = 0.70). SOD1G37R is a curious outlier as it is defined as
‘wild-type like’ due to its structural similarities with SOD1WT (Hart et al., 1998) and has a
long variable disease duration of ~17 years (Wang et al., 2008), yet in our assays presents
severe structural destabilisation on similar levels as the aggressive SOD1 G93A and SOD1V148G
variants (~2.2 and ~2.3 years patient survival respectively).
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Figure 5.11: Determination of the abundance of monomeric conformations detected by mass
spectrometry. (A) Representative mass spectrum of SOD1G93A. (B) Plotting the abundance of each
charge state allowed for the determination of 3 Gaussian distributions that correspond to increasing
charge states and decreasing peak width, indicative of 3 conformations (compact = blue,
intermediate = green, unfolded = red). (C) The abundance of each specific conformation for each
SOD1 variant shows the monomeric distribution where SOD1WT, SOD1H46R, and SOD1D90A present a
primarily compact monomeric distribution, compared to the other variants which showed high
abundances of intermediate and unfolded monomer conformations. Error bars represent SD of the
mean from 3 separate DTT/EDTA treatments of 3 separate nano-electrosprays (D) Plotting the
percentage abundance of destabilised monomer (unfolded and intermediate conformation) against the
relative ThT intensity from our aggregation assays showed a weak correlation (r 2 = 0.31), however
omission of SOD1G37R from the linear fit gave a much stronger correlation (r2 = 0.70).
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The concepts of aggregate strains and prion-like seeding have recently become prominent
within the study of neurodegenerative disease, especially relating to ALS (Bergh et al., 2015,
Bidhendi et al., 2016, Lang et al., 2015). Owing to the high level of unfolded SOD1G37R
observed in the MS-based assay, an experiment was performed to elucidate if this unfolded
species could template onto other preformed SOD1 aggregates. SOD1 G93A was chosen to be
the ‘seed’ variant, where a minimal amount of preformed aggregate seed (seed was 0.3% total
protein by mass) was added to the assay. Remarkably, it was observed that SOD1G37R did not
respond to the addition of seed, whereas SOD1WT showed an appreciable response (Fig. 5.12
B and D) and SOD1G93A showed significantly altered aggregation kinetics (Fig. 5.12 A and
D). SOD1G37R showed no difference in either fibril elongation rate (measured as change in
ThT fluorescence) (Fig. 5.12 C and D), or lag phase (Fig 5.12 D), indicating that the addition
of the seed was not affecting either the nucleation time, or the generation of fibrillar
structures. The kinetics of SOD1WT were difficult to determine due to a weak sigmoidal fit,
however, it was clear from the assay (Fig. 5.12 A) that the addition of SOD1 G93A seed
increased aggregation. Addition of seed to SOD1G93A aggregation significantly increased the
elongation rate (Fig. 5.12 D) compared to no seed, and also significantly decreased the lag
phase (Fig. 5.12 E), indicating that the addition of seed was pushing the aggregation reaction
towards fibril elongation, overcoming the need to form aggregate nuclei. In figure 5.12 F, the
fold increase in the mean maximum ThT fluorescence was compared between variants after
seeding showed that SOD1G37R had only a slight increase in max fluorescence, compared to
SOD1WT which was higher than SOD1G37R, and SOD1G93A which was substantially higher
than both other variants.

Taken together, this work suggests that SOD1 G37R may be

aggregating as a different strain that is dependent upon the substitution of arginine at
position-37.
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Figure 5.12: SOD1G37R is resistant to seeding by preformed SOD1G93A aggregates. Aggregation of
SOD1 was promoted with DTT, EDTA, and shaking, with the formation of fibrillar structures being
monitored by ThT fluorescence. Preformed SOD1G93A aggregates were added (or not) at a final
amount of 0.3% total protein. (A) Aggregation assay of SOD1G93A normalised to the maximum signal
showing the ThT fluorescence over time for each sample. Dotted lines represent the maximum
fluorescence of SOD1WT (red) and SOD1G37R (blue). (B) Aggregation assay of SOD1WT with and
without seed, normalised to the maximum fluorescent signal. (C) Aggregation assay of SOD1G37R
with and without seed, normalised to the maximum fluorescence signal (D) Kinetic analysis gave the
fibril elongation rate (measured as change in ThT fluorescence), showing that seeded SOD1 G93A had a
significantly increased fibril elongation rate compared to other treatments. SOD1WT is not shown here
due to it not aggregating without seed. (E) Kinetic analysis gave the lag phase of aggregation,
showing that addition of seed significantly decreased the lag phase of SOD1 G93A but not SOD1G37R.
(F) Comparing the fold increase in the max fluorescence (Fmax) values when aggregation was seeded
for each variant, showing that SOD1G93A and SOD1WT had greater increases compared to SOD1G37R.
Each assay presented here was performed in the same microplate where error bars represent SEM of 4
technical replicates. Statistical significance was determined using a one-way ANOVA (*** = P <
0.001).
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5.3 Discussion
In this work we have shown that the reduction and chelation of SOD1 variants induces
unfolding into multiple conformational states, and that the major difference between SOD1
variants is the abundance of each of these states. It is well known that disruption of the metal
ions and the intramolecular disulfide has severe effects upon SOD1 structural stability (Banci
et al., 2009, Hayward et al., 2002, Lynch et al., 2004, Svensson et al., 2010, Tiwari and
Hayward, 2003). Indeed, in the native conformation (metal bound, disulfide bonded form)
most ALS-associated SOD1 variants have high melting temperatures, however, when reduced
and metal-free, some variants, such as SOD1G93A, melt below physiological temperature
(Furukawa and O'Halloran, 2005, Rodriguez et al., 2005). Taking this into account, it is clear
that the conformational distribution we observed in MS assays is a result of the lower thermal
stabilities of the SOD1 variants when in their reduced apo-form, which was induced via
incubation in DTT and EDTA at physiological temperature. Take SOD1G93A for example,
which in its reduced apo-form, has a reported melting temperature of 31.2 ± 0.3 °C
(Furukawa and O'Halloran, 2005). We observed that SOD1G93A was significantly destabilised
following DTT/EDTA treatment at physiological temperature, in agreement with this
previous work. The most interesting aspect of the MS-based assay however, was that it was
able to further separate the products of destabilisation, determining the existence and relative
abundance, of several conformational states. Previously published thermal stability data has
not detected these states (Furukawa and O'Halloran, 2005, Rodriguez et al., 2005), most
likely due to the low resolution provided by the technique, or that these conformations are in
a constant state of flux. Indeed, the absence of unfolded SOD1WT, SOD1H46R and SOD1D90A
in peak 1 from analytical SEC which corresponded to the elution of the peaks containing
unfolded SOD1G37R, SOD1G93A, and SOD1V148G, indicates that the unfolded conformation
may be dependent upon dilution, as well as temperature. However, upon electrospray, the
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assay was limited to ambient temperature (~20 °C), well below the previously mentioned
melting temperature, indicating that any unfolding resulting in the SEC distributions observed
occurred during DTT/EDTA-treatment, rather than during or immediately prior to MS
analysis.
Interestingly, the SOD1 monomer has been defined as having two-state folding dynamics
(Stroppolo et al., 2000) but here we clearly see evidence of an intermediate state. Previously,
Khare and colleagues used discrete molecular dynamics to monitor SOD1 unfolding in silico
finding evidence of an intermediate folding state(Khare et al., 2003), however they discarded
this result as it did not fit the published experimental data at the time. In order to delineate the
differences observed by experimentation and modelling, we would propose using atomic
force spectroscopy on SOD1 dimers and monomers to determine energies of unfolding and
refolding, as well as using the data acquired to guide in silico modelling towards defining
specific structures at each point along the folding/unfolding pathways.
Higher resolution analyses of disordered SOD1 have been conducted using NMR, where
reduced apo-SOD1G93A was found to be highly unstructured, with little propensity to form
secondary structure (Luchinat et al., 2014), and reduced apo-SOD1WT was found to assume a
monomeric native-like β-barrel structure with disordered loops (Sekhar et al., 2015). This
model of reduced apo-SOD1WT matches the analysis presented here where the relatively low
charge state distribution and low drift time are indicative of a more compact monomermic
species, close to what we observed for disulfide oxidised holo-SOD1WT (see section 3.2.2)
(Sekhar et al., 2015). Likewise, other work has considered reduced apo-SOD1G93A to be
representative of several other SOD1 variants, including SOD1G37R, which is in partial
agreement with our results (Luchinat et al., 2014). SOD1G37R was the most destabilised
variant observed, with SOD1G93A a close second. In-cell NMR spectroscopy revealed that the
levels of unstructured reduced apo-SOD1G37R and reduced apo-SOD1G93A were similar when
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overexpressed in mammalian cells, failing to detect any tertiary structure (Luchinat et al.,
2014). In contrast, the MS-based assay performed here detected reduced apo-SOD1 species
inhabiting quaternary, tertiary, and unstructured states, as determined by IM-MS, across all of
our SOD1 variants. The discrepancy is potentially due to the manner of purification, or
differences in the generation of destabilised SOD1, where here SOD1 was co-expressed with
the yeast copper chaperone for SOD1, and the purified holo-protein was destabilised with
addition of chelator and reductant at the same time. In contrast, Luchinat (2014) and
colleagues purified recombinant SOD1 without yCCS co-expression and overexpress SOD1
variants in mammalian cells with only endogenous levels of the human copper chaperone for
SOD1 to facilitate folding, i.e. the work present here has investigated SOD1 that has been
unfolded from its native conformation, whereas Luchinat (2014) and colleagues have
investigated SOD1 structures that are yet to reach a fully folded state. Regardless of the
order, the removal of post-translational modifications from SOD1 is widely thought to result
in a product that is similar to the immature polypeptide that can take part in aggregation.
The isolated protein and cell-based aggregation assays showed a clear difference between
specific SOD1 variant aggregation propensities. For the most part, aggregation in the cellular
context correlated with aggregation of isolated protein, with the exception of SOD1 G37R.
SOD1G37R was a consistent outlier throughout this work, and even more so when taking into
account the interesting correlation between patient survival time and SOD1 mutation, where
SOD1 variants more prone to aggregation are correlated with a more rapid disease
progression (Wang et al., 2008). Given the association with a long disease course, one might
expect SOD1G37R to have a low aggregation propensity in cells, as well as a low isolated
protein aggregation propensity. However, its in-cell aggregation was significantly increased
compared to SOD1WT, similar to that observed for SOD1G93A and SOD1V148G. A potential
explanation for this is the difference between the intracellular environment compared to that
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of an isolated protein assay. The isolated protein assay contains only purified SOD1 protein
at a relatively low concentration (uncrowded) of 30 µM dimer, and is optimised to produce
fibrillar aggregates at a rapid rate with vigorous shaking (section 2.7.1). The cytoplasm
contains an abundance of protein and other macromolecules in high concentration (~400
mg/mL), resulting in a crowded environment (Fulton, 1982, Zeskind et al., 2007). This
crowding effect, along with other cellular processes, are most likely changing the dynamics
of SOD1 aggregation, when compared to isolated protein. Indeed, transfection of cells
typically results in variable expression levels of the protein of interest, across the population
of cells that have taken up the vector. In the case presented here, the highest expressing cells
are the ones most likely to develop inclusions (data not shown), jjconsistent with the idea that
protein concentration is an important factor contributing to aggregation. Another explanation
is the energy driven aggregation that occurs in cells. Previous work has shown that the large
inclusions (similar to the inclusions we examine here) are dependent upon microtubule
transport (Farawell et al., 2015) and are not a simply a product of random aggregation. It is
possible that aggregation occurs after misfolded SOD1 has been transported to the site of an
inclusion.
The analytical SEC and MS analysis lends credence to the crowding idea, where destabilised
SOD1 was concentrated prior to SEC (~450 µM) and the presence of high molecular weight
species was observed only for SOD1G37R (although peak shoulders were apparent for
SOD1G93A and SOD1V148G but were unresolvable in MS), indicating a rapid formation of
oligomeric species for this variant. These oligomeric species were sensitive to dilution, as
evidenced by the most abundant species in our MS analysis of the SOD1G37R void volume
being monomeric. This potentially translates into a greater cellular aggregation propensity
due to the high concentration of SOD1 with certain cells, but a lower propensity of isolated
protein to aggregate due to the comparatively lower concentration of SOD1 in our assay.
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Furthermore, there is a possibility that SOD1G37R forms aggregate nuclei rapidly, leading to a
decreased pool of available monomer to template onto extending fibrils, although we cannot
rule out the possibility of a competing amorphous aggregation pathway for SOD1G37R.
Recent work has emphasised the role that different aggregation pathways, leading to the
formation of different aggregate strains, may play in the role of amyotrophic lateral sclerosis
(Bergh et al., 2015, Bidhendi et al., 2016, Lang et al., 2015). Using binary epitope mapping,
Bergh and colleagues (2015) observed that mice overexpressing human SOD1D90A developed
SOD1 aggregates that were composed of competing strains termed strains A and B. Each
strain demonstrated differential kinetics and mortality in mice. A follow on from this found
that the injection of mice expressing human SOD1G85R with either of these strains resulted in
the development of ALS-like symptoms at different rates, and also presented different
pathophysiology (Bidhendi et al., 2016). The strain hypothesis may explain, at least in part,
why different SOD1 mutants present variable disease progression in patients. Indeed, the
work presented in this chapter indicates that SOD1G37R may be aggregating into a strain
distinct from SOD1G93A, similar to previous work that suggested SOD1G37R mice spinal cord
homogenates could not transmit disease to a SOD1G85R mouse, but that SOD1G93A mice
homogenates could transmit disease (Ayers et al., 2014a). Given the MS data showed that
SOD1G37R had the highest abundance of unfolded monomer, it might be predicted to have
substantially altered aggregation dynamics in the presence of preformed aggregate seed
(decreased lag phase, increased elongation rate), however this was not the case. This
SOD1G37R strain may be, for the most part, benign, explaining the comparatively long disease
duration of this SOD1 variant, although further characterisation of in vitro and in vivo
SOD1G37R aggregates would need to be performed to substantiate this.
In conclusion, the work presented here underscores the necessity of combining mass analysis
techniques with traditional size determination techniques, as the relationship between size
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and mass may be drastically altered by conformational changes to molecules. Native mass
spectrometry is an excellent technique as it provides a means to not only separate different
conformers, but identify modification states, as we have shown above. The conformers we
identified in this work related to different misfolded monomeric states common to several
ALS-associated SOD1 variants, showing that disulfide reduction and metal chelation resulted
in differential conformational states, which correlates with both isolated protein aggregation
and cellular aggregation. However, SOD1G37R did not follow this relationship; it was
observed to have a high abundance of unfolded protein, yet a comparatively low aggregation
propensity. Seeding SOD1G37R aggregation with preformed SOD1G93A aggregates had no
effect on its aggregation kinetics, suggesting that SOD1G37R may aggregate as a different
strain. Understanding the interplay between unfolding and subsequent aggregation, as well as
the potential for the formation of variable aggregate strains of more SOD1 variants may shed
light on the phenomenon of SOD1 variant related differential patient survival times, and may
also provide information on the disease causing protein species in SOD1-associated ALS.
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6. Tryptophan-32 of SOD1 is an
Aggregation Modulating Residue
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6.1 Introduction
Neuron death in SOD1-associated ALS is suggested to proceed from a gain of cytotoxic
function, rather than loss of SOD1 enzymatic function. Evidence has shown that SOD1
mediated cytotoxicity can proceed through many mechanisms, including dysregulation of the
ubiquitin proteasome system, mitochondrial dysfunction, disruption of cytoskeletal elements,
and potential generation of reactive nitrogen species (Cleveland and Rothstein, 2001, Ilieva et
al., 2009). The exact SOD1 species affecting these pathways is yet to be elucidated but recent
work using novel antibodies detected misfolded SOD1 in both fALS and sALS patient tissue
(Bosco et al., 2010, Forsberg et al., 2010, Pokrishevsky et al., 2012b). Other work has shown
that these misfolded SOD1 species can act in a prion-like fashion and transmit molecular
pathology which invariably causes cellular pathology (Ayers et al., 2014a, Grad et al., 2011).
A propagation of misfolding suggests that there may be conserved structural features
contributing to the molecular transmission.
SOD1 structure has been studied extensively since its association with fALS was first
discovered. In its native state, SOD1 is a 32 kDa homodimer where each monomer contains a
catalytically active copper ion, a zinc ion, and an intramolecular disulfide bond (McCord and
Fridovich, 1969). These post-translational modifications impart remarkable stability to
SOD1, allowing it to resist heat denaturation up to 90 °C and retain relatively high enzymatic
activity under denaturing conditions (Rodriguez et al., 2002, Senoo et al., 1988). Indeed, the
high stability of SOD1 is at odds with its accumulation into inclusions, and proteopathic
nature in ALS. This conundrum can be partly explained in 20% of fALS cases that are
associated with mutations in SOD1. These mostly single nucleotide missense mutations that
are known to occur throughout the SOD1 primary sequence (http://alsod.iop.kcl.ac.uk - (Abel
et al., 2013a) can have differential effects upon SOD1 structure by disrupting metal ion
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coordination, disulfide formation/reduction susceptibility, and dimerization, each of which
can result in the downstream consequences of misfolding and/or aggregation (Valentine et al.,
2005).
The combination of ALS associated mutations causing destabilisation of SOD1 structure, and
the apparent role of wild-type SOD1 in sALS, strongly suggests that there are common
features within SOD1 structure that are contributing to disease. An interesting observation
from studies of SOD1 transgenic mouse models and cell culture models of ALS
overexpressing human SOD1 (hSOD1) is that murine SOD1 (mSOD1) very rarely coaggregates with the hSOD1 even though the sequence identity between isoforms is 83%
(Bergh et al., 2015, Grad et al., 2011). Grad and colleagues (2011) have previously shown
that oxidative damage can expose a disease specific epitope in hSOD1, and that this damaged
SOD1 can transmit misfolding to other SOD1 molecules intercellularly (Grad et al., 2014).
Misfolding transmission was shown to occur to hSOD1 but not mSOD1 when incubated with
misfolded hSOD1, suggesting that mSOD1 may be resistant to this prion-like mechanism.
They were able to significantly reduce transmission of hSOD1 misfolding by substituting a
serine at position-32, where the exposed antibody epitope was localised. Tryptophan-32
(Trp32) has been previously implicated as a site of oxidative modification in hSOD1 purified
from human blood and transgenic mouse blood, and also shown to potentiate aggregation in a
cell system (Taylor et al., 2007). Trp32 is located on β-strand III in a region which is nonconserved between mice and humans (Fig. 1 A and B), but is highly conserved across fALS
patients with a SOD1 mutation (Fig. 1 A and C). Here we investigated the effect of a serine
substitution at position-32 (W32S) on the aggressive fALS-associated SOD1 variants
SOD1G93A and SOD1V148G, to further our understanding of the effect this substitution was
having in regards to structural stability, isolated protein aggregation kinetics, and aggregation
in cell systems. We found that whilst W32S substitution leads to the generation of a greater
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abundance of unfolded SOD1 prior to isolated protein aggregation, W32S variants have a
significantly reduced aggregation potential even when presented with preformed aggregate
seeds from which to template. A set of experiments carried out in a cell system showed
similar results, W32S variants formed fewer inclusions in cells as well as contributing less to
the formation of dual coloured W32-W32S SOD1 inclusions compared to their disease only
mutation counterparts.

Figure 6.1: Loop II and β-strand III of SOD1 have low mutation frequency in humans and are
non-conserved when compared to murine SOD1. (A) An alignment of murine and human SOD1
showing the mutation frequency (only point mutations) within humans, and the conservation of
residues between humans and mice. Highlighted red is loop-III and β-III, which has low ALS
mutation frequency in humans and low species conservation between humans and mice. (B)
Expansion of the highlighted region showing mutation sites (orange) and position-32 (blue box), with
stars representing conservation score (none = non-conserved, 1 = semi-conserved, 2 = conserved). (C)
Crystal structure of a SOD1 monomer showing locations of all point mutations associated with ALS
(orange spheres) and Trp32 (blue sticks) (PDB accession: 1HL5 - (Strange et al., 2003))
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6.2 Results
6.2.1 W32S variants have decreased aggregation propensities
To compare the aggregation of our disease causing variants to that of their W32S
counterparts we used our previously established aggregation assay based on published work
(Furukawa et al., 2008). This assay utilises DTT and EDTA to destabilise the native SOD1
structure, by reducing the intramolecular disulfide and chelating the copper and zinc ions, as
well as shaking to induce the formation of fibrillar structures that are thioflavin T reactive.
SOD1WT was previously shown to be resistant to our typical assay conditions (20 mM DTT
and 5 mM EDTA) so we increased the concentration of DTT to 30 mM to induce aggregation
of both SOD1WT and SOD1WT-W32S. We observed that under these conditions that the W32S
form of each SOD1 variant had significantly decreased aggregation propensities (Fig 6.2 A,
B and C). Interestingly, SOD1G93A-W32S was the only W32S variant to show typical sigmoidal
fibrillar aggregation kinetics (Fig. 6.2 B), therefore allowing for the determination of both
fibril elongation rate and the lag-phase time (Fig. 6.2 D). We found that SOD1G93A-W32S had a
significantly decreased fibril elongation rate, and a significantly increased lag-phase,
indicating that the W32S substitution was affecting both the formation of aggregate nuclei
and templating of the aggregating subunits onto fibrils. The lack of sigmoidal aggregation
profiles for the other W32S variants suggested that they were either resistant to the effects of
DTT and EDTA, not aggregating, or were aggregating down a non-fibrillar pathway not
detected by thioflavin T.
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Figure 6.2: Isolated protein aggregation of W32S variants. SOD1-W32S aggregation was
compared to that of disease specific SOD1 variants using 20 mM DTT, 5mM EDTA, and shaking to
promote aggregation. (A) SOD1WT vs SOD1WT-W32S were aggregated with 30 mM DTT due to
previous assays showing a decreased aggregation potential of SOD1WT to aggregate at lower DTT
concentrations. (B) SOD1G93A vs SOD1G93A-W32S, where SOD1G93A-W32S showed sigmoidal aggregation
kinetics. (C) SOD1V148G vs SOD1V148G-W32S. For all assays dotted lines represent SEM of the mean
from 3 technical replicates. (D) Δ ThT fluorescence and the lag phase were calculated from an
analysis of SOD1G93A and SOD1G93A-W32S aggregation kinetics and show that SOD1G93A-W32S had a
significantly decreased fibril elongation rate and a significantly increased lag-phase. Error bars
represent standard error and statistical significance was determined from n=3 technical replicates
using student’s t-test (*** = P < 0.005).

6.2.2 Native mass spectrometry analysis of W32S variants
In order to determine the effect that the W32S substitution was having on SOD1 in the
context of dimer dissociation, disulfide reduction, and metal chelation, native mass
spectrometry was utilised. Native mass spectrometry is a useful technique that can reliably
161

separate ions based on mass and charge allowing for assignment of conformational and
oligomeric status, as well as the modification states of these conformations and oligomers
(Mehmood et al., 2015).
Firstly, the dimer dissociation constants of the W32S variants were determined using mass
spectrometry as previously described (McAlary et al., 2013b, Rose et al., 2011). When
comparing the dimer dissociation of disease causing variants against their W32S counterparts
(Fig. 6.3), it was found that for all variants that the W32S forms had an increased propensity
to dissociate. This increased dissociation propensity was minor in variants SOD1WT-W32S
(Fig. 6.3 A) and SOD1G93A-W32S (Fig. 6.3 C) (1.22 and 1.5 fold increases in W32S variants
respectively), but relatively larger in SOD1V148G-W32S, which had an approximately 4.2 fold
increase in dimer dissociation constant over SOD1V148G. This increase in the dimer
dissociation constant of SOD1V148G-W32S suggests that there is cross-talk between the two
areas the Trp32 and Val148 residues occupy within the SOD1 structure. In addition, given the
distance of W32 from the dimer interface, these data suggest that W32S substitution induces
destabilisation of the tertiary structure, which results in quaternary destabilisation.
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Figure 6.3: Dimer dissociation of W32S variants. W32S variant dimer dissociation was assessed
using native mass spectrometry, by analysing the monomer and dimer ion abundances at different
solution concentrations of SOD1. (A) SOD1WT and SOD1WT-W32S dissociation curves. (B) SOD1G93A
and SOD1G93A-W32S dissociation curves. (C) SOD1V148G and SOD1V148G-W32S dissociation curves. (D)
Comparison of dimer KD’s between variants. For all panels, error bars represent SEM of 3 separate
nano-electrosprays of 3 separate dilutions. Dimer KD’s were determined from binding plots in
Appendix C. Significance was determined via one-way ANOVA with a Tukey’s post-test (*** = P <
0.001).

Next we performed analytical size-exclusion chromatography (SEC) to simultaneously
analyse the oligomeric distribution, and prepare the W32S variants for native mass
spectrometry, after DTT and EDTA treatment. SOD1 variants were incubated for 2 hours in
DTT and EDTA in 1 × PBS at 37 °C, before being concentrated to approximately 450 µM at
4 °C and loaded onto an S-75 column, equilibrated in 200 mM NH4OAc for elution at room
temperature. The elution profiles of the W32S variants were, for the most part, similar to
those of their disease only counterparts (Fig. 6.4). SOD1 WT-W32S showed peaks eluting at
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12.3 mL and 14.2 mL, where the abundance of the monomeric peak was decreased in
comparison to that of SOD1WT (Fig. 6.4 A). Both SOD1G93A-W32S and SOD1V148G-W32S (Fig
6.4 B and C respectively) showed no monomeric peak, similar to their disease only
counterparts. Interestingly, SOD1G93A and SOD1V148G showed evidence of higher order
oligomers with a shoulder eluting (~8.5 - 11 mL) on the dimer peak, whereas their W32S
counterparts showed no such shoulders, therefore indicating no formation of oligomers. The
lack of oligomer formation fits with the decreased aggregation propensity observed in our
previous aggregation assay, and further suggests that the W32S substitution is affecting the
formation of aggregate nuclei.

Figure 6.4: Analytical size-exclusion chromatography of W32S variants. SOD1 variants were
incubated at 37 °C, in 1 × PBS, with 20 mM DTT and 5 mM EDTA, for 2 hours. After incubation,
samples were concentrated at 4 °C to a volume of 100 µl and loaded onto an analytical S-75 column
equilibrated in 200 mM NH4OAc, and eluted at 0.5 ml/min. Blue is disease variant and red is W32S
variant (i.e. blue = SOD1G93A, red = SOD1G93A-W32S). (A) SOD1WT and SOD1WT-W32S elution profiles.
(B) SOD1G85R and SOD1G85R-W32S elution profiles. (C) SOD1G93A and SOD1G93A-W32S elution profiles.
(D) SOD1V148G and SOD1V148G-W32S elution profiles.
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After analytical SEC analysis we pooled the fractions off the column and diluted them to a
concentration of 10 µM for native mass spectrometry (MS) analysis. By pooling the samples
we were able to assess the conformational and oligomeric changes induced by DTT/EDTA
treatment as a whole. For each W32S variant we observed that the oligomeric distribution
was

primarily

monomeric

(SOD1WT-W32S

monomer

=

91.8%,

SOD1G93A-W32S

monomer = 96.2%, and SOD1V148G-W32S monomer = 97.6% total signal) (Fig. 6.5), similar to
what we previously observed in section 5.2.5. The charge state distribution of the monomer
for all variants ranged from 7 – 21+, also similar to what we previously saw for the disease
only variants. We also found a similar Gaussian distribution of the monomeric charge states
indicating the existence of conformations similar to what was previously observed.
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Figure 6.5: Mass spectra of pooled column fractions of DTT/EDTA-treated W32S variants.
Fractions, across the elution profile, containing SOD1 were pooled, diluted to a concentration of
10 µM, and subject to mass spectrometry. (A) SOD1WT-W32S showing a high abundance of monomer
(grey labels) compared to dimer (black labels). Inset is an expansion of the highly charged 10 – 20 +
monomer ions, normalised to the 10+ ion intensity. (B) SOD1G93A-W32S showing that highly charged
monomer is the major species present. (C) SOD1V148G-W32S showing that the highly charged monomer
is the major species present.
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To this end we determined the relative abundance of each conformation, by fitting Gaussian
distributions to the charge states, for the W32S variants and compared them to their disease
mutation specific counterparts discovering that in each case the W32S variants showed a
greater abundance of unfolded and intermediate conformations (Fig 6.6). While there was no
statistical significant difference, there seemed to be a trend towards SOD1WT-W32S populating
a greater abundance of intermediate and unfolded conformations (Fig 6.6 A). Similarly,
SOD1G93A-W32S was found to have statistically significant differences between conformations,
specifically a lower abundance of compact, but a higher abundance of intermediate and
unfolded conformations when compared to SOD1G93A. This indicates that the W32S
substitution is highly destabilising to reduced apo-SOD1G93A. Likewise, SOD1V148G-W32S had
a greater abundance of intermediate conformation, compared to SOD1V148G, but no difference
was apparent when examining the unfolded conformation, indicating that the W32S
substitution was affecting the transition from compact to intermediate conformation but not
from intermediate to unfolded conformation in this variant.
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Figure 6.6: Comparing the relative abundance of conformations for SOD1 disease variants and
W32S variants. By applying Gaussian fits to the monomer charge states from the pooled fraction
mass spectrometry we could determine the existence of 3 conformations, defined by charge state
distribution, termed as compact, intermediate, and unfolded. (A) Comparison between SOD1WT
(black) and SOD1WT-W32S (grey) with no significant difference between variants. Inset is an expansion
of the intermediate and unfolded conformation relative abundances. (B) Comparison between
SOD1G93A (dark green) and SOD1G93A-W32S (light green) showing significant differences for all
conformations. (C) Comparison between SOD1V148G (dark orange) and SOD1V148G-W32S (light orange)
showing significant differences in abundance for the compact and intermediate conformations, but not
the unfolded conformation. Error bars represent SD of the mean of 3 separate DTT/EDTA treatments
and 3 nano-electrosprays. Significance was determined using a one-way ANOVA with a Tukey’s
post-test (*** = P < 0.001, ** = P < 0.01, * = P < 0.05).
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Following determination of the abundances of conformations, we then assessed the
modification states of monomer ions representative of each conformation observed in the MS
experiments (listed in table 6.1). For SOD1WT-W32S, the major protein species of the compact
conformation (M8+ ion) was reduced apo-SOD1 (E,E,SH) (Fig. 6.7 A). A relatively small
abundance of -18 and -36 Da species was observed, which are potentially S-gamma-glutamyl
from cysteine and dehydroalanine from cysteine respectively (Wang et al., 2010). The other
protein species within the ion were identified as sequential +22 Da adducts which is typical
of sodium, indicating that there was a level of structure in this ion that allowed the binding of
sodium or that the lower charge was unable to prevent sodium binding. The intermediate
conformation of SOD1WT-W32S (M10+) major species was reduced apo-SOD1 -36 Da,
indicating a conversion of cysteine to dehydroalanine or two dehydrations on the polypeptide
(Wang et al., 2010). We also observed +16, +32, and +48 Da modifications here that are
potentially the additions of 1, 2, and 3 oxygens respectively (oxidation), (Fig. 6.7 B). The
unfolded conformation ion (M17+) major protein species was reduced apo-SOD1 with a +48
Da modification that we identify as 3 × oxidation, owing to the existence of the +16 and +32
Da modifications (1 and 2 × oxidation respectively) (Fig. 6.7 C). In comparison to the high
level of sodium modification seen on the compact SOD1WT-W32S conformation, the compact
SOD1G93A-W32S conformation showed no evidence of sodium binding, although the ion peak
itself had a tail that was poorly resolved (Fig. 6.7 G). The major species was identified as
reduced apo-SOD1 with minor species being identified as dehydration modifications (-18 and
-36 Da). Oxidative modification was also present here in the form of +16, +32, and +48 Da
modifications, similar to what was observed previously. Both the intermediate (M11+) and
unfolded (M16+) conformations of SOD1G93A-W32S (Fig. 6.7 H and I) showed similar protein
species profiles, where the major species was reduced apo-SOD1.
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The protein species observed between conformations for SOD1V148G-W32S were similar, with
the major species always being reduced apo-SOD1 (Fig. 6.7 J, K and L). The modification
states change in relative abundance between the different conformations, with the
dehydration modifications being most abundant in the compact conformation (M8+)
(Fig. 6.7 J). The other modifications identified were +16, +32 and +58 Da. The +16 and + 32
Da modifications are oxidation. The +58 Da modification is potentially a carboxymethyl
from cysteine. Taken together, these results show that the major base protein species is
reduced apo-SOD1 for all of the W32S variants, similar to what was previously reported in
section 5.2.5 (Fig. 5.10), and that although modification states have different abundances
across the monomer charge state distribution, they remain similar for the most part.
Table 6.1: Modifications detected on different charge states of SOD1 variants. Post-translational
modifications detected on DTT/EDTA-treated W32S variants by mass spectrometry.
Mass Difference
-36
-18
0
+16
+32
+48
+58

Identification
Dehydroalanine from cysteine
S-gamma-glutamyl from cysteine
Full length protein
S-OH on cysteine
S-O2H on cysteine
S-O3H on cysteine
Carboxymethyl on cysteine
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Figure 6.7: Identification of protein species across the monomeric charge state distribution of
DTT/EDTA-treated W32S variants. Monomer ion species from each conformation had specific
protein species identified by mass (Monomer ion charge state of 8+ = M8+). (A) SOD1WT-W32S M8+
showing that the major protein species was reduced apo-SOD1 (E,E,SH) with sequential +22 Da
adducts indicative of sodium. The -18 and -36 Da adducts are indicative of 1 and 2 × dehydration
modifications respectively. (B) SOD1WT-W32S M10+ showing that the major protein species was reduced
apo-SOD1 -36 Da (2 × dehydration or dehydroalanine). Other species corresponding to +16, +32 and
+48 Da which correspond to 1, 2 and 3 oxygens respectively. (C) SOD1WT-W32S M17+ showing that the
major species is reduced apo-SOD1 +48 Da (potential 3 × oxidation), with a low abundance of -18
and -36 Da, as well as +16 and +32 Da which indicate oxidation (1 and 2 × respectively). (D)
SOD1G93A-W32S M8+ showing the major species is reduced apo-SOD1 with both dehydration and
oxidation modifications present (-36 and -18 Da for dehydration, +32 Da for 2 × oxidation). (E)
SOD1G93A-W32S M11+ where the major species is reduced apo-SOD1 and oxidation (+32 and +48 Da)
and dehydration (-18 and -36 Da) are present. (F) SOD1G93A-W32S M16+ showing protein species that
are similar to the M11+ ion. (G) SOD1V148G-W32S M8+ showing the major species was reduced apoSOD1, with the -18 and -36 Da modifications present as well. The + 16 and + 32 modifications
identified as oxidative modifications are present, as well as a modification of +58 Da which is
potentially carboxymethyl on cysteine. (H) SOD1V148G-W32S M11+ with the major species being reduced
apo-SOD1 and other species present similar to M8+. (I) SOD1V148G-W32S M16+ where the major species
is reduced apo-SOD1 and modifications similar to M8+ are present.

6.2.3 Seeded aggregation of W32S variants
The observation that DTT/EDTA treatment resulted in a greater abundance of destabilised
protein for our W32S variants, relative to their W32 counterparts, prompted us to test the
effect of adding preformed aggregate seed to these variants. Seeded aggregation does not
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require nuclei to form and as such eliminates this step from the aggregation process. This
allows us to test whether the W32S variants are poor nucleators or poor aggregators more
generally. To this end we performed aggregation assays similar to those above, with the
exceptions that lower concentrations of DTT and EDTA (10 mM and 1 mM respectively)
were used, as well as the addition of preformed aggregate to a final amount of 0.3 % total
protein.
Given that the SOD1G93A variant more consistently showed reproducible aggregation kinetics
between assays, and the fact that SOD1G93A-W32S had kinetics upon which lag phase and
elongation rate could be analysed, we elected to focus our analysis of seeded aggregation on
this disease variant. Given the reported stochastic nature of SOD1 aggregation and potential
differences between assays, here we show the results of 3 independent experiments. All
assays were performed using aggregated SOD1G93A as seed, and in each independent
experiment showed similar trends for the aggregation of SOD1G93A and SOD1G93A-W32S. Both
SOD1G93A and SOD1G93A-W32S were susceptible to seeding but SOD1G93A showed a much
higher aggregation propensity in comparison (Fig. 6.8 A). Analysis of the lag-phase of
aggregation revealed a trend across assays for seeded variants to have decreased lag-phases
compared to assays conducted without seed, indicative of the addition of seed effectively
eliminating the requirement of primary nucleation (Fig. 6.8 B). The lag-phase of
SOD1G93A-W32S did not decrease to the same extent as that of SOD1 G93A with the addition of
seed. We also observed that the rate of fibril elongation (as measured by change in ThT
fluorescence) was, at least in assays 2 and 3, significantly reduced when comparing seeded
SOD1G93A to seeded SOD1G93A-W32S, suggesting that the W32S substitution was affecting
elongation by lowering its rate (Fig. 6.8 C). These results taken together indicate that W32
plays a role at multiple points throughout fibrillar aggregation dynamics.
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Further analysis was also performed after normalisation of all treatments to their respective
minimum and maximum ThT fluorescence values (Fig. 6.9 A, B, and C). Interestingly, after
inputting this data into the derived Boltzmann sigmoidal formulae to determine the values of
specific events (lag-phase and elongation rate) (Fig. 6.9 D, E respectively), it was apparent
that the results were different to those shown in figure 6.8, where the data were normalised to
the maximum ThT value in each assay. It is also interesting to note the presence of an
irregularity in the elongation phase of the seeded SOD1G93A, presenting itself as a ‘jiggle’ in
the ThT curve. Owing to the difficulty of precisely determining the molecular events within
an assay such as this we cannot be sure as to what is causing this. It appears ot only occur in
the seeded samples, indicating that the presence of seed is modifying the aggregation by
means greater than just providing nuclei on which to template.
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Figure 6.8: Seeded aggregation of SOD1G93A-W32S. SOD1G93A and SOD1G93A-W32S were aggregated
with (or without) preformed SOD1G93A aggregate seed in the presence of ThT. (A) 3 separate
aggregation assays of SOD1G93A and SOD1G93A-W32S showing similar trends between assays, where
SOD1G93A-W32S was resistant to seeding. (B) Analysis of the lag-phase for each assay showing a trend
where seeded SOD1G93A-W32S had a decreased lag-phase time but not as much as seeded SOD1G93A.
(C) Analysis of the rate of elongation (measured as Δ ThT signal) showing a trend of seeded
SOD1G93A-W32S having a slower rate of elongation compared to seeded SOD1G93A. Error bars represent
SEM of the mean from 4 technical replicates (data points not analysedif the sigmoidal fit r2 < 0.8) and
significance was determined using a one-way ANOVA with a Tukey’s post-test (*** = P < 0.005,
** = P < 0.01, * = P < 0.05, ns = not significant).
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Figure 6.9: Analysis of normalised seeded assays including fits. The data from figure 6.8 was
analysed by normalising the mean values per-treatment of each aggregation assay. (A, B and C) Each
separate aggregation assay with data and fits coloured to match the treatments (G93A = orange, G93A
+seed = green, G93A-W32S = purple, G93A-W32S +seed = blue). R values of Boltzmann sigmoidal
fits are inset in each panel. (D) Analysis of the mean lag-phase of aggregation of each treatment. (E)
Analysis of the mean elongation rate of aggregation of each treatment. Error bars represent SEM of
the mean from 3 assays (data points not analysed if the sigmoidal fit r2 < 0.8) and significance was
determined using a one-way ANOVA with a Tukey’s post-test (*** = P < 0.005, ** = P < 0.01, * = P
< 0.05, ns = not significant).
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Following these seeded aggregation assays we selected one well of each seed treatment at
random for which to perform transmission electron microscopy (TEM) to confirm
aggregation (or the lack thereof) and assess aggregate morphology. We placed samples onto
carbon coated nickel-mesh grids and negatively stained them using uranyl acetate. TEM
images showed that seeded SOD1G93A produced aggregates with a fibrillar morphology
(Fig. 6.10 A and B), in line with the relatively high ThT fluorescence value observed from
the previous plate assay. In contrast, the seeded SOD1G93A-W32S (assay 1) produced small
negatively stained puncta (Fig. 6.10 C and D). This indicates that even with the addition of
seed there was minimal formation of aggregate by SOD1 G93A-W32S and the aggregates
produced were small and amorphous, further suggesting that W32 plays a role in fibril
elongation, although the ThT signal of aggregation suggests these small puncta may contain
β-sheet structure.
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Figure 6.10: Transmission electron microscopy of SOD1G93A and SOD1G93A-W32S aggregates.
Samples from isolated protein aggregation assays were placed onto TEM grids and negatively stained
with uranyl acetate prior to imaging. (A) Seeded aggregation of SOD1G93A showing clear fibril
structures. (B) Increased magnification of seeded SOD1G93A aggregates, clearly showing fibril
structures. (C) Seeded aggregation of SOD1G93A-W32S showing an abundance of small distinct
negatively stained structures. (D) Increased magnification of one of the SOD1G93A-W32S structures
showing a lack of ordered structure.

6.2.4 Cellular aggregation and seeding of W32S variants
The isolated protein aggregation assays showed that W32S substitution was decreasing the
aggregation propensity of SOD1, affecting both aggregate nucleation and fibril elongation.
Studies in cells and in animal models suggest that SOD1 aggregates formed in cells may
differ when compared to those formed isolated protein assays (Bergh et al., 2015, Farrawell
et al., 2015). Considering this, the cellular aggregation of the W32S variants was tested by
transiently transfecting NSC-34 cells with SOD1-EGFP fusion proteins, comparing the
formation of intracellular inclusions between the disease variants and their corresponding
W32S forms using confocal microscopy. It was observed that every W32S variant had a
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significantly decreased number of cells containing inclusions compared to their disease
mutation only counterparts, agreeing with similar work performed previously where
SOD1G93A-W32F was expressed in cultured cells (Taylor et al., 2007). SOD1V148G-W32S had a
considerably substantial decrease in the number of cells containing inclusions, in line with
previous isolated protein aggregation assays, suggesting a particularly strong interaction of
Trp32 in the V148G SOD1 mutation.
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Figure 6.11: W32S variants have a lower aggregation propensity than their disease specific
counterparts when expressed in cells. NSC-34 cells were imaged 48 hrs post-transfection and the
number of transfected cell containing inclusions was counted. (A) Representative images of NSC-34’s
transfected with SOD1G85R, SOD1G85R-W32S, SOD1V148G, and SOD1V148G-W32S showing cells containing
bright puncta that were determined to be inclusions (arrows). White bars are 50 µm. (B) Manual
counting of cells with inclusions 48 hours post-transfection showed that SOD1 variants had
differential aggregation propensities when expressed in NSC-34’s. Significance is determined against
SOD1WT-EGFP, and where marked significance is between disease specific variant and W32S variant
for the same mutant (ie SOD1A4V-EGFP vs SOD1A4V-W32S-EGFP). Error bars represent SD of the mean
from 3separate transfections on different days. Statistical significance was determined via a one-way
ANOVA with a Tukey’s multiple comparison test where ^ symbols are comparisons to
SOD1WT-EGFP and * symbols are comparisons between W32 and W32S variants (*** = P < 0.001,
** = P < 0.01, * = P < 0.05, ns = not significant).
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Following determination of the aggregation of our W32S variants, we next tested their ability
to template onto preformed aggregates in cultured cells. To achieve this we performed
co-transfections, of SOD1-EGFP and SOD1-tdTomato, in NSC-34 cells (an advantageous
cell line due to the preclusion of interaction with any endogenous human SOD1). Cells were
transfected with EGFP (empty vector, SOD1mutant, or SOD1mutant-W32S) and tdTomato fusions
(SOD1mutant), and 48 hours post-transfection individual cells were imaged using confocal
microscopy. From these images, the fluorescence intensity was determined of both EGFP and
tdTomato in inclusions and compared to their corresponding diffuse fluorescence intensities
in the remainder of the cell, to determine a ratio of EGFP signal to tdTomato signal specific
to the inclusions. In every case the ratio of vector-EGFP signal in the inclusion was minimal,
indicating that the EGFP tag was not co-aggregating with the SOD1-tdTomato fusions,
suggesting that the co-aggregation observed for our SOD1-EGFP fusions was likely
proceeding through SOD1 contact only. In all cases, in the absence of the W32S substitution,
co-aggregation of the EGFP and tdTomato tagged variant occurred at a ratio that was close to
1:1, suggesting almost equal contribution of both tags. However, there was a clear bias
favouring the SOD1mutant-EGFP fusion, indicating that the EGFP fusions were more likely to
contribute to inclusion formation, in agreement with our previous analysis showing that
SOD1-tdTomato fusions had decreased aggregation propensities compared to SOD1-EGFP
fusions (Section 5.2.1, Fig 5.1 B). Again, the most likely cause for this is the size of the
tdTomato tag. The W32S-EGFP fusions had significantly reduced ratios of EGFP signal in
inclusions in all cases, indicating that the W32S substitution was also affecting the ability of
SOD1 to template onto already formed aggregates in the cellular context.
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Figure 6.12: Dual colour transfection seeding analysis of W32S variants. NSC-34 cells were cotransfected with either EGFP, SOD1(disease variant)-EGFP, or SOD1(disease variant-W32S)-EGFP, and
SOD1(disease variant)-tdTomato, and imaged 48 hours post-transfection. (A) Representative images of cotransfected cells in the EGFP and tdTomato channels showing inclusions (white outline). (B) Analysis
of co-transfections, showing the ratio of EGFP to tdTomato fluorescence signal in the inclusion,
where each data point is a separate cell. Error bars represent SD of the mean from 3 separate
transfections on different days with at least 10 cells imaged per transfection (3 for vector-EGFP
measurements). Statistical significance was determined via a one-way ANOVA with a Tukey’s
multiple comparison post-test (*** = P < 0.001, ** = P < 0.01, * = P < 0.05, ns = non-significant).
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6.3 Discussion
Here we have shown that a substitution of a serine in place of the tryptophan at position-32
can drastically alter the aggregation of SOD1 both in isolated protein assays and in a cellular
context, affecting the ability of SOD1 to template onto preformed aggregate species. An
interesting observation made here, was that in each case, treatment of the W32S variants with
DTT and EDTA resulted in the formation of higher abundances of destabilised SOD1
conformations when compared to their disease mutation only counterparts. Previous work has
emphasised that the amount of destabilised/unfolded SOD1 in a system is a determinant of its
aggregation (Lang et al., 2012). That we observed higher abundances of destabilised W32S
variants after DTT/EDTA-treatment, and lower aggregation propensities of the W32S
variants, signifies the importance of Trp32 in SOD1 aggregation. Furthermore, there are
multiple sequence segments predicted to have favourable energies to facilitate fibrillar
aggregation, with these segments being

14

VQGIINFE21,

30

KVWGSIKGL38,

101

DSVISLS107,

and 147GVIGIAQ153 (Ivanova et al., 2014). Ivanova and colleagues (2014) determined that the
C-terminal segments,

101

DSVISLS107 and

147

GVIGIAQ153, dominated the formation of fibrils

in their aggregation assays, which were performed under conditions similar to that performed
here. They also determined that a proline substitution at residue 35 (isoleucine) did not block
fibrillar aggregation of SOD1 leading them to conclude that segment 30KVWGSIKGL38 does
not form the β-sheet spine of the SOD1 fibrils they observed with electron microscopy. This
is interesting in the context of the work presented here as, from our analysis of the abundance
of unfolded protein, we would expect that the W32S variants would proceed to form fibrillar
structures due to the presence of unmodified sequence segments
101

DSVISLS107, and

14

VQGIINFE21,

147

GVIGIAQ153, however this was not the case. Indeed, the initial

aggregation of SOD1G93A-W32S was the only non-seeded W32S variant to show fibrillar
aggregation kinetics (Fig. 6.2 C and E), however the decrease in elongation rate, increase in
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lag-phase, and significantly lower maximum fluorescence were suggestive of a significant
decrease in aggregation propensity. However, we cannot rule out the interaction of segments
14

VQGIINFE21,

101

DSVISLS107, and

147

GVIGIAQ153 in the fibrillar structures observed here.

It is interesting to speculate that perhaps the stochasticity routinely observed in SOD1
aggregation (Abdolvahabi et al., 2016) is a result of these competing aggregation prone
segments, which may also play roles in the formation and propagation of different aggregate
strains observed in animal models (Ayers et al., 2014a, Bergh et al., 2015, Bidhendi et al.,
2016, Lang et al., 2015). Importantly, the work presented here demonstrates that regardless of
how the aggregates are formed (isolated or in-cell) the loss of the tryptophan (or gain of
serine) reduces the amount of aggregation observed.
The idea that protein aggregation in neurodegenerative disease follows a prion-like pathway
is gaining increasing traction. Indeed, the pathophysiology of ALS, where motor neurone loss
is ordered and progresses in correlation with an increase in protein aggregate load, seems to
suggest a prion-like feature is affecting disease progression and spread. SOD1 is one such
protein that is implicated to have prion-like properties, as evidenced by previous work
showing the cell to cell transmission of misfolding using novel antibodies. Grad and
colleagues (2011) identified Trp32 as a potential factor in the prion-like properties of SOD1,
suggesting this residue as a target for therapeutics. The seeded aggregation assays and dualcolour transfection work presented here agree with their hypothesis that Trp32 is a dominant
contributor in SOD1 aggregation and transmission, and provides greater understanding of the
events at a molecular level. Our cell based assays determined that, across a panel of SOD1
variants, W32S substitution resulted in a significantly decreased participation in inclusion
formation. Although it is not yet fully understood, it is possible that SOD1, and its
aggregates, can exit cells through various pathways (cell death, transport vesicle mediated
exocytosis) (Grad et al., 2014, Munch et al., 2011, Sabado et al., 2014). This released SOD1
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can be taken up into cells via macropinocytosis (Munch et al., 2011, Zeineddine et al., 2015),
potentially facilitating the aggregation or misfolding of the endogenous SOD1 within the new
cell. Although the cell based assays presented here do not investigate cell-to-cell aggregation
transmission, the data are consistent with the idea that the blocking of the intracellular
aggregation induced by the W32S substitution would affect further propagation. Our analysis
clearly indicates that Trp32 is a significant component of the molecular dynamics that govern
the intracellular aggregation of SOD1, but that it is not the only determinant of aggregation as
we still observed inclusion formation and co-aggregation of W32S variants albeit at a
significantly lower level. A possible explanation for this may be the other sequence segments
that have been suggested to contribute to aggregation as discussed above (Ivanova et al.,
2014).
An advantage of our mass spectrometry based analysis is that we are able to identify the
existence of specific protein species that are generated prior to aggregation. This is important
in the context of SOD1 aggregation, where protein modification states (metal binding and
disulfide status) have significant effects upon stability (Hayward et al., 2002, Lynch et al.,
2004, Svensson et al., 2010, Tiwari and Hayward, 2003) and therefore aggregation propensity
(Arnesano et al., 2004, Ding and Dokholyan, 2008). Previous work investigating Trp32 has
shown that this residue is susceptible to oxidative modification, promoted by interaction with
bicarbonate ion, and that this modification can lead to the formation of Trp32 cross-linked
non-native SOD1 dimers (Medinas et al., 2010). Our previous mass spectrometry based
analysis of the DTT/EDTA treated SOD1 species (section 5.2.5) showed no evidence of any
oxidative modification to Trp32 of any of our SOD1 variants (Fig. 5.10) suggesting that
oxidation of Trp32 was not playing a role in our experiments, which was expected due to the
lack of bicarbonate in any of the steps leading to our analyses, and the highly reducing
environment in our aggregation assays. This, and the striking decrease in aggregation
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propensity of our W32S variants, suggests that Trp32 does not require oxidative modification
to modulate aggregation.
Perhaps the defining feature of Trp32 is that it is an aromatic amino acid and that aromatic
amino acids are implicated in protein aggregation (Gazit, 2002, Pawar et al., 2005). Previous
work has shown that removal of aromatic side chains (Phe19 and Phe20) in Amyloid βprotein (Aβ) modulates its aggregation kinetics by increasing the length of the lag-phase,
indicating that they are affecting nucleation of small oligomers. Furthermore, the compound
1,4-naphthoquinon-2-yl-L-tryptophan (NQTrp) significantly inhibited the formation of Aβ
oligomers, significantly reduced the cytotoxic effect of Aβ oligomers in cultured neurons,
and completely restored movement in an Alzheimer’s disease drosophila model (ScherzerAttali et al., 2010). The molecular rationale provided for this, by Scherzer-Attali and
colleagues (2010), was that NQTrp was binding to the phenylalanine residues at positions 19
and 20 and blocking self-association of Aβ through this interaction. Similar interactions have
been shown with SOD1, where 5-fluorouridine was found to bind to Trp32 by X-ray
crystallography (Wright et al., 2013), and that 5-fluorouridine can inhibit in vitro aggregation
of SOD1A4V (Nowak et al., 2010). These small molecules, or similar analogues, could
potentially be used to prevent SOD1 aggregation or misfolding transmission in a cellular
context, however, more work would be required to determine this.
In conclusion, the data presented here provides further evidence signifying the importance of
W32 in the aggregation and propagation of aggregation in SOD1 associated fALS. Using a
combination of mass spectrometry based conformational analysis and aggregation assays, we
have shown that the W32S substitution dramatically alters the aggregation propensity of
several fALS associated SOD1 mutants, whilst decreasing their stability. We further show
that the aggregation propensity of W32S variants is decreased in cells, even when fALS
associated disease variant aggregates are available for templating. This underpins the
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conclusion that Trp32 is a promising target for therapeutic strategies involving small
molecule or antibody based treatments.
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7. Conclusions and Future Research
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7.1 Overview
The main focus of this thesis was to investigate a range of ALS associated SOD1 variants, in
regards to particular disease linked characteristics such as dimer dissociation, aggregation,
and unfolding, as well as the interplay between these characteristics. Given that mutations in
SOD1 are associated with fALS, and that there is growing evidence implicating SOD1 in
sALS cases, it is important to understand how different SOD1 mutations alter protein
dynamics to result in common structural modifications that differ from the wild-type.
Advancing our understanding of this process could potentially lead to a determination of a
structural basis for disease and the subsequent development of targeted therapeutics. In order
to address this, several ALS associated SOD1 variants were used to examine dimer
dissociation, aggregation propensity, response to denaturation, and the effect of a serine
substitution at the disease implicated tryptophan at position-32.
In agreement with previous studies, the work presented here indicates that SOD1 variants
display significantly modified structural dynamics across the range of characteristics that
were investigated. The most interesting observations surrounded the SOD1G37R variant, which
is associated with a relatively slow progression of ALS pathology in patients.

It was

observed that SOD1G37R showed vastly different gas-phase dynamics to that of SOD1WT, a
propensity to unfold similarly to the aggressive SOD1G93A and SOD1V148G variants, as well as
an interesting inability to template onto preformed SOD1G93A aggregates. This work also
draws attention to the significant effect of Trp32 in SOD1 aggregation, where a W32S
substitution was found to increase the abundance of unfolded protein under aggregation
conditions yet decrease aggregation, similar to the SOD1G37R mutation. As a result of this
combined work, it is proposed that a sequence segment that includes residues 32 and 37 are
involved in SOD1 associated aggregation and aggregation transmission.
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7.2 SOD1 is a Potential Model Protein for the Investigation of in
vacuo Protein Dimer Characteristics
The utility of native mass spectrometry, when investigating the characteristics of protein
structure, is remarkable. The first body of work presented here attempted to assess the ability
of routinely used native mass spectrometry techniques to determine differences in the
dissociation and unfolding pathways of several fALS associated SOD1 mutants. It was
discovered that the in vacuo dissociation and unfolding characteristics of SOD1 were not
representative of the previously reported variant dependant solution-phase characteristics,
indicating that analyses performed on data acquired from the gas-phase must be interpreted
carefully to ensure relevance to solution. However, when viewing these gas-phase data from
a pure biophysical perspective it is highly intriguing that SOD1 G37R presented remarkably
different dissociation and unfolding dynamics, comparative to the other mutants, disagreeing
with current dimer charge partitioning models. Current models stipulate that in an
asymmetric dimer system, the monomer carrying more charge unfolds at a lower energy
before the complex dissociates, and that monomers from more symmetrically charged dimers
are subject to comparatively much smaller structural perturbations prior to complex
dissociation (Wanasundara and Thachuk, 2009). Our results disagreed with this model, with
the unexpected observation that the evolution of more asymmetrically charged monomers
from the comparatively less unfolded SOD1G37R dimer, showed no apparent change in
dissociation rate to the other SOD1 variants. However, it becomes clear from study of a
heterodimer (composed of both SOD1WT and SOD1G37R) that these curious observations
appear to be a result of allosteric effects imparted by the arginine substitution at position-37.
Furthermore, this indicates that SOD1 would be an exceptional model protein for which to
study gas-phase protein dimer characterisitcs, owing to the number of naturally occurring
mutants and the differential metallation states; combining to make a highly modular system
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from which gas-phase characteristics can be tested against models derived from the extensive
structural characterisation data currently in the literature. Therefore, from the context of gas
phase analysis, this work may influence future studies that assess protein dissociation and
unfolding via in vacuo based techniques.

7.3 SOD1 Post-translational Modification and ALS
The ability to resolve proteins based on mass, charge, and cross-sectional size, provided by
mass spectrometry is unparalleled. This is highlighted by the work presented in this thesis by
the interrogation of recombinant SOD1 post-translational modification (PTM) states and the
ability to examine corresponding conformational and aggregation states. The initial
assessment of SOD1 PTM directed our downstream analysis and was useful in the
determination of dimer KD values of differentially glutathionylated SOD1 in a mixed sample,
highlighting the necessity of determining protein PTM state prior to structural or functional
assessment. It is readily apparent that protein biological structure, and therefore function, is
modulated by PTMs and that this is likely to be an important factor in diseases such as ALS.
The human genome currently has ~21 000 protein coding genes identified, and the proteome
is even larger still, estimated at anywhere between ~10 000 to several billion (Ponomarenko
et al., 2016) different protein species when PTMs are considered. Protein species are defined
as synthesised polypeptide sequences that have undergone transcriptional, translational, or
post-translational processing that may modify the protein in some way, including nucleotide
polymorphisms, gene splicing events, proteolysis, PTM, and binding of cofactors (Schluter et
al., 2009). One could also include different folding states, such as natively folded, misfolded,
or aggregated, under the umbrella of different protein species. Indeed, the PTM state of
SOD1 has been implicated in disease including the bicarbonate dependent oxidative
modification of W32 to a formylkynurenine that can cross-link to form non-native dimers
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(Coelho et al., 2014, Medinas et al., 2010), and the exposure of a disease associated epitope
in glutathionylated SOD1 (Redler et al., 2014).
Furthermore, the effect of glutathionylation on SOD1 structure extends beyond the
augmentation of dimer dissociation. In vitro glutathionylation of Cys111 of SOD1 was shown
to induce non-native oligomerization, as well as reactivity to the C4F6 antibody in several
recombinantly expressed fALS associated SOD1 variants (Redler et al., 2014). The C4F6
antibody is generated against apo-SOD1G93A (Urushitani et al., 2007) and recognises an
epitope within amino acid sequence positions 80-119 (Bosco et al., 2010), with residues 9093 being critical for antibody binding (Ayers et al., 2014b). It reacts strongly with both sALS
and fALS post-mortem tissue (Ayers et al., 2014b, Bosco et al., 2010). It could be argued,
that glutathionylation may contribute to disease both by increasing the dissociation
propensity of SOD1 dimers, and by facilitating misfolding. It is interesting to note however,
that hSOD1 extracted from human and murine neural tissue was not glutathionylated, but
rather cysteinylated at Cys111 (Auclair et al., 2014), a modification which can also alter
dimer interfacing (Auclair et al., 2013a), however, it is unknown whether cysteinylation can
induce misfolding. Current knowledge also suggests that Cys111 plays a role in SOD1
associated pathogenesis via cross-linking as substitution of this residue showed a marked
decrease in oligomers and inclusions in cultured cells (Cozzolino et al., 2008, Niwa et al.,
2007), as well as delaying phenotype onset in SOD1H46R/C111S mice (Nagano et al., 2015). As
stated earlier, oxidative modification of W32 is implicated as a cause for the formation of
non-native SOD1 oligomers, mediated by oxidative damage (Coelho et al., 2014). Cultured
cells expressing ALS-associated SOD1 mutants with a W32F substitution showed decreased
cell death and aggregate load (Taylor et al., 2007), similar to what was observed in variants
where Cys111 was replaced. This suggests that oxidatively induced cross-linking of either
Trp32 or Cys111 may contribute to pathogenic aggregation, however our analysis using
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mass spectrometry showed no modification to Trp32, suggesting that oxidative modification
of Trp32 may not be necessary for aggregation to proceed. This being said, we cannot rule
out that some form of oxidative modification is occurring at a later time point in our isolated
protein assay or in our cell based assays.
There are likely dozens of possible SOD1 protein species that can be derived from various
modifications and identification of the toxic species or structural feature is paramount to
development of targeted therapeutics. While high-resolution analyses such as X-ray
crystallography and Nuclear Magnetic Resonance (NMR) provide angstrom level structural
information these techniques may not be effective at elucidating a target structure, as it is
likely that any such toxic species exists in low abundance and is not amenable to the
increased concentrations or chemical environments that are required of these techniques.
Mass spectrometry based techniques, however, while relatively low resolution compared to
X-ray and NMR data, offer mass resolving capabilities that are invaluable for delineating
protein species within a mixture. This capability was demonstrated here in regards to SOD1
glutathionylation and dimer dissociation.

7.4 SOD1 Mutation and its Relation to Aggregation
Extensive study has been conducted on fALS associated SOD1 variants and primarily due to
the presence of SOD1 positive aggregates in patient tissue. One of the main focal points of
this study has been around the structural stability of the protein. When considering natively
folded mutant SOD1, it is apparent that whilst mutation can have an effect on stability, the
destabilisation effect of mutation is effectively muted if disulfide formation and binding of
metal cofactors is successful. An example of this is the similar melting temperatures of native
SOD1WT (~90 °C) and mutant forms of SOD1 (Furukawa and O'Halloran, 2005, Rodriguez et
al., 2002). The stabilising effects of the intramolecular disulfide and copper binding are a
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product of folding facilitated by the copper-chaperone for SOD1 (hCCS) (Furukawa et al.,
2004, Rae et al., 2000). The reduced apo-form of SOD1WT has a significantly decreased
thermal stability with a melting temperature of ~43 °C (Lindberg et al., 2002). From these
stability based observations, it would stand to reason that the formation of SOD1 aggregates
potentially proceeds through an immature form of SOD1 that is destabilised by mutation (Fig.
7.2). This idea is consistent with the work presented in this thesis that showed differential
levels of destabilisation of our SOD1 variants, primarily in the reduced apo-state, with higher
levels of unfolding correlating with increased thioflavin T positive aggregate formation in
isolated protein assays. SOD1G37R was an outlier here showing relatively low thioflavin T
fluorescence, comparative to the level of destabilised SOD1 observed using mass
spectrometry. Even more interesting was that SOD1G37R showed levels of intracellular
aggregation similar to that of SOD1A4V, suggesting the formation of non-fibrillar aggregates
in vitro may be a characteristic of SOD1G37R. It could be speculated that rather than mutation
affecting only conformational stability, it also directs the process of SOD1 aggregation and
the specific structures generated through precise intermolecular contacts. This potentially
contributes to differential patient survival times of SOD1 associated fALS cases. SOD1
associated fALS patients with a SOD1G93A or SOD1V148G mutations die rapidly after
diagnosis (means of 2.1 and 1.2 years respectively), whereas patients carrying SOD1 G37R
have a mean survival time of 17.6 years (Wang et al., 2008), suggesting a different or milder
molecular basis of pathology.
Another curious observation was the inability of SOD1G93A aggregate seeds to induce
increased aggregation in a solution containing abundant unfolded SOD1G37R. This inability of
SOD1G37R to template onto preformed aggregates is similar to the observations described here
that show a serine substitution at amino acid Trp32 of SOD1 significantly decreased seeded
and non-seeded aggregation across multiple variants. Gly37 is relatively close to Trp32, and
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it is possible that a steric effect or charge repulsion effect is occurring to block the selfassociation of this segment of the SOD1 polypeptide, as the arginine side chain is bulkier
than that of glycine, and in addition, it can be charged. Relative to the whole SOD1 primary
structure, the sequence segment around position-32 and 37 is remarkably conserved amongst
SOD1 associated fALS patients (http://alsod.iop.kcl.ac.uk (Abel et al., 2013a), but compared
to mice the segment is highly non-conserved (Grad et al., 2011). These collective
observations suggest that this sequence segment of SOD1 is a potential mediator and initiator
of aggregation and misfolding propagation..
Previous work has emphasized the importance of particular sequence segments
(14VQGIINFE21,

30

KVWGSIKGL38,

101

DSVISLS107, and

147

GVIGIAQ153) of SOD1 for the

initial self-assembly into aggregates (Ivanova et al., 2014). Analysis of the SOD1 amino acid
sequence using the aggregation hot-spot finder tool ‘Aggrescan’ (Conchillo-Sole et al., 2007)
identifies 6 aggregation hot-spots, including a sequence segment encompassing Trp32 (Fig.
7.1), similar to the above mentioned segments. This may indicate that blocking aggregation
of any one segment, including the Trp32 encompassing segment, could lead to SOD1
aggregation being facilitated by other sequence segments, although we did not directly
observe this. The results presented here suggest that altering Trp32 significantly supressed
(for SOD1G93A we observed a ~50% reduction of inclusions in cultured cells (Fig. 6.10 B) but
does not totally block aggregation, this is consistent with the region encompassing W32 being
important but not necessary for aggregation. An explanation for this can be drawn from the
stochastic nature of protein aggregation (Abdolvahabi et al., 2016), resulting in several types
of aggregates such as amorphous or variously structured fibrillar aggregates (Fig. 7.2). It is
possible then that the segment most likely responsible for ordered aggregation is the segment
containing Trp32. Therefore, any unfolded SOD1 is likely to proceed down a disordered
aggregation pathway due to the probability of the initiation of ordered aggregation at a
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particular segment being low. To test this, one could perform a high number of ThT based
assays on recombinant SOD1-W32S protein to examine stochastic differences in fibrillar
kinetics; aggregates that appear at low frequency with significantly different kinetics that (are
propagatable) are likely generating different strains of aggregate that are dependent on other
sequence segments.

Figure 7.1: SOD1 fALS-associated mutations and aggregation hot spots. Six aggregation hotspots (blue line) are identified by Aggrescan (Conchillo-Sole et al., 2007) with one hot spot (*)
corresponding to a sequence segment encompassing Trp32 and Gly37, with high conservation of
residues across SOD1 associated fALS cases.

7.5 Aggregate Strains and Prion-like Characteristics are
Dependent on Specific Residues
An increasing amount of evidence suggests that SOD1 may have prion-like characteristics
(Ayers et al., 2014a, Ayers et al., 2016, Bidhendi et al., 2016, Grad et al., 2011, Grad et al.,
2014, Munch et al., 2011, Pokrishevsky et al., 2012a). Briefly, Prion protein (PrP) is a protein
that can assume an energetically favourable and protease resistant non-native conformation,
associated with neurodegenerative disease, that can transform native PrP into this same form
and transmit misfolding to nearby cells and also separate organisms (Málaga-Trillo and
Sempou, 2009, Riesner, 2003). In the case of neurodegenerative diseases such as Alzheimer’s
(amyloid-β), Parkinson’s (α-synuclein) and ALS (SOD1, TDP-43, FUS etc.), the pathological
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propagation is typically the recruitment of soluble proteins onto aggregates. The fact that
these aggregates may display different kinetics and structural arrangements has resulted in
them being categorized as different ‘strains’. Another significant distinction is that evidence
for the infectious transmission of the above mentioned diseases is limited (Irwin et al., 2013).
Owing to these distinctions, the term ‘prion-like’ is commonly used to define the mechanism
of propagation in these diseases.
Organism-to-organism transmissibility of ALS was effectively shown to occur in a study that
injected spinal cord homogenate from terminal transgenic mice expressing either SOD1 G93A
or SOD1G37R into the spinal cords of mice expressing low levels of SOD1 G85R-YFP (yellow
fluorescent protein). It was observed that the injection of SOD1G93A homogenate was able to
induce ALS-like symptoms and pathology in the SOD1G85R-YFP mice, and that this could be
further passaged to newborn SOD1G85R-YFP mice. Interestingly, the homogenate from the
SOD1G37R mice did not induce ALS symptoms or pathology, even though the SOD1G37R mice
developed an ALS-like pathology (Ayers et al., 2014a). As stated previously, Gly37 is
proximal to Trp32, and it is highly possible that the lack of transmission observed in these
mice is a consequence of the structure or strain of aggregate that SOD1G37R develops, and
perhaps the propagation competent epitope is not (or less) exposed in this structure, resulting
in the low expressed endogenous SOD1G85R-YFP being unable to effectively template onto
the exogenous material. This agrees with our previous statement that mutation directs
aggregation not only through reduced conformational stability, but perhaps by exposure of
precise intermolecular contacts (Fig. 7.1).
Recent work has identified the presence of two separate aggregate strains from transgenic
mice overexpressing SOD1D90A (Bergh et al., 2015). These strains were found to have
different kinetics, structures, and stabilities and were therefore termed A and B strains. The
coarse-grain structure of these aggregates was identified using binary epitope mapping, and
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interestingly the common core of the structures was found to roughly encompass the SOD1
amino acid sequence from 1 – 39 (more precisely Strain A: 1-39 and 100-127, Strain B: 172). Furthermore, injection of these strains into mice overexpressing human SOD1 WT showed
propagation and maintenance of the physical characteristics of each strain, where epitope
mapping again showed similar results in strain extracted from inoculated mice to that of the
donor mice (Bidhendi et al., 2016). Perhaps the most interesting component of this work is
that both strains maintained a common aggregate core composed of residues 1-39, which
strongly suggests that this sequence segment is contributing to both aggregation and
propagation by providing the main structure of the aggregate species. Other work has
highlighted part of this segment, and in particular Trp32, as a key component of the prionlike characteristics of SOD1 in ALS (Grad et al., 2011). The work here, where the decreased
ability of W32S variants to template onto preformed aggregates both in isolated protein
assays and in cells was observed supports the idea that SOD1 aggregation is primarily
dependent upon Trp32 or at least the sequence segment containing Trp32. Although we
observed a significant decrease in co-aggregation between disease only and W32S variants,
there was still evidence that co-aggregation was occurring, meaning that further work would
need to be performed in order to examine the contribution of different aggregation prone
sequence segments to the formation and propagation of SOD1 aggregates. If Trp32 and its
sequence segment are the main contributors to the spread of SOD1 aggregates in SOD1
associated fALS cases, then it would provide an ideal target for therapeutic intervention
owing to it being unique as the only tryptophan residue in the SOD1 sequence.
We propose a model of SOD1 folding, misfolding and aggregation below based the current
literature and the knowledge gained from this study. Following synthesis, SOD1 is thought to
assume a partially folded conformation which can be stabilised by the binding of zinc
(Furukawa and O'Halloran, 2006). Once zinc is non-covalently bound to the polypeptide, the
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copper chaperone for SOD1 (hCCS) forms a heterodimer with the copper deficient folding
intermediate and directs the correct coordination of copper into SOD1. The CCS is also
thought to facilitate the formation of the intramolecular disulfide between Cys57 and Cys146,
thus creating a mature SOD1 monomer that can form a homodimer with other mature SOD1
monomers (Furukawa et al., 2004, Rae et al., 2000). At virtually any point on this pathway
the process can be disrupted or proceed in an aberrant way due to mutation or other erroneous
interactions such as oxidative modification, reduction, incorrect input of metal cofactors, and
post-translational modifications. Disruption of proper folding pushes the equilibrium
increasingly to off-folding pathways through which SOD1 can misfold and form aggregate
structures of varying morphology (Sekhar et al., 2015). Firstly, small oligomers are necessary
step on the path to larger aggregates and have been detected in vitro (Banci et al., 2007),
although the intracellular concentration of these species is potentially too low to detect
(Polling et al., 2014). Following from small oligomers is the formation of larger aggregates
which grow from the successive addition of destabilised SOD1 monomers to the main body
of aggregate. It is not fully clear if SOD1 aggregate structure is ordered or amorphous as
staining with common amyloid dyes (congo red and thioflavin S) has been reported to be
negative and weak (Kerman et al., 2010), but use of sequence specific antibodies has shown
some order within the seemingly amorphous structures (Bergh et al., 2015, Lang et al., 2015).
Taking the evidence for SOD1 prion-like propagation into account suggests that a misfolded
monomer or structured aggregate is able to propagate itself inter and extracellularly (Bergh et
al., 2015, Bidhendi et al., 2016, Grad et al., 2011). Propagation of aggregate structures
between mice has shown that they can cause differential rates of disease progression
(Bidhendi et al., 2016) or no progression at all (Ayers et al., 2014a). Of all these proposed
misfolded and aggregated forms it is unclear which one is the primary neurotoxic species
responsible for ALS, but it is clear that SOD1 mediated toxicity can proceed through many
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mechanisms, including dysregulation of the ubiquitin proteasome system, mitochondrial
dysfunction, disruption of cytoskeletal elements, and potential generation of reactive nitrogen
or oxygen species, as well as other mechanisms (Cleveland and Rothstein, 2001, Ilieva et al.,
2009). This complexity makes choosing a specific target for therapeutic development
difficult.
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Figure 7.2: Schematic of SOD1 folding, proposed misfolding, and the associated cytotoxic
consequences. Following synthesis, SOD1 proceeds to fold into a mature monomer first by binding
of zinc to the nascent chain which is followed by noncovalent association with the copper chaperone
for SOD1 (CCS) which facilitates binding of copper and formation the intramolecular disulfide,
following which two mature monomers form the native homodimer (although metal occupancy can
vary, leading to dimers composed of mixed metallated monomers). At any step in this pathway
mutation or covalent modification can prevent correct folding. The more unstable intermediate steps,
and to some extent a mature SOD1 monomer destabilised by modification or mutation, can misfold or
form small oligomeric species. Misfolded monomer and small oligomers are thought to be neurotoxic
as well as contribute to the formation of larger aggregates that can be amorphous or ordered. Different
molecular contact points between the monomers that constitute ordered aggregates are thought to
contribute to the formation of different aggregate strains that are associated with variable disease
progression. A specific toxic effect caused by the unknown disease causing SOD1 species is yet to be
identified, however mitochondrial dysfunction, ER stress, dysregulation of the UPS, oxidative and
nitrosative stress, as well as disruption of the cytoskeleton are all correlated with SOD1 associated
fALS.
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7.6 Therapeutic Strategies for Targeting SOD1 in ALS
The development of therapeutics for the treatment of ALS has been hindered in no small part
due to the difficulty of discovering a common cause of pathology. Mutations in SOD1 are
associated with ~2% of all ALS cases, and although SOD1 is implicated in sALS and nonSOD1 associated fALS cases (Bosco et al., 2010, Forsberg et al., 2010, Pokrishevsky et al.,
2012b), it is still not fully clear how much SOD1 contributes to these cases (Kerman et al.,
2010). Regardless, alleviation of disease for sufferers of SOD1 associated ALS is a path that
should be pursued. Genetic sequencing technology can identify people at risk of developing
SOD1 associated ALS, allowing for the application of more effective treatment prior to
symptom onset as once the phenotype is noticeable the damage to neural pathways may
already be extensive. Classical therapeutic development strategy has relied upon
understanding structure and targeting specific motifs with small molecules to block an active
site or induce an allosteric effect that inhibits or excites activity (Mandal et al., 2009). It has
been proposed that targeting SOD1 with small molecules designed to maintain the native
state would be an effective strategy as it could potentially lower the abundance of misfolded
SOD1 in a cell system. A portion of the research into small molecules aimed at attenuating
SOD1 toxicity has focused on cross-linking SOD1 monomers to maintain the dimer (Auclair
et al., 2010, Hallewell et al., 1989, Ray et al., 2004). The main problem associated with this
approach is that any covalent cross-linking agent will potentially have high cross-reactivity in
an in vivo environment. Another weakness is that SOD1 is present at high concentrations
throughout all tissue and to assert effective binding in neurons would require large
stoichiometric quantities of drug. Furthermore, this would not address the issue of the
multiple states of folding SOD1 can assume dependent upon mutation, binding of metal
cofactors and disulfide status. Even though there may very well be an unidentified highly
defined structural basis for the initiation and propagation of SOD1 toxicity in ALS cases,
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elucidating this will be exceedingly difficult given these protein species are uncooperative
with current high resolution techniques due to low abundance and structural flexibility.
Although a small molecule with a high specificity to the toxic SOD1 conformation would be
ideal, it is currently unfeasible.
The answer may lie in the usage of antibodies raised against specific epitopes of misfolded
SOD1 that are associated with ALS. Indeed, research has shown that vaccination, prior to
symptom onset of transgenic mice expressing SOD1G37R, with recombinant human apoSOD1G93A extended survival approximately 4 weeks. Antibody titres in these mice were also
found to have a positive correlation with life span (Urushitani et al., 2007). A similar
approach was shown to be effective in cultured cells where induced misfolding of hSOD1WT
was propagated from culture-to-culture through incubation in condition media, which was
blocked by addition of misfolded SOD1 specific antibodies to the condition media prior to
incubation (Grad et al., 2011). An advantage of this approach is that antibodies that are highly
selective for the identified subpopulations of misfolded SOD1 could be used, meaning that
there would be no interference with natively folded SOD1. A disadvantage to this strategy
would be that antibodies would be unable to enter the intracellular space of disease affected
cells, and would therefore rely upon the hypothesis that SOD1 misfolding is transmitted cellto-cell in a prion-like manner, and not through other mechanisms.
Rather than stabilising misfolded SOD1 or targeting its misfolded forms with binding
partners, an effective strategy could be to ensure proper folding in the first place or clearance
of the offending species by controlling cellular protein quality control machinery. Targeting
the protein quality control mechanisms within neurons has previously shown some promise.
Such mechanisms include the proteasome, heat-shock response, and autophagy. Upregulation
of the proteasome would enhance clearance of misfolded protein, and in theory reduce the
toxic effects associated with these species. Indeed, enhanced survival of Huntingtin disease
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patient derived skin fibroblasts was observed when over-expression of the proteasome
activator28γ subunit was induced (Seo et al., 2007). Research has also shown similar effects
with overexpression of heat-shock factor protein-1, which induces the expression of the
chaperone heat-shock proteins and upregulates the heat-shock response, has shown to be
effective at reducing the phenotype and toxicity in models of neurodegenerative disease (Lin
et al., 2013, Pierce et al., 2013). In the context of SOD1-associated ALS, autophagy is a
questionable target due to evidence suggesting both detrimental and beneficial effects of
upregulation. For example, targeting autophagy using lithium has shown a delay in symptoms
onset and disease duration in transgenic SOD1G93A mice (Fornai et al., 2008), but similar
work has shown that lithium has no effect in these mice (Pizzasegola et al., 2009) or even in
humans (UKMND-LiCALS, 2013). The heat-shock response, the proteasome, and to a lesser
extent, autophagy, all show some promise as viable therapeutic targets, but in the case of
SOD1, ensuring proper structural integrity is potentially simpler than targeting these broad
systems.
Proper folding and maturation of SOD1 is dependent upon correct metal coordination and its
association with the aptly named ‘copper chaperone for SOD1’ (hCCS), as well as the proper
functioning of cellular copper homeostasis. Therefore, theoretically, upregulation of hCCS
would result in an increase in SOD1 – hCCS interactions, inducing proper folding of the
nascent protein and preventing its aggregation, however, practically, overexpression of
human CCS in transgenic SOD1G93A mice (hCCS:SOD1G93A) significantly decreased survival
time and increased the neurological deficits of the model (Son et al., 2007). This suggests that
an aberrant interaction between hCCS and SOD1 is involved in SOD1-associated ALS,
making this target questionable. However, understanding of the models implies that
increasing both SOD1 and CCS load in an organism would further perturb copper
homeostasis and therefore lead to an increased abundance of apo-SOD1, which is more likely
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to misfold and aggregate, therefore it was postulated that delivery of copper into mice would
alleviate disease by increasing the levels of copper bound SOD1. Delivery of copper into
SOD1G93A mice using the drug CuII(atsm) was found to significantly increase lifespan even in
symptomatic mice (Soon et al., 2011). A study that orally treated SOD1G37R mice with
CuII(atsm) found that the levels of SOD1 in neural tissue were increased and that there was a
greater relative abundance of holo-SOD1 compared to untreated mice, as well as this increase
in holo-SOD1 concentration having a positive correlation with increased survival (Roberts et
al., 2014). Furthermore, recent research has shown a further amelioration of neurotoxicity and
significantly increased survival of the previously mentioned transgenic hCCs:SOD1G93A
mice, when treated with CuII(atsm). Remarkably, the lifespan of these mice increased from
~30 days to 20 months, as well as this again correlating with an increased concentration of
holo-SOD1 in the neural tissue. Interestingly, discontinuing treatment led to a development of
ALS-like symptoms and death, however restoring treatment rescued these symptomatic mice
(Williams et al., 2016). Although the effects of CuII(atsm) are exceptional, it is not yet known
if the same outcomes would be observed in metal binding region mutants of SOD1, such as
SOD1H46R which disrupts copper coordination, or highly destabilising mutants which have a
lower affinity for zinc (Crow et al., 1997, Luchinat et al., 2014), which are suggested to have
a deficient interaction with hCCS that may lead to the formation of toxic hetero-oligomers
composed of both proteins (Wright et al., 2016). Analysis of the interactions between hCCS
and different SOD1 mutants would need to be performed in order to elucidate the efficacy of
mediating correct folding through CCS. We have performed a preliminary experiment where
SOD1G37R folding was monitored by mass spectrometry in real time as it was incubated with
the yCCS (Appendix C – Fig. C4). It would be possible to quickly assess the difference in the
folding of SOD1 mutants at variable concentrations and in the presence of different metals
using this technique in future.
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7.7 Concluding Statements
Neurodegenerative diseases associated with protein deposition have been the focus of intense
study for decades. Although most neurodegenerative diseases have characteristic symptoms
and pathologies that are different from each other, a common theme is the misfolding and
aggregation of specific proteins into potentially neurotoxic species. The process of misfolding
and aggregation produces many different species including misfolded monomers, small nonnative oligomers, and large intracellular inclusions, making it difficult to identify a particular
species that may be the causative agent of disease. In light of this, research into protein
folding, misfolding, and aggregation has been extensive, with the hypothesis that
understanding these processes will yield a viable therapeutic target that will limit or stop
these events from occurring. In the case of SOD1, there is now growing evidence that
misfolding and a prion-like propagation is contributing to the ordered spatiotemporal
progression of pathology observed in SOD1-associated ALS cases. The work presented in
this thesis has provided further evidence for the rationale that unfolded or nascent SOD1 can
accumulate into aggregate structures, and that the kinetics and dynamics of formation, as well
as the type of structure, can be influenced by both ALS associated mutation and non-ALS
associated mutation. We draw particular emphasis to amino acid Trp32 in SOD1 which
significantly augments the aggregation of the protein. It is hoped that the implication that
Trp32 of SOD1 as a key determinant of the formation of aggregates will aid in the
development of therapeutics to treat ALS.
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Appendix A: Media and general buffer compositions
All media and buffer were made up using distilled H2O, unless stated otherwise.
MEDIA
Luria-Bertani (LB) broth
Tryptone
Yeast Extract
NaCl

10 g/L
5 g/L
10 g/L

LB agar
Tryptone
Yeast Extract
NaCl
Agar

10 g/L
5 g/L
10 g/L
15 g/L

BUFFERS
1 × Phosphate buffered saline
NaCL
8 g/L
KCl
0.2 g/L
Na2HPO4
1.44 g/L
KH2PO4
0.24 g/L
Make up to 800 mL volume with dH2O, adjust to pH 7.4 and fill to 1 L with dH2O
5 × SDS-PAGE sample buffer
Tris-HCl (pH 6.8)
Glycerol
SDS
2-Mercaptoethanol
Bromophenol blue

200 mM
50 % (v/v)
1 g/L
300 mM
0.4 % (w/v)

Native-PAGE sample buffer
Tris-HCl (pH 6.8)
Glycerol
Bromophenol blue

200 mM
50 % (v/v)
0.4 % (w/v)
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Coomassie blue stain
Coomassie blue
Methanol
Glacial acetic acid

2 g/L
40 % (v/v)
10 % (v/v)

Rapid destain
Methanol
Glacial acetic acid

40 % (v/v)
10 % (v/v)

Ammonium acetate (200 mM)
7.5 M NH4OAc

2.66 % (v/v)
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Appendix B: Plasmid sequences and maps
pACA-forward-yCCS-hSOD1 plasmid sequence
SOD1
yCCS
TCGACCTCTAGACCAAGCTTGGCTGCAGGTCGACGGATCTCGATCCCGCGAAATTAATACGA
CTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACCATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCGACGGCCCAGTGCAGGGCAT
CATCAATTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTGTGGGGAAGCATTAAAGGAC
TGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGATAATACAGCAGGCTGTACC
AGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTGGGCCAAAGGATGAAGAGAG
GCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGTGTGGCCGATGTGTCTATTG
AAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGGCCGCACACTGGTGGTCCAT
GAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTACAAAGACAGGAAACGCTGG
AAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAATAACAGATTGATTCAGTTTCACTTT
CACTGGGGTTCACTTGATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGC
AGAACTTCACTTGGTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAAC
CTGATGGACTGGCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAG
AAAGTTGTTGATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTT
CGATCCTCGTGGCCTCCTTCCTGAATCCCTGGATTACTGGACCTACCCAGGCTCACTGACCA
CCCCTCCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGC
GAGCAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGAT
GGTGGACAACTGGCGCCCAGCTCAGCTAAGAAGGAGATATACCATGACCACGAACGATACAT
ACGAGGCTACTTATGCCATTCCCATGCACTGTGAAAATTGCGTGAATGATATAAAGGCATGC
CTAAAAAATGTCCCAGGAATCAATTCATTGAATTTCGATATAGAGCAACAAATAATGAGCGT
GGAAAGCTCAGTAGCCCCTTCAACCATCATCAACACCTTGCGAAACTGTGGTAAAGACGCCA
TCATAAGAGGCGCCGGGAAGCCGAATTCTTCCGCGGTCGCTATCTTAGAGACCTTTCAAAAA
TATACTATAGACCAGAAAAAGGACACCGCCGTGAGGGGCCTAGCAAGAATCGTTCAGGTTGG
AGAGAATAAGACTCTTTTTGACATCACTGTAAATGGCGTCCCAGAGGCGGGAAATTACCACG
CCAGCATTCACGAGAAAGGCGACGTCTCCAAGGGCGTGGAATCTACTGGTAAAGTTTGGCAC
AAGTTCGACGAACCCATTGAATGCTTCAACGAGAGTGATTTGGGCAAGAACTTGTACAGTGG
GAAGACCTTTCTGAGCGCTCCCTTGCCAACATGGCAACTTATCGGCCGCAGCTTTGTCATTT
CCAAGTCTCTGAACCACCCAGAAAACGAGCCTTCCTCCGTTAAGGACTACTCATTTCTGGGA
GTCATTGCGAGAAGCGCTGGTGTGTGGGAAAATAATAAACAAGTGTGTGCGTGTACCGGAAA
GACTGTTTGGGAAGAGAGAAAAGATGCCTTGGCCAACAACATCAAATAGGCTCAGCCACTGA
AGAACAGGCAAATCAAAGCTTCCTTCAAATAAGATGGTCCCATAGTCTGTATCCAAATAATG
AATCTTCGGGTGTTTCCCTTTAGCTAAGCACAGATCCGGCTGCAACAAAGCCCGAAAGGAAG
CTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGG
GTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATGGGAATTCCCCGCGCGCGA
TGCCCTTTCGTCTTCGAATAAATACCTGTGACGGAAGATCACTTCGCAGAATAAATAAATCC
TGGTGTCCCTGTTGATACCGGGAAGCCCTGGGCCAACTTTTGGCGAAAATGAGACGTTGATC
GGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGATCACTACCGGGCGTATTTTTT
GAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATCACTGGATATAC
CACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTC
AATGTACCTATAACCAGACCGTTTAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAA
AATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCC
GGAATTTCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTT
ACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGAT
TTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTA
TTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCA
CCAGTTTTGATTTAAACGTGGCGAATATGGACAACTTCTTCGCCCCCGTTTTCACTATGGGC
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AAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGT
CTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGC
AGGGCGGGGCGTAATTTTTTTAAGGCAGTTATTGGTGCCCTTAAACGCCTGGTTGCTACGCC
TGAATAAGTGATAATAAGCGGATGAATGGCAGAAATTCGAGCCCGCCTAATGAGCGGGCTTT
TTTTTAGCCCGCCTAATGAGCGGGCTTTTTTTTCGAAAGCAAATTCGACCCATCGCGCGCGG
GGAGTCAACTCAGCAAAAGTTCGATTTATTCAACAAAGCCACGTTGTGTCTCAAAATCTCTG
ATGTTACATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTGTCTGCTTACATAA
TATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGC
GGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAG
ATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAG
AGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGC
GGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGA
ATGACTTGGTTGAGTAGTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGA
GAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAAC
GATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCC
TTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATG
CCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTC
CCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGG
CCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTGGCGGT
ATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGG
GAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTA
AGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCAT
TTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTA
ACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAG
ATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTG
GTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGC
GCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTG
TAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGAT
AAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGG
CTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGAT
ACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTAT
CCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTG
GTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCT
CGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCC
TTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCG
TATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGATCAA
ATTGTAAACGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTT
TAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGT
TGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAA
GGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTT
TTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAG
CTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGC
GCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAA
TGCGCCGCTACAGGGCGCGTGATCTGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGA
GCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGAGCTTGGAATTG
CGAATAATAATTTTTTCACGTTGAAAATCTCCAAAAAAAAAGGCTCCAAAAGGAGCCTTTAA
TTGTATCGGTTTATCAGCTTGCTTTCGAGGTGAATTAGCTTGGAATTGCGAATAATAATTTT
TTCACGTTGAAAATCTCCAAAAAAAAAGGCTCCAAAAGGAGCCTTTAATTGTATCGGTTTAT
CAGCTTGCTTTCGAGGTGAATT
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Figure B1. Restriction map of pEGFP-N1 plasmid.

SODWT-EGFP
SOD1
EGFP
SalI site used for original cloning (Turner et al)
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACG
TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGC
CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA
TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCG
GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCC
ACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGT
CGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATAT
AAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCT
CAAGCTTCGAATTCTGCAGTCGACAAGCATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCG
ACGGCCCAGTGCAGGGCATCATCAATTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTG
TGGGGAAGCATTAAAGGACTGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGA
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TAATACAGCAGGCTGTACCAGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTG
GGCCAAAGGATGAAGAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT
GTGGCCGATGTGTCTATTGAAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGG
CCGCACACTGGTGGTCCATGAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTA
CAAAGACAGGAAACGCTGGAAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAAGCGTCG
ACGGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTT
CACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCG
TGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTG
CTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAG
GCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGA
GGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCA
TGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGAC
GGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCT
GCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGC
GCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAG
CTGTACAAGTAAAGCGGCCGCGACTCTAGATCATAATCAGCCATACCACATTTGTAGAGGTT
TTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAAT
TGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAA
ATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAAT
GTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAA
TAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGT
GGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCAT
CACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGG
AGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAA
AGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCA
CACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGGAAATGTG
CGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACA
ATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTCCTGAGGCGGAAAGAACCA
GCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTA
TGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCA
GGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCC
GCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTT
TTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGA
GGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTC
GCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTC
GGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGC
GCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAG
ACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGAC
GTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCT
GTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGC
ATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCA
CGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCT
CGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCG
TGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTC
ATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGA
TATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCG
CTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTC
TGGGGTTCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACC
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GCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCT
CCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCTAGGGGGAGGCTAACTGAAACAC
GGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACG
CACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTTCGGTCCCAGGGCTGGCACTCTGTCGA
TACCCCACCGAGACCCCATTGGGGCCAATACGCCCGCGTTTCTTCCTTTTCCCCACCCCACC
CCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCAACGTCGGGGCGGCAGGCCCTGCCATA
GCCTCAGGTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGAT
CTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCC
ACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGC
GTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCA
AGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTG
TCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATAC
CTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGG
GTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGT
GCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTA
TGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGT
CGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTG
TCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGC
CTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGC
TCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCATGCAT

SOD1-tdTomato
SOD
tdTomato
SalI site used for original cloning (Turner et al)
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCG
TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACG
TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGC
CCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA
TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCG
GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCC
ACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGT
CGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATAT
AAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTCGAGCT
CAAGCTTCGAATTCTGCAGTCGACAAGCATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCG
ACGGCCCAGTGCAGGGCATCATCAATTTCGAGCAGAAGGAAAGTAATGGACCAGTGAAGGTG
TGGGGAAGCATTAAAGGACTGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTGGAGA
TAATACAGCAGGCTGTACCAGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTG
GGCCAAAGGATGAAGAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGT
GTGGCCGATGTGTCTATTGAAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTGG
CCGCACACTGGTGGTCCATGAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTA
CAAAGACAGGAAACGCTGGAAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCAAGCGTCG
ACGGTACCGCGGGCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGGTCAT
CAAAGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCATGAACGGCCACGAGTTCGAGA
TCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACC
AAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCATGTACGGCTCCAA
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GGCGTACGTGAAGCACCCCGCCGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCT
TCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCC
TCCCTGCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCCCCGA
CGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCC
GCGACGGCGTGCTGAAGGGCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCGGCCACTAC
CTGGTGGAGTTCAAGACCATCTACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTACTA
CGTGGACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACG
AGCGCTCCGAGGGCCGCCACCACCTGTTCCTGGGGCATGGCACCGGCAGCACCGGCAGCGGC
AGCTCCGGCACCGCCTCCTCCGAGGACAACAACATGGCCGTCATCAAAGAGTTCATGCGCTT
CAAGGTGCGCATGGAGGGCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGG
GCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCC
TTCGCCTGGGACATCCTGTCCCCCCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCC
CGCCGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGA
TGAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCACG
CTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCCCCGACGGCCCCGTAATGCAGAA
GAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAAGG
GCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCGGCCGCTACCTGGTGGAGTTCAAGACC
ATCTACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTACTACGTGGACACCAAGCTGGA
CATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAGCGCTCCGAGGGCCGCC
ACCACCTGTTCCTGTACGGCATGGACGAGCTGTACAAGAGCGGCCGCGACTCTAGATCATAA
TCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTG
AACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGG
TTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTA
GTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTAATATTTT
GTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCG
GCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGG
AACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTA
AAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCG
AACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGT
AGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGT
CAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACAT
TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAG
GAAGAGTCCTGAGGCGGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTC
CCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGT
GTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCA
GCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCA
TTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCT
CTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGA
TCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTC
CGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCT
GATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCT
GTCCGGTGCCCTGAATGAACTGCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGG
GCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTG
GGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCAT
CATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACC
AAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGAT
GATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAG
CATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGG
TGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTAT
CAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCG
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CTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTC
TTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGACGCCCAACC
TGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTT
TTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCA
CCCTAGGGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGA
CGGCAATAAAAAGACAGAATAAAACGCACGGTGTTGGGTCGTTTGTTCATAAACGCGGGGTT
CGGTCCCAGGGCTGGCACTCTGTCGATACCCCACCGAGACCCCATTGGGGCCAATACGCCCG
CGTTTCTTCCTTTTCCCCACCCCACCCCCCAAGTTCGGGTGAAGGCCCAGGGCTCGCAGCCA
ACGTCGGGGCGGCAGGCCCTGCCATAGCCTCAGGTTACTCATATATACTTTAGATTGATTTA
AAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAA
AATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTA
CCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTT
CAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCA
AGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCC
AGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCA
GCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCG
AACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCG
GACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGG
AAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTT
TGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGG
TTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGT
GGATAACCGTATTACCGCCATGCAT
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Figure C1: Calibration of Synapt-G1 HDMS using myoglobin and cytochrome c. Myglobin and
cytochrome c were prepared in 2% acetic acid 49% MeOH 49% Milli-Q and nano-electrosprayed
under gentle conditions under IM-MS mode. Mass and drift time data was acquired at wave heights of
8, 9, and 10 V.

Figure C2: Plots of [D]eq against [M]eq 2 revealing Kd values for uSOD1 and gsSOD1 variants.
Least squares regression (R2) is shown. Dimer KD values are derived from the line of best fit gradient.
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Figure C3: Plots of [D]eq against [M]eq 2 revealing Kd values for uSOD1 and gsSOD1 variants.
Least squares regression (R2) is shown. Dimer KD values are derived from the line of best fit gradient.
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Figure C4: Refolding of SOD1G37R monitored by mass spectrometry. Purified recombinant
SOD1G37R was unfolded by incubation in 20 mM DTT 5 mM EDTA 1 × PBS. Following unfolding,
the protein was concentrated using a centrifugal concentrator to a concentration of ~450 µM and
loaded onto a Superdex-75 10/300 GL column equilibrated in 200 mM NH4OAc. The eluted fraction
containing SOD1 were pooled and diluted to a concentration of 15 µM. Purified recombinant yCCS
was equilibrated into 200 mM NH4OAc similarly. SOD1G37R and yCCS were mixed at a ratio of 10:1
respectively, incubated at 22 °C, and the mixture was nano-electrosprayed under gentle conditions.
(A) The relative abundance of monomeric SOD1 decreased with longer incubation times. (B) Plotting
the relative abundance of dimer against incubation time showed the refolding of SOD1 G37R (black) to
be at final dimer abundance similar to native SOD1G37R (red), well above SOD1G37R that was not
mixed with yCCS (blue). (C) By denaturing the final product of the assay, we determined at time 0
the mass of SOD1G37R was consistent with disulfide reduced protein (~15904 Da), and that at 60 mins
the mass was consistent with disulfide oxidised protein (15902 Da).
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Figure C5: Lag-phase of aggregation vs mean disease duration. This figure is associated with
figure 5.2 and shows the relationship between the observed lag-phase of the first in vitro aggregation
assay to cells with inclusions at 48 hours. The r2 value is inset (0.83), however there are only 4 data
points. Error bars represent SEM.
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